NZ625913B2 - Heterocyclic inhibitors of glutaminase - Google Patents

Heterocyclic inhibitors of glutaminase Download PDF

Info

Publication number
NZ625913B2
NZ625913B2 NZ625913A NZ62591312A NZ625913B2 NZ 625913 B2 NZ625913 B2 NZ 625913B2 NZ 625913 A NZ625913 A NZ 625913A NZ 62591312 A NZ62591312 A NZ 62591312A NZ 625913 B2 NZ625913 B2 NZ 625913B2
Authority
NZ
New Zealand
Prior art keywords
substituted
arylalkyl
aryl
alkoxy
occurrence
Prior art date
Application number
NZ625913A
Other versions
NZ625913A (en
Inventor
Lijing Chen
Bindu Goyal
Guy Laidig
Jim Li
Eric Brian Sjogren
Timothy Friend Stanton
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Priority claimed from PCT/US2012/065816 external-priority patent/WO2013078123A1/en
Publication of NZ625913A publication Critical patent/NZ625913A/en
Publication of NZ625913B2 publication Critical patent/NZ625913B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The disclosure relates to heterocyclic inhibitors of glutaminase of general formula (I) where one X represents S and the other X represents CH=CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl. The pharmaceutical compositions comprising heterocyclic inhibitors of glutaminase of general formula (I) and their use in the treatment of cancer or immunological or neurological diseases are also disclosed. neral formula (I) and their use in the treatment of cancer or immunological or neurological diseases are also disclosed.

Description

Heterocyclic Inhibitors of Glutaminase Related Applications This application claims the benefit of priority to U.S. Provisional Patent 5 Application No. 61/562,266, filed November 21, 2011, U.S. Provisional Patent ation No. ,370, filed June 28, 2012, and U.S. Provisional Patent Application No. 61/727,195, filed November 16, 2012 which applications are hereby incorporated by reference in their entirety. 10 Background Glutamine supports cell survival, growth and proliferation through metabolic and non-metabolic mechanisms. In actively proliferating cells, the metabolism of glutamine to lactate, also referred to as "glutaminolysis" is a major source of energy in the form of NADPH. The first step in glutaminolysis is the deamination of glutamine to form 15 glutamate and ammonia, which is catalyzed by the glutaminase enzyme. Thus, deamination via glutaminase is a control point for glutamine metabolism.
Ever since g's ation that s tumor cells exhibited high rates of glucose consumption and lactate secretion in the presence of oxygen (Warburg, 1956), researchers have been exploring how cancer cells utilize metabolic pathways to be able 20 to ue actively proliferating. Several reports have demonstrated how glutamine metabolism ts macromolecular synthesis necessary for cells to replicate oys, 1995; DeBardinis, 2008).
Thus, glutaminase has been theorized to be a potential therapeutic target for the treatment of diseases characterized by ly proliferating cells, such as cancer. The 25 lack of suitable glutaminase tors has made validation of this target impossible.
Therefore, the creation of glutaminase tors that are specific and capable of being formulated for in vivo use could lead to a new class of therapeutics.
Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common 30 general knowledge in the field. - 1a - Summary of ion According to a first aspect, the present ion provides use of a compound of formula I or a pharmaceutically able salt thereof for the manufacture of a medicament for treating cancer or an immunological or neurological disease, wherein 5 formula I is: (I), wherein: L represents CH2SCH2, CH2CH2, CH2CH2CH2, CH2, CH2S, SCH2, CH2NHCH2, CH=CH, or , wherein any en atom of a CH or CH2 unit may be 10 replaced by alkyl or alkoxy, any hydrogen of an NH unit may be replaced by alkyl, and any hydrogen atom of a CH2 unit of CH2CH2, CH2CH2CH2 or CH2 may be replaced by hydroxy; one X represents S and the other X represents CH=CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl; 15 Y, independently for each occurrence, represents H or CH2O(CO)R7; R7, independently for each occurrence, represents H or substituted or unsubstituted alkyl, alkoxy, lkyl, alkylaminoalkyl, heterocyclylalkyl, or heterocyclylalkoxy; Z ents H or R3(CO); R1 and R2 each independently represent H, alkyl, alkoxy or hydroxy; 20 R3, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, lkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, arylalkyl, heteroaryloxy, heteroaryloxyalkyl or C(R8)(R9)(R10), R5) or OR6, wherein any free hydroxyl group may be 25 acylated to form C(O)R7; R4 and R5 each independently represent H or substituted or unsubstituted alkyl, hydroxyalkyl, acyl, aminoalkyl, acylaminoalkyl, l, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or - 1b - heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7; R6, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkyl, aryl, arylalkyl, 5 aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7; and R8, R9 and R10 each independently represent H or substituted or unsubstituted alkyl, 10 y, hydroxyalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, carbonyl, alkoxycarbonylamino, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, y, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or R8 and R9 together with the carbon to which they are 15 attached, form a carbocyclic or heterocyclic ring system, n any free hydroxyl group may be acylated to form C(O)R7, and wherein at least two of R8, R9 and R10 are not H; wherein, where indicated, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, 20 yalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkoxy, aryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl is optionally substituted with one or more substituents selected from halogen, hydroxyl, carboxyl, alkoxycarbonyl, formyl, acyl, ter, thioacetate, thioformate, alkoxyl, phosphoryl, phosphate, onate, 25 phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, hio, e, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, an arylalkyl, aryl, and heteroaryl.
According to a second aspect, the present invention provides a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a 30 nd of formula I, - 1c - (I), or a pharmaceutically able salt thereof, wherein: L represents CH2SCH2, CH2CH2, CH2CH2CH2, CH2, CH2S, SCH2, CH2NHCH2, CH=CH, or , wherein any hydrogen atom of a CH or CH2 unit may be 5 replaced by alkyl or alkoxy, any hydrogen of an NH unit may be replaced by alkyl, and any hydrogen atom of a CH2 unit of CH2CH2, CH2CH2CH2 or CH2 may be replaced by hydroxy; one X represents S and the other X represents CH=CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl; 10 Y, independently for each occurrence, represents H or CH2O(CO)R7; R7, independently for each occurrence, represents H or substituted or unsubstituted alkyl, alkoxy, aminoalkyl, minoalkyl, cyclylalkyl, or heterocyclylalkoxy; Z represents H or R3(CO); R1 and R2 each ndently represent H, alkyl, alkoxy or hydroxy; 15 R3, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, yalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl or C(R8)(R9)(R10), N(R4)(R5) or OR6, wherein any free hydroxyl group may be 20 acylated to form C(O)R7; R4 and R5 each independently represent H or substituted or tituted alkyl, hydroxyalkyl, acyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or 25 aryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7; R6, ndently for each occurrence, represents substituted or unsubstituted alkyl, yalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, lkylalkyl, heterocyclyl, 30 heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or - 1d - heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7; and R8, R9 and R10 each independently represent H or substituted or unsubstituted alkyl, hydroxy, hydroxyalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, 5 alkoxycarbonyl, alkoxycarbonylamino, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, yalkyl, cycloalkyl, cycloalkylalkyl, cyclyl, heterocyclylalkyl, heteroaryl, arylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or R8 and R9 er with the carbon to which they are attached, form a carbocyclic or heterocyclic ring system, wherein any free 10 hydroxyl group may be acylated to form C(O)R7, and wherein at least two of R8, R9 and R10 are not H; wherein, where indicated, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, yalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, 15 heterocyclylalkoxy, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl is optionally tuted with one or more substituents selected from halogen, hydroxyl, carboxyl, alkoxycarbonyl, formyl, acyl, ter, etate, thioformate, alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, dryl, 20 alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, an kyl, aryl, and heteroaryl.
According to a third aspect, the present invention provides a compound of formula I, (I), 25 or a pharmaceutically acceptable salt thereof, n: L represents CH2SCH2, CH2CH2, CH2CH2CH2, CH2, CH2S, SCH2, CH2NHCH2, CH=CH, or , wherein any hydrogen atom of a CH or CH2 unit may be replaced by alkyl or alkoxy, any hydrogen of an NH unit may be replaced by alkyl, and any hydrogen atom of a CH2 unit of CH2CH2, CH2CH2CH2 or CH2 30 may be replaced by hydroxy; - 1e - one X represents S and the other X represents CH=CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl; Y, independently for each occurrence, represents H or O)R7; R7, independently for each occurrence, represents H or substituted or tituted alkyl, 5 alkoxy, aminoalkyl, minoalkyl, heterocyclylalkyl, or heterocyclylalkoxy; Z represents H or R3(CO); R1 and R2 each independently represent H, alkyl, alkoxy or y; R3, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, 10 arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl or C(R8)(R9)(R10), N(R4)(R5) or OR6, wherein any free hydroxyl group may be acylated to form C(O)R7; R4 and R5 each independently represent H or substituted or unsubstituted alkyl, 15 yalkyl, acyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, kyl, aryloxy, aryloxyalkyl, cycloalkyl, lkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7; 20 R6, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, cyclylalkyl, heteroaryl, arylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form 25 C(O)R7; and R8, R9 and R10 each independently represent H or substituted or unsubstituted alkyl, hydroxy, hydroxyalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, alkoxycarbonyl, alkoxycarbonylamino, alkenyl, , alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, 30 heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or R8 and R9 together with the carbon to which they are attached, form a yclic or heterocyclic ring system, wherein any free - 1f - hydroxyl group may be acylated to form C(O)R7, and wherein at least two of R8, R9 and R10 are not H; provided that when L represents CH2SCH2, X represents S, and Z represents R3(CO), both R3 groups are not optionally substituted phenyl, aralkyl, heteroaryl, 5 substituted or tituted alkyl, or alkoxy; wherein, where indicated, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, acylaminoalkyl, alkenyl, , alkoxyalkyl, aryl, kyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkoxy, heteroaryl, heteroarylalkyl, heteroaryloxy, or 10 heteroaryloxyalkyl is optionally tuted with one or more substituents selected from halogen, hydroxyl, carboxyl, alkoxycarbonyl, formyl, acyl, thioester, thioacetate, thioformate, alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, e, sulfonate, oyl, sulfonamido, sulfonyl, heterocyclyl, an 15 arylalkyl, aryl, and heteroaryl.
Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise”, “comprising”, and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”. 20 The t invention es a compound of formula I, WO 2013/078123 PCT/US2012/065816 0 R34 N~N N’N z ,N—</ Jfi/(L) I ‘>—NC Y X X Y R1 R2 (1), or a pharmaceutically acceptable salt thereof, wherein: L represents CstCHz, CH2CH2, CH2CH2CH2, CH2, Cst, SCHz, CHzNHCHz, CH=CH, or zAfi\ wherein any hydrogen atom of a , ably CH2CH2, CH or CH2 unit may be replaced by alkyl or alkoxy, any hydrogen of an NH unit may be replaced by alkyl, and any hydrogen atom of a CH2 unit of CH2CH2, CH2CH2CH2 or CH2 may be replaced by hydroxy; X, independently for each occurrence, represents S, O or CH=CH, preferably S or CH=CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl; 10 Y, independently for each occurrence, represents H or CH2O(CO)R7; R7, ndently for each occurrence, ents H or substituted or unsubstituted alkyl, alkoxy, aminoalkyl, alkylaminoalkyl, heterocyclylalkyl, arylalkyl, or heterocyclylalkoxy; Z represents H or R3(CO); 15 R1 and R2 each independently represent H, alkyl, alkoxy or hydroxy; R3, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, y, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, 20 heteroaryloxyalkyl or C(Rg)(R9)(R10), N(R4)(R5) or 0R6, n any free hydroxyl group may be acylated to form C(O)R7; R4 and R5 each independently represent H or substituted or unsubstituted alkyl, hydroxyalkyl, acyl, lkyl, acylaminoalkyl, alkenyl, alkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, 25 heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or aryloxyalkyl, wherein any free yl group may be acylated to form C(O)R7; R6, ndently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, 30 arylalkyl, aryloxy, aryloxyalkyl, lkyl, cycloalkylalkyl, heterocyclyl, 2 WO 2013/078123 PCT/US2012/065816 heterocyclylalkyl, aryl, heteroarylalkyl, aryloxy, or heteroaryloxyalkyl, wherein any free yl group may be acylated to form C(O)R7; and R8, R9 and R10 each ndently represent H or substituted or unsubstituted alkyl, hydroxy, hydroxyalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, alkoxycarbonyl, alkoxycarbonylamino, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or R8 and R9 together with the carbon to which they are 10 attached, form a carbocyclic or heterocyclic ring system, wherein any free hydroxyl group may be acylated to form C(O)R7, and wherein at least two of R8, R9 and R10 are not H.
In certain embodiments, the present invention provides a pharmaceutical preparation suitable for use in a human t, sing an effective amount of any 15 of the compounds described herein (e.g., a compound of the invention, such as a compound of formula I), and one or more pharmaceutically acceptable excipients. In n embodiments, the pharmaceutical preparations may be for use in treating or preventing a condition or disease as described herein. In certain embodiments, the ceutical preparations have a low enough pyrogen activity to be suitable for 20 enous use in a human patient.
The present invention further provides methods of treating or preventing cancer, immunological or neurological diseases as described herein, comprising administering a compound of the invention.
Detailed Description of the Drawings 25 Figure 1 shows that intraperitoneal administration of nd 188 to mice results in reduced tumor size in a HCTl l6 colon oma xenograft model.
Detailed Description of the Invention The present invention provides a compound of formula I, WO 78123 PCT/US2012/065816 0 R34 N~N N’N z ,N—</ Jfi/(L) I ‘>—NC Y X X Y R1 R2 (1), or a pharmaceutically able salt thereof, wherein: L represents CstCHz, CH2CH2, CH2CH2CH2, CH2, Cst, SCHz, CHzNHCHz, CH=CH, or zAfi\ n any hydrogen atom of a , preferably CH2CH2, CH or CH2 unit may be replaced by alkyl or alkoxy, any hydrogen of an NH unit may be replaced by alkyl, and any hydrogen atom of a CH2 unit of CH2CH2, CH2CH2CH2 or CH2 may be replaced by hydroxy; X, ndently for each occurrence, represents S, O or CH=CH, preferably S or CH=CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl; 10 Y, independently for each occurrence, represents H or CH2O(CO)R7; R7, independently for each occurrence, represents H or substituted or unsubstituted alkyl, alkoxy, aminoalkyl, alkylaminoalkyl, heterocyclylalkyl, kyl, or heterocyclylalkoxy; Z represents H or R3(CO); 15 R1 and R2 each independently represent H, alkyl, alkoxy or hydroxy; R3, independently for each ence, represents substituted or unsubstituted alkyl, yalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, 20 heteroaryloxyalkyl or C(Rg)(R9)(R10), N(R4)(R5) or 0R6, wherein any free hydroxyl group may be acylated to form C(O)R7; R4 and R5 each independently represent H or substituted or tituted alkyl, hydroxyalkyl, acyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, 25 heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7; R6, independently for each occurrence, represents substituted or unsubstituted alkyl, yalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, 30 arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, 4 WO 2013/078123 PCT/US2012/065816 heterocyclylalkyl, aryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7; and R8, R9 and R10 each independently ent H or substituted or unsubstituted alkyl, hydroxy, hydroxyalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, alkoxycarbonyl, alkoxycarbonylamino, alkenyl, alkoxy, alkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or R8 and R9 together with the carbon to which they are 10 attached, form a carbocyclic or heterocyclic ring system, wherein any free yl group may be acylated to form C(O)R7, and wherein at least two of R8, R9 and R10 are not H.
In certain embodiments wherein alkyl, hydroxyalkyl, amino, ino, aminoalkyl, inoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, y, 15 aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, aryloxy, or heteroaryloxyalkyl are substituted, they are substituted with one or more substituents selected from substituted or unsubstituted alkyl, such as perfluoroalkyl (e.g., trifluoromethyl), alkenyl, alkoxy, alkoxyalkyl, aryl, aralkyl, arylalkoxy, aryloxy, aryloxyalkyl, hydroxyl, halo, alkoxy, such as 20 perfluoroalkoxy (e.g., trifluoromethoxy), alkoxyalkoxy, hydroxyalkyl, hydroxyalkylamino, hydroxyalkoxy, amino, aminoalkyl, alkylamino, aminoalkylalkoxy, aminoalkoxy, acylamino, acylaminoalkyl, such as perfluoro acylaminoalkyl (e.g., trifluoromethylacylaminoalkyl), y, lkyl, cycloalkylalkyl, cycloalkylalkoxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, 25 heterocyclylalkoxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, heteroaryloxy, aryloxyalkyl, heterocyclylaminoalkyl, heterocyclylaminoalkoxy, amido, amidoalkyl, amidine, imine, oxo, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl, including perfluoroacyl (e.g., C(O)CF3)), carbonylalkyl (such as carboxyalkyl, alkoxycarbonylalkyl, formylalkyl, or acylalkyl, including 30 perfluoroacylalkyl (e.g., -alkle(O)CF3)), carbamate, carbamatealkyl, urea, ureaalkyl, sulfate, sulfonate, sulfamoyl, sulfone, sulfonamide, sulfonamidealkyl, cyano, nitro, azido, sulfhydryl, alkylthio, thiocarbonyl (such as ter, thioacetate, or rmate), phosphoryl, phosphate, phosphonate or phosphinate. 5 WO 2013/078123 PCT/US2012/065816 In certain embodiments, L represents 2, CH2CH2, CH2CH2CH2, CH2, CH2S, SCH2, or CH2NHCH2, wherein any hydrogen atom of a CH2 unit may be replaced by alkyl or alkoxy, and any hydrogen atom of a CH2 unit of CH2CH2, CH2CH2CH2 or CH2 may be replaced by yl. In certain embodiments, L represents CH2SCH2, CH2CH2, CH2S or SCH2. In certain embodiments, L represents CH2CH2. In certain embodiments, L is not CH2SCH2 In certain embodiments, Y represents H.
In n embodiments, X represents S or CH=CH. In certain embodiments, one or both X represents CH=CH. In certain embodiments, each X represents S. In 10 certain embodiments, one X represents S and the other X represents CH=CH.
In n embodiments, Z represents R3(CO). In certain embodiments wherein Z is R3(CO), each occurrence of R3 is not identical (e. g., the nd of a I is not symmetrical).
In certain embodiments, R1 and R2 each represent H. 15 In certain embodiments, R3 represents arylalkyl, arylalkyl, lkyl or heterocycloalkyl. In certain embodiments, R3 ents C(Rg)(R9)(R10), wherein R8 represents aryl, arylalkyl, aryl or heteroaralkyl, such as aryl, arylalkyl or heteroaryl, R9 represents H, and R10 represents hydroxy, hydroxyalkyl, alkoxy or alkoxyalkyl, such as hydroxy, hydroxyalkyl or . 20 In certain embodiments, L represents CH2SCH2, CH2CH2, CH2S or SCH2, such as CH2CH2, CH2S or SCH2, Y represents H, X represents S, Z represents R3(CO), R1 and R2 each represent H, and each R3 represents arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl. In certain such embodiments, each occurrence of R3 is identical. 25 In certain embodiments, L represents CH2SCH2, CH2CH2, CH2S or SCH2, Y represents H, X represents S, Z represents R3(CO), R1 and R2 each represent H, and each R3 represents C(Rg)(R9)(R10), wherein R3 ents aryl, arylalkyl, heteroaryl or heteroaralkyl, such as aryl, kyl or heteroaryl, R9 represents H, and R10 represents hydroxy, hydroxyalkyl, alkoxy or alkoxyalkyl, such as hydroxy, hydroxyalkyl or 30 alkoxy. In certain such embodiments, each occurrence of R3 is identical.
In certain embodiments, L represents CH2CH2, Y represents H, X represents S or CH=CH, Z represents R3(CO), R1 and R2 each represent H, and each R3 represents substituted or unsubstituted arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl. 6 WO 2013/078123 PCT/US2012/065816 In certain such embodiments, each X represents S. In other embodiments, one or both occurrences ofX represents CH=CH, such as one occurrence ofX represents S and the other occurrence ofX represents CH=CH. In certain embodiments of the foregoing, each occurrence of R3 is identical. In other embodiments of the foregoing wherein one occurrence ofX represents S and the other occurrence ofX represents CH=CH, the two occurrences of R3 are not identical.
In certain embodiments, L represents , Y represents H, X represents S, Z represents R3(CO), R1 and R2 each represent H, and each R3 represents C(Rg)(R9)(R10), wherein R8 represents aryl, arylalkyl or heteroaryl, R9 represents H, 10 and R10 represents hydroxy, hydroxyalkyl or alkoxy. In certain such embodiments, R8 represents aryl and R10 represents hydroxyalkyl. In certain such embodiments, each occurrence of R3 is identical.
In certain embodiments wherein L represents CH2, CH2 or , X represents 0, and Z represents R3(CO), both R3 groups are not alkyl, such as methyl, 15 or C(Rg)(R9)(R10), wherein R3, R9 and R10 are each independently hydrogen or alkyl.
In certain embodiments wherein L represents CHZCHZ, X represents S, and Z represents R3(CO), both R3 groups are not phenyl or aryl, such as 2-fiaryl.
In certain embodiments wherein L represents CH2CH2, X represents 0, and Z represents R3(CO), both R3 groups are not R5) wherein R4 is aryl, such as 20 , and R5 is H.
In certain embodiments wherein L represents CHZSCHZ, X represents S, and Z ents R3(CO), both R3 groups are not aryl, such as ally substituted , l, such as benzyl, heteroaryl, such as 2-furyl, 2-thienyl or l,2,4-trizole, substituted or unsubstituted alkyl, such as , chloromethyl, dichloromethyl, n- 25 propyl, n-butyl, t-butyl or hexyl, heterocyclyl, such as pyrimidine-2,4(lH,3H)-dione, or , such as methoxy, oxy or ethoxy.
In certain embodiments wherein L represents CH2SCH2, X represents S, and Z represents R3(CO), both R3 groups are not N(R4)(R5) wherein R4 is aryl, such as substituted or unsubstituted phenyl (e.g., phenyl, 3-tolyl, 4-tolyl, 4-bromophenyl or 4- 30 nitrophenyl), and R5 is H.
In certain embodiments wherein L represents CH2CH2CH2, X represents S, and Z represents R3(CO), both R3 groups are not alkyl, such as methyl, ethyl, or WO 2013/078123 PCT/US2012/065816 propyl, cycloalkyl, such as cyclohexyl, or C(Rg)(R9)(R10), wherein any of R8, R9 and R10 together with the C to which they are attached, form any of the foregoing.
In certain embodiments, the compound is not one of the following: (J\O)CHN”L:>m<1L:>ww<1JMNHC(-O)Pri n--Pr(J\O)CHN AMNHC(-O)Prn e(O)CHN AMNHC()OMe S 5 Et(O)CHN NHC(OE , ’ /N N\ W%1\S S mom-O a /N N\ ©(O)CHN1yw<1S S o mom-O o 9 SH N/N N\N Hs JL \>7(CH2)2S(CH2)2</iS S (O)CHN NHC(O) Nl/N\ N\N (CH2)23(SM/ Me(HzC)s(O)CHNL ANHC(O)——(CH2)5Me , NIN/ N\N J\S(\>~(CI-{(2)28(CH2)Z<I MeO((O)CHN/I\ /LN(HC(0)0Me Cl Ji:(\>—CH2)ZS(OWE—<1 Cl 02” (O)CHNJ\ NHC(O N02 9 N/N N\N JR»((CH2)28(SJ\CH2)2—</ CIH20(O)CHN/I\ ANHQ(O)CHZCI o N/N\ ”\N 0 /II\ >—(CH2)ZS(CH2)2‘<i/ HN—< HN \ S S (O)CHN NHC(O) \ NH >—NH 0 o WO 2013/078123 PCT/US2012/065816 /N N N\N JLS<><<CH2)2S(CH2)2—</| CleC(O)CHN/‘\ /L(NHC(0)0HCI2 OzN‘QNHC(O)NHis/\>’(CH2)2S(CH2)2’</:\|NANHQOWH N02 /N N\ |s(\>‘((CH2)2S(SCH2)2</|N N Me(HZC)4(/‘\O)CHN 0)—-(CH2)4Me’ N/N N\N 2N‘©(O)CHNJL >(CH2)ZS(CH2)2</iS S NHC(O)QN02 9 N02 NN/ / OZN 02N (J\O)CHNJLS(>((CH2)28(CH2)2—<81'L\ ANHCO N02 MeO /N OMe (J\O)CHNJ\S(>7((CH2)28(CH2)Z<J\NI \ / M90 JMNHCO 0M9 N\N /N ”IL\>‘(O)CHN|fi>(CH2)ZS(CH2)2<|ANHC(O)‘<\N\|I N/N N N/ N\N Cl©(O)CHNJL >(CH2>ZS<CH2>2<iS S NHC(O)QCI 9 /N N N\N J|\S(\>_CH2)23(CH2)2'</S/|L n- Pr((J\O)CHN /LNHC(O)Pr-n l l OHCHNJ\jig»((CH2)25(CH2)2-</:j\l\ ANHCK) 10 9 N/ Me‘©(O)CHNLS\>7<CH2>28<CH2>2</\|SiNHC(OO>QM6 ’ 9 WO 2013/078123 PCT/US2012/065816 Me I:(\>7(5(CH2)2S<CH2)Z<IN\N Me NHC((O)NH ANHQ(O)NH £:(\>7(“th3(Cth'</S|N\N NHc(O)NH /LNHC(O)NH Br N/ N\N Br—©(O)CHN/“\SN(\>7((CH2)28(SJ\CH2)Z‘</N(HCO Br NIN/ N\N (CH2)2S(CH2)2‘</| n—Bu((O)CHN/i\ ANHQ(O—)Bun is/N(>7((CH2)28(S/kCH2)2-<\ /\|“ MeQNHC(0)NH ANHM(O)NH Me /N N\ /H\S(\>’(5(CH2)2S(SCH2)2’</|N N (EO)CHN Ammo(O)Et NIN/ N\N J\S(\>’(3(CH2)2S(SCH2)2‘</| PhHN((O)CHNJ\ ANHQ(O)NHPh N|/:\>’(CH2)3-</\|N H30(O)CHNJ\ ANHQ(O)CH3 >< >< H3C(O)CHN/i\ ANHC(O)CH3 h(O)CHNJ\ ANNC(O)Ph 10 H30(O)CHN NHC(O)CH3 01» I 7(CH2)4»</:\|N PhHN((O)CHN/i\ ANHQ(O)NHPh The present ion further provides a compound of formula la, 10 WO 2013/078123 PCT/US2012/065816 0 Z N\N N 3N4 XK (L) \ )\\R11 N Y x / Y R1 R2 (Ia), or a pharmaceutically able salt thereof, wherein: L ents CstCHz, CH2CH2, CH2CH2CH2, CH2, Cst, SCHz, CHzNHCHz, CH=CH, ‘ ,preferably CH2CH2, wherein any hydrogen atom of a CH or CH2 unit may be replaced by alkyl or , any hydrogen of an NH unit may be replaced by alkyl, and any hydrogen atom of a CH2 unit of CH2CH2, CH2CH2CH2 or CH2 may be replaced by hydroxy; X ents S, O or CH=CH, preferably S or CH=CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl; 10 Y, independently for each occurrence, represents H or CH2O(CO)R7; R7, independently for each occurrence, represents H or substituted or unsubstituted alkyl, alkoxy, aminoalkyl, minoalkyl, heterocyclylalkyl, arylalkyl, or heterocyclylalkoxy; Z represents H or R3(CO); 15 R1 and R2 each independently ent H, alkyl, alkoxy or hydroxy, preferably H R3 represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl or 20 C(Rg)(R9)(R10), N(R4)(R5) or 0R6, wherein any free hydroxyl group may be acylated to form C(O)R7; R4 and R5 each independently represent H or substituted or unsubstituted alkyl, hydroxyalkyl, acyl, lkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, 25 heterocyclylalkyl, heteroaryl, arylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7; R6, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, 30 arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, l l WO 2013/078123 PCT/US2012/065816 heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7; and R8, R9 and R10 each independently represent H or substituted or unsubstituted alkyl, hydroxy, hydroxyalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, alkoxycarbonyl, alkoxycarbonylamino, l, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, arylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or R8 and R9 together with the carbon to which they are 10 attached, form a carbocyclic or heterocyclic ring system, wherein any free hydroxyl group may be acylated to form C(O)R7, and wherein at least two of R8, R9 and R10 are not H; R11 represents substituted or unsubstituted aryl, kyl, aryloxy, aryloxyalkyl, aryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or 15 C(R12)(R13)(R14), N(R4)(R14) or OR14, wherein any free hydroxyl group may be acylated to form C(O)R7; R12 and R13 each ndently respresent H or substituted or unsubstituted alkyl, hydroxy, yalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, alkoxycarbonyl, alkoxycarbonylamino, alkenyl, alkoxy, alkoxyalkyl, aryl, 20 arylalkyl, aryloxy, yalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7, and wherein both of R12 and R13 are not H; and R14 represents substituted or unsubstituted aryl, arylalkyl, aryloxy, aryloxyalkyl, 25 heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl.
In certain embodiments wherein alkyl, yalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, l, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl are substituted, they are 30 substituted with one or more substituents ed from substituted or unsubstituted alkyl, such as perfluoroalkyl (e.g., trifluoromethyl), alkenyl, , alkoxyalkyl, aryl, aralkyl, arylalkoxy, aryloxy, aryloxyalkyl, hydroxyl, halo, alkoxy, such as perfluoroalkoxy (e.g., trifluoromethylalkoxy), alkoxyalkoxy, hydroxyalkyl, 12 WO 2013/078123 PCT/US2012/065816 hydroxyalkylamino, hydroxyalkoxy, amino, aminoalkyl, mino, aminoalkylalkoxy, aminoalkoxy, acylamino, acylaminoalkyl, such as perfluoro inoalkyl (e.g., trifluoromethylacylaminoalkyl), acyloxy, cycloalkyl, cycloalkylalkyl, cycloalkylalkoxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, heterocyclylalkoxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, heteroaryloxy, heteroaryloxyalkyl, cyclylaminoalkyl, heterocyclylaminoalkoxy, amido, amidoalkyl, amidine, imine, oxo, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl, including roacyl (e.g., C(O)CF3)), carbonylalkyl (such as carboxyalkyl, alkoxycarbonylalkyl, alkyl, or acylalkyl, including 10 perfluoroacylalkyl (e.g., (O)CF3)), carbamate, carbamatealkyl, urea, ureaalkyl, sulfate, sulfonate, sulfamoyl, sulfone, sulfonamide, sulfonamidealkyl, cyano, nitro, azido, dryl, alkylthio, thiocarbonyl (such as thioester, thioacetate, or thioformate), phosphoryl, phosphate, phosphonate or phosphinate.
In certain embodiments, R11 represents substituted or unsubstituted arylalkyl, 15 such as substituted or unsubstituted benzyl.
In n embodiments, L represents CH2SCH2, CH2CH2, CH2CH2CH2, CH2, CH2S, SCH2, or CH2NHCH2, wherein any hydrogen atom of a CH2 unit may be replaced by alkyl or alkoxy, and any hydrogen atom of a CH2 unit of CH2CH2, CH2CH2CH2 or CH2 may be replaced by yl. In certain embodiments, L 20 represents CH2SCH2, CH2CH2, CH2S or SCH2, preferably CH2CH2. In certain embodiments, L is not CH2SCH2.
In certain embodiments, each Y represents H. In other embodiments, at least one Y is O)R7.
In certain embodiments, X represents S or CH=CH. In certain embodiments, 25 X represents S.
In certain embodiments, R1 and R2 each represent H.
In certain embodiments, Z represents R3(CO). In certain embodiments wherein Z is R3(CO), R3 and R11 are not identical (e. g., the compound of formula I is not rical). 30 In certain embodiments, Z represents R3(CO) and R3 represents kyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl. In certain ments, Z ents R3(CO) and R3 represents C(Rg)(R9)(R10), wherein R8 represents aryl, arylalkyl, heteroaryl or heteroaralkyl, such as aryl, arylalkyl or heteroaryl, R9 represents H, and l 3 WO 2013/078123 PCT/US2012/065816 R10 represents hydroxy, hydroxyalkyl, alkoxy or alkoxyalkyl, such as hydroxy, hydroxyalkyl or alkoxy. In certain ments, Z represents R3(CO) and R3 ents heteroarylalkyl.
In certain embodiments, L represents CH2SCH2, CH2CH2, CH2S or SCH2, such as CH2CH2, Y represents H, X represents S, Z represents R3(CO), R1 and R2 each ent H, R3 represents arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl, and R11 represents arylalkyl. In certain such embodiments, R3 represents heteroarylalkyl.
In certain embodiments, L represents CH2SCH2, CH2CH2, CH2S or SCH2, 10 such as CH2CH2, Y represents H, X represents S, Z represents R3(CO), R1 and R2 each ent H, and each R3 represents C(Rg)(R9)(R10), wherein R8 represents aryl, arylalkyl, heteroaryl or heteroaralkyl, such as aryl, kyl or heteroaryl, R9 represents H, and R10 represents hydroxy, hydroxyalkyl, alkoxy or alkoxyalkyl, such as hydroxy, hydroxyalkyl or alkoxy, and R11 represents arylalkyl. In certain such 15 embodiments, R3 represents heteroaryl.
In certain embodiments, L ents CH2CH2, Y ents H, X represents S or CH=CH, such as S, Z represents R3(CO), R1 and R2 each represent H, R3 represents tuted or unsubstituted arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl, and R11 ents arylalkyl. In certain such embodiments, R3 represents 20 heteroarylalkyl.
In certain embodiments, L represents CH2CH2, Y represents H, X represents S, Z ents , R1 and R2 each represent H, R3 ents C(Rg)(R9)(R10), wherein R8 represents aryl, arylalkyl or heteroaryl, R9 represents H, and R10 represents hydroxy, hydroxyalkyl or alkoxy, and R11 represents arylalkyl. In n 25 such embodiments, R8 represents aryl and R10 represents hydroxyalkyl. In certain other embodiments, R8 represents heteroaryl.
In certain embodiments, the compound is selected from any one of the compounds disclosed in Table 3. Preferably, the compound is selected from compound 1, 2, 6, 7, 8, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 29, 30 30, 31, 32, 33, 35, 36, 38, 39, 40, 41, 43, 44, 47, 48, 50, 51, 52, 54, 55, 58, 63, 64, 65, 67, 68, 69, 70, 71, 72, 73, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 92, 93, 94, 95, 97,99,100,102,105,107,111,112,114,115,116,117,118,120,121,122,123, 126,127,133,135,136,138,140,141,143,146,147,148,152,153,155,156,157, 14 WO 2013/078123 2012/065816 158,159,160,161,162,163,164,165,166,168,169,170,172,173,174,175,176, 8,179,180,181,182,185,186,187,188,189,190,193,194,195,196,197, 198,199,200,201,202,203,204,205,208,210,211,213,214,216,217,219,220, 226,227,228,229,231,232,234,235,236,237,239,240,241,242,243,244,245, 246,247,248,249,250,251,252,255,256,257,258,259,260,261,262,263,264, 265,266,267,268,269,270,271,273,274,275,276,278,279,280,281,282,283, 285,286,287,288,290,291,292,293,294,295,296,297,298,299,300,302,304, 1038,306,307,308,309,310,311,313,314,315,316,317,318,319,320,321,322, 323,324,325,327,329,332,333,334,335,336,337,338,339,340,341,342,343, 10 344,345,346,527,347,348,349,350,351,352,353,354,355,358,359,360,361, 362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378, 379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395, 396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412, 413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429, 15 430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446, 447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463, 464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480, 481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497, 498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514, 20 515,516,517,518,519,520,521,522,523,528,529,530,531,532,533,534,535, 536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552, 553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569, 570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586, 587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603, 25 604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620, 621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,638, 639,640,641,644,645,646,647,648,649,650,651,652,653,654,655,656,657, 658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674, 675,676,677,678,679,680,681,682,683,684,685,686,687,688,689,690,692, 30 4,695,696,697,698,699,700,701,702,703,704,705,707,708,or709.
In certain embodiments, compounds of the ion may be prodrugs of the compounds of formula I, e.g., wherein a hydroxyl in the parent compound is presented as an ester or a carbonate, or carboxylic acid present in the parent 15 WO 2013/078123 PCT/US2012/065816 compound is presented as an ester. In certain such embodiments, the prodrug is metabolized to the active parent compound in vivo (e.g., the ester is hydrolyzed to the corresponding hydroxyl, or carboxylic acid).
In certain embodiments, compounds of the invention may be racemic. In certain embodiments, compounds of the invention may be enriched in one omer. For e, a compound of the invention may have greater than 30% ee, 40% ee, 50% ee, 60% ee, 70% ee, 80% ee, 90% ee, or even 95% or greater ee. In certain embodiments, compounds of the invention may have more than one stereocenter. In certain such embodiments, compounds of the invention may be 10 enriched in one or more diastereomer. For example, a compound of the invention may have greater than 30% de, 40% de, 50% de, 60% de, 70% de, 80% de, 90% de, or even 95% or greater de.
In certain embodiments, the present invention relates to methods of treatment with a compound of formula I, or a pharmaceutically acceptable salt thereof. In 15 certain embodiments, the therapeutic preparation may be enriched to provide predominantly one enantiomer of a compound (e.g., of formula I). An enantiomerically enriched mixture may comprise, for example, at least 60 mol percent of one enantiomer, or more preferably at least 75, 90, 95, or even 99 mol percent. In certain embodiments, the compound enriched in one enantiomer is substantially free 20 of the other enantiomer, wherein substantially free means that the substance in question makes up less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1% as compared to the amount of the other enantiomer, e.g. , in the composition or compound e. For example, if a ition or compound mixture contains 98 grams of a first enantiomer and 2 grams of a second 25 enantiomer, it would be said to contain 98 mol percent of the first omer and only 2% of the second enantiomer.
In certain embodiments, the therapeutic preparation may be enriched to e inantly one diastereomer of a compound (e.g., of formula I). A diastereomerically enriched mixture may se, for example, at least 60 mol 30 percent of one reomer, or more ably at least 75, 90, 95, or even 99 mol percent.
In certain embodiments, the present invention relates to s of ent with a compound of formula I, or a ceutically acceptable salt thereof. In 16 WO 2013/078123 PCT/US2012/065816 certain embodiments, the therapeutic preparation may be ed to provide inantly one enantiomer of a compound (e.g., of formula I). An enantiomerically enriched mixture may comprise, for example, at least 60 mol percent of one enantiomer, or more preferably at least 75, 90, 95, or even 99 mol percent. In n embodiments, the compound enriched in one enantiomer is substantially free of the other enantiomer, wherein substantially free means that the substance in question makes up less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1% as compared to the amount of the other enantiomer, e.g. , in the composition or nd mixture. For example, if a composition or 10 compound mixture contains 98 grams of a first enantiomer and 2 grams of a second omer, it would be said to contain 98 mol percent of the first enantiomer and only 2% of the second omer.
In certain embodiments, the therapeutic preparation may be enriched to provide predominantly one diastereomer of a compound (e.g., of formula I). A 15 diastereomerically enriched mixture may comprise, for example, at least 60 mol percent of one diastereomer, or more preferably at least 75, 90, 95, or even 99 mol percent.
In certain embodiments, the present invention provides a pharmaceutical preparation suitable for use in a human patient, sing any of the compounds 20 shown above (e.g., a compound of the invention, such as a compound of a I), and one or more pharmaceutically able excipients. In n embodiments, the pharmaceutical preparations may be for use in ng or preventing a condition or disease as described herein. In certain embodiments, the pharmaceutical preparations have a low enough pyrogen activity to be suitable for use in a human patient. 25 Compounds of any of the above structures may be used in the manufacture of medicaments for the treatment of any es or conditions disclosed herein.
Uses of enzyme inhibitors Glutamine plays an important role as a carrier of en, carbon, and energy. It is used for hepatic urea synthesis, for renal ammoniagenesis, for 30 gluconeogenesis, and as respiratory fuel for many cells. The conversion of glutamine into glutamate is initated by the mitochondrial enzyme, glutaminase (“GLS”). There are two major forms of the enzyme, K-type and L-type, which are distinguished by their Km values for glutamine and response to glutamate, wherein the Km value, or 17 WO 2013/078123 PCT/US2012/065816 Michaelis constant, is the concentration of substrate required to reach half the maximal velocity. The L-type, also known as “liver-type” or GLS2, has a high Km for glutamine and is glutamate resistant. The K-type, also known as “kidney-type or GLS1, has a low Km for ine and is inhibited by glutamate. An alternative splice form of GLSl, referred to as glutmainase C or “GAC”, has been identified recently and has similar actiVity characteristics of GLS 1. In certain embodiments, the compounds may selectively inhibit GLS1, GLS2 and GAC. In a preferred embodiment, the compounds selectively inhibit GLS1 and GAC.
In addition to serving as the basic building blocks of protein synthesis, amino 10 acids have been shown to contribute to many processes critical for growing and diViding cells, and this is particularly true for cancer cells. Nearly all definitions of cancer e reference to dysregulated proliferation. Numerous s on ine metabolism in cancer indicate that many tumors are aVid glutamine ers (Souba, Ann. Surg., 1993; Collins et al., J. Cell. Physiol., 1998; Medina, J. 15 Nutr., 2001; Shanware et al., J. Mol. Med., 2011). An ment of the invention is the use of the compounds described herein for the treatment of cancer.
In certain ments, the cancer may be one or a variant of Acute Lymphoblastic Leukemia (ALL), Acute d Leukemia (AML), cortical oma, AIDS-Related Cancers (Kaposi Sarcoma and ma), Anal Cancer, 20 Appendix , al Teratoid/Rhabdoid Tumor, Basal Cell Carcinoma, Bile Duct Cancer (including Extrahepatic), Bladder Cancer, Bone Cancer (including Osteosarcoma and Malignant s Histiocytoma), Brain Tumor (such as Astrocytomas, Brain and Spinal Cord Tumors, Brain Stem Glioma, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal 25 Tumors, Craniopharyngioma, Ependymoblastoma, Ependymoma, Medulloblastoma, Medulloepithelioma, Pineal Parenchymal Tumors of Intermediate Differentiation, Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma), Breast Cancer Bronchial Tumors, Burkitt Lymphoma, Basal Cell Carcinoma, Bile Duct , Cancer (including Extrahepatic), Bladder Cancer, Bone Cancer (including 30 Osteosarcoma and Malignant Fibrous Histiocytoma), Carcinoid Tumor, Carcinoma of Unknown Primary, Central Nervous System (such as Atypical id/Rhabdoid Tumor, Embryonal Tumors and Lymphoma), Cervical Cancer, Childhood Cancers, Chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia 1 8 WO 2013/078123 PCT/US2012/065816 (CML), c Myeloproliferative Disorders, Colon Cancer, Colorectal Cancer, pharyngioma, Cutaneous T-Cell Lymphoma (Mycosis Fungoides and Sezary Syndrome), Duct, Bile (Extrahepatic), Ductal Carcinoma In Situ (DCIS), Embryonal Tumors (Central Nervous System), Endometrial Cancer, Ependymoblastoma, Ependymoma, Esophageal Cancer, Esthesioneuroblastoma, Ewing a Family of Tumors, Extracranial Germ Cell Tumor, onadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer (like Intraocular Melanoma, blastoma), Fibrous Histiocytoma of Bone (including Malignant and Osteosarcoma) Gallbladder Cancer, Gastric (Stomach) Cancer, Gastrointestinal 10 Carcinoid Tumor, Gastrointestinal l Tumors (GIST), Germ Cell Tumor (Extracranial, Extragonadal, Ovarian), Gestational blastic Tumor, Glioma, Hairy Cell Leukemia, Head and Neck Cancer, Heart Cancer, Hepatocellular (Liver) Cancer, Histiocytosis, Langerhans Cell, Hodgkin Lymphoma, Hypopharyngeal Cancer, Intraocular Melanoma, Islet Cell Tumors (Endocrine, Pancreas), Kaposi 15 Sarcoma, Kidney (including Renal Cell), Langerhans Cell Histiocytosis, Laryngeal Cancer, Leukemia (including Acute blastic (ALL), Acute Myeloid (AML), Chronic Lymphocytic (CLL), Chronic enous (CML), Hairy Cell), Lip and Oral Cavity Cancer, Liver Cancer (Primary), Lobular Carcinoma In Situ (LCIS), Lung Cancer mall Cell and Small Cell), Lymphoma (AIDS-Related, Burkitt, 20 Cutaneous T-Cell is Fungoides and Sezary Syndrome), Hodgkin, Non- Hodgkin, Primary Central Nervous System (CNS), Macroglobulinemia, Waldenstrom, Male Breast Cancer, Malignant Fibrous cytoma of Bone and Osteosarcoma, Medulloblastoma, oepithelioma, Melanoma (including Intraocular (Eye)), Merkel Cell Carcinoma, Mesothelioma (Malignant), Metastatic 25 Squamous Neck Cancer with Occult Primary, Midline Tract Carcinoma Involving NUT Gene, Mouth Cancer, Multiple ine Neoplasia Syndromes, Multiple Myeloma/Plasma Cell Neoplasm, Mycosis Fungoides, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Myelogenous Leukemia, Chronic (CML), Myeloid Leukemia, Acute (AML), Myeloma and Multiple Myeloma, 30 Myeloproliferative ers (Chronic), Nasal Cavity and Paranasal Sinus , Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral , Oral Cavity Cancer, Lip and,Oropharyngeal Cancer, Osteosarcoma and Malignant Fibrous Histiocytoma of Bone, Ovarian Cancer (such as 19 WO 2013/078123 PCT/US2012/065816 Epithelial, Germ Cell Tumor, and Low ant ial Tumor), Pancreatic Cancer (including Islet Cell Tumors), Papillomatosis, Paraganglioma, Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pharyngeal Cancer, romocytoma, Pineal Parenchymal Tumors of Intermediate Differentiation, Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Pleuropulmonary Blastoma, Pregnancy and Breast Cancer, Primary Central Nervous System (CNS) Lymphoma, Prostate Cancer, Rectal , Renal Cell (Kidney) Cancer, Renal Pelvis and Ureter, Transitional Cell Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland 10 , Sarcoma (like Ewing Sarcoma Family of Tumors, Kaposi, Soft , Uterine), Sezary Syndrome, Skin Cancer (such as ma, Merkel Cell Carcinoma,Nonmelanoma), Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, us Cell Carcinoma, Squamous Neck Cancer with Occult Primary, atic, Stomach (Gastric) Cancer, entorial Primitive 15 Neuroectodermal Tumors, T-Cell Lymphoma(Cutaneous, Mycosis Fungoides and Sezary Syndrome), Testicular Cancer, Throat , Thymoma and Thymic oma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and , Trophoblastic Tumor (Gestational), Unknown Primary, Unusual Cancers of Childhood, Ureter and Renal Pelvis, Transitional Cell Cancer, Urethral Cancer, 20 Uterine Cancer, Endometrial, Uterine Sarcoma, Waldenstrom Macroglobulinemia and Wilms Tumor.
In some instances, oncogenic mutations promote glutamine metabolism. Cells expressing oncogenic K-Ras exhibt increased ultilization of glutamine (Weinberg et al., Proc. Natl. Acad. Sci. USA, 2010; Gaglio et al., Mol. Syst. Biol., 2011). In certain 25 embodiments, the cancer cells have a mutated K-Ras gene. In certain embodiments, the cancer is associated with tissue of the bladder, bone marrow, breast, colon, , kidney, liver, lung, ovary, pancreas, prostate, skin or thyroid. The c-Myc gene is known to be altered in us cancers (Zeller et al., Genome biology, 2003).
Increased Myc protein expression has been correlated with increased expression of 30 glutaminase, leading to up-regulation of glutamine metabolism (Dang eta 1., Clin.
Cancer Res., 2009; Gao et al., Nature, 2009). In n embodiments, the cancer cells have an oncogenic c-Myc gene or elevated Myc protein expression. In some embodiments, the cancer is associated with tissue of the bladder, bone, bowel, breast, 20 WO 2013/078123 PCT/US2012/065816 central nervous system (like brain), colon, gastric system (such as stomach and intestine), liver, lung, ovary, prostate, , and skin.
While many cancer cells depend on exogenous glutamine for survival, the degree of glutamine dependence among tumor cell subtypes may make a tion of cells more susceptible to the reduction of glutamine. As an example, gene expression analysis of breast cancers has identified five intrinsic subtypes (luminal A, luminal B, basal, HER2+, and -like) (Sorlie et al., Proc Natl Acad Sci USA, 2001). Although glutamine deprivation has an impact on cell growth and viability, basal-like cells appear to be more sensitive to the reduction of exogenous glutamine 10 (Kung et al., PLoS Genetics, 2011). This supports the concept that glutamine is a very important energy source in basal-like breast cancer cell lines, and suggests that tion of the glutaminase enzyme would be beneficial in the treatment of breast cancers comprised of basal-like cells. Triple-negative breast cancer (TNBC) is characterized by a lack of estrogen receptor, progesterone receptor and human 15 epidermal growth factor or 2 expression. It has a higher rate of relapse following chemotherapy, and a poorer prognosis than with the other breast cancer subtypes (Dent et al., Clin Cancer res, 2007). Interestingly, there s to be significant similarities in metabolic profiling between TNBC cells and basal-like breast cancer cells (unpublished data). Therefore, an embodiment of the invention is 20 the use of the compounds described herein for the treatment of TNBC and basal-type breast cancers.
Cachexia, the massive loss of muscle mass, is often associated with poor performance status and high mortality rate of cancer patients. A theory behind this process is that tumors require more glutamine than is normally supplied by diet, so 25 muscle, a major source of ine, starts to breakdown in order to supply enough nutrient to the tumor. Thus, inhibition of glutaminase may reduce the need to own . An ment of the invention is the use of the present compounds to prevent, inhibit or reduce cachexia.
The most common neurotransmitter is glutamate, derived from the enzymatic 30 sion of glutamine via glutaminase. High levels of glutamate have been shown to be neurotoxic. Following traumatic insult to neuronal cells, there occurs a rise in neurotransmitter release, particularly ate. Accordingly, inhibition of glutaminase has been esized as a means of treatment following an ischemic 2l WO 2013/078123 PCT/US2012/065816 insult, such as stroke (Newcomb, PCT WO 99/09825, Kostandy, Neurol. Sci., 2011).
Huntington’s disease is a progressive, fatal neurological condition. In genetic mouse models of Huntington’s disease, it was observed that the early manifestation of the disease ated with dysregulated glutamate release (Raymond et al., Neuroscience, 2011). In HIV-associated dementia, HIV ed macrophages exhibit upregulated glutaminase activity and increased glutamate release, leading to neuronal damage (Huang et al.,] Neurosci., 2011). Similarly, in another ogical disease, the activated microglia in Rett Syndrome release glutamate causing neuronal damage.
The release of excess glutamate has been associated with the up-regulation of 10 inase (Maezawa et al., J. Neurosci, 2010). In mice bred to have reduced glutaminase levels, sensitivity to psychotic-stimulating drugs, such as amphetamines, was dramatically reduced, thus suggesting that glutaminase inhibition may be beneficial in the treatment of schizophrenia (Gaisler—Salomon et al., Neuropsychopharmacology, 2009). Bipolar disorder is a devastating illness that is 15 marked by recurrent episodes of mania and depression. This disease is treated with mood stabilizers such as lithium and valproate; however, chronic use of these drugs appear to increase the abundance of glutamate receptors (Nanavati et al., J.
Neurochem., 2011), which may lead to a decrease in the drug’s effectiveness over time. Thus, an alternative ent may be to reduce the amount of glutamate by 20 inhibiting glutaminase. This may or may not be in conjunction with the mood stabilizers. Memantine, a partial nist ofN—methyl-D-aspartate receptor (NMDAR), is an ed therapeutic in the treatment of Alzheimer’s disease.
Currently, ch is being conducted looking at memantine as a means of treating vascular dementia and Parkinson’s disease (Oliverares et al., Curr. Alzheimer Res., 25 2011). Since memantine has been shown to partially block the NMDA glutamate receptor also, it is not unresasonable to speculate that decreasing glutamate levels by inhibiting glutaminase could also treat mer’s e, vascular ia and Parkinson’s disease. Alzheimer’s disease, bipolar disorder, HIV-associated ia, Huntington’s disease, ischemic insult, Parkinson’s disease, schizophrenia, 30 stroke, tic insult and vascular dementia are but a few of the neurological es that have been correlated to increased levels of glutamate. Thus, ting glutaminase with a compound described herein can reduce or prevent neurological 22 WO 2013/078123 PCT/US2012/065816 diseases. Therefore, in one embodiment, the compounds may be used for the treatment or prevention of neurological diseases.
Activation of T lymphocytes induces cell growth, eration, and cytokine production, thereby placing tic and biosynthetic demands on the cell. ine serves as an amine group donor for nucleotide synthesis, and glutamate, the first component in glutamine metabolism, plays a direct role in amino acid and glutathione synthesis, as well as being able to enter the Krebs cycle for energy production (Carr et al., J. Immunol., 2010). Mitogen-induced T cell proliferation and ne production require high levels of glutamine metabolism, thus inhibiting 10 glutaminase may serve as a means of immune modulation. In multiple sclerosis, an inflammatory autoimmune disease, the activated microglia exhibit up-regulated inase and release increased levels of extracellular glutamate. Glutamine levels are lowered by sepsis, injury, burns, y and endurance exercise (Calder et al., Amino Acids, 1999). These situations put the individual at risk of 15 immunosuppression. In fact, in general, glutaminase gene expression and enzyme activity are both increased during T cell activity. Patients given glutamine following bone marrow transplantation resulted in a lower level of infection and d graft v. host disease (Crowther, Proc. Nutr. Soc., 2009). T cell proliferation and activiation is involved in many immunological diseases, such as inflammatory bowel disease, 20 Crohn’s disease, sepsis, psoriasis, arthritis (including rheumatoid tis), multiple sclerosis, graft v. host e, infections, lupus and diabetes. In an embodiment of the invention, the nds described herein can be used to treat or prevent immunological diseases. c encephalopathy (HE) represents a series of transient and reversible 25 neurologic and psychiatric dysfunction in patients with liver disease or portosystemic shunting. HE is not a single clinical entity and may reflect reversible lic encephalopathy, brain atrophy, brain edema, or a combination of these factors; however, the current hypothesis is that the accumulation of a, mostly derived from the intestine, plays a key role in the pathophysiology (Khunger etal., Clin Liver 30 Dis, 2012). The deamination of glutamine in small intestine, renal and muscle synthesis all contribute to ammonia production. Impaired hepatic clearance caused by hepatocellular nce or portosystemic shunting causes increased accumulation of ammonia. Ammonia toxicity affects astrocytes in the brain via glutamine synthetase, 23 WO 2013/078123 2012/065816 which metabolizes the ammonia to produce increased glutamine. Glutamine, in turn, attracts water into the astrocytes, leading to swelling and ive dysfunction of the mitochondria. The resulting cerebral edema is thought to contribute to neurologic dysfianction seen in HE (Kavitt et al., Clin Gastroenterol Hepatol, 2008). In an embodiment of the invention, the compounds described herein can be used to treat or prevent HE.
Primary sensory neurons in the dorsal root ganglion have been shown to elevate their glutaminase enzyme activity following inflammation (Miller et al., Pain Research and Treatment, 2012). It is believed that the resulting increased glutamate 10 production contributes to both central and peripheral sensitization, identified as pain.
An aspect of the invention is the use of the present compounds herein for the treatment or shment of pain. In certain embodiments, the pain can be neuropathic pain, chemotherapy-induced pain or atory pain.
High blood glucose levels, high insulin levels, and insulin resistance are risk 15 factors for ping diabetes mellitus. Similarly, high blood pressure is a risk factor for developing cardiovascular disease. In a recent report from a large human cohort study, these four risk factors were inversely correlated with glutamine-to- ate ratios in the blood stream (Chen et al, Circulation, 2012). Furthermore, plasma glutamine-to-glutamate ratios were inversely correlated with the eventual 20 nce of diabetes mellitus over 12 years (Cheng et al, ation, 2012). ments with animal models were consistent with these findings. Mice fed glutamine-rich diets ted lower blood glucose levels in a glucose tolerance test after 6 hours of fasting, and intraperitoneal ion of glutamine into mice rapidly decreased their blood re (Cheng et al, Circulation, 2012). Therefore, it is 25 plausible that glutaminase inhibitors, which cause increased glutamine levels and decrease glutamate levels, would decrease the incidence of diabetes mellitus and cardiovascular disease. In particular, the liver and small intestine are major sites of glutamine utilization in diabetic s, and glutaminase activity is higher than normal in these organs in streptozotocin-induced diabetic rats (Watford et al, Biochem 30 J, 1984; Mithieux et al, Am J Physiol Endrocrinol Metab, 2004). In an ment of the invention, the compounds described herein can be used to treat diabetes. In another embodiment of the invention, the present compounds can be used to reduce high blood pressure. 24 WO 2013/078123 PCT/US2012/065816 In one embodiment, the method of treating or preventing cancer, immunological and neurological diseases may comprise administering a compound of the invention conjointly with a chemotherapeutic agent. Chemotherapeutic agents that may be conjointly administered with compounds of the invention include: aminoglutethimide, amsacrine, anastrozole, asparaginase, bcg, bicalutamide, bleomycin, buserelin, busulfan, campothecin, capecitabine, carboplatin, carmustine, chlorambucil, chloroquine, tin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dichloroacetate, trol, diethylstilbestrol, 10 docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, ein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ecan, letrozole, leucovorin, lide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, 15 megestrol, melphalan, mercaptopurine, mesna, metformin, rexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, axel, onate, pentostatin, perifosine, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, sorafenib, streptozocin, sunitinib, suramin, tamoxifen, temozolomide, olimus, teniposide, testosterone, thioguanine, thiotepa, titanocene ride, 20 topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, and vinorelbine.
Many combination therapies have been developed for the treatment of cancer.
In certain embodiments, compounds of the invention may be conjointly administered with a ation therapy. Examples of combination therapies with which compounds of the invention may be conjointly administered are included in Table 1. 25 Table l: Exemplary combinatorial therapies for the treatment of cancer.
Name Therapeutic agents ABV Doxorubicin, Bleomycin, stine ABVD Doxorubicin, Bleomycin, stine, azine AC (Breast) Doxorubicin, Cyclophosphamide AC (Sarcoma) Doxorubicin, tin AC (Neuroblastoma) Cyclophosphamide, bicin ACE Cyclophosphamide, Doxorubicin, Etoposide 25 WO 2013/078123 PCT/US2012/065816 Name Therapeutic agents ACe Cyclophospharnide, Doxorubicin AD Doxorubicin, Dacarbazine AP Doxorubicin, Cisplatin ARAC-DNR Cytarabine, ubicin B-CAVe Bleomycin, Lornustine, Doxorubicin, Vinblastine BCVPP Carmustine, hospharnide, Vinblastine, Procarbazine, Prednisone BEACOPP Bleomycin, ide, Doxorubicin, Cyclophospharnide, stine, Procarbazine, Prednisone, Filgrastirn BEP Bleornycin, Etoposide, tin BIP Bleomycin, Cisplatin, Ifosfarnide, Mesna BOMP Bleomycin, Vincristine, Cisplatin, Mitornycin CA Cytarabine, Asparaginase CABO Cisplatin, Methotrexate, Bleomycin, Vincristine CAF Cyclophospharnide, Doxorubicin, Fluorouracil CAL-G Cyclophospharnide, Daunorubicin, Vincristine, Prednisone, Asparaginase CAMP Cyclophospharnide, Doxorubicin, Methotrexate, Procarbazine CAP hospharnide, Doxorubicin, Cisplatin CaT Carboplatin, Paclitaxel CAV hospharnide, Doxorubicin, Vincristine CAVE ADD CAV and Etoposide 6 Cyclophospharnide, Doxorubicin, Etoposide CC Cyclophospharnide, Carboplatin CDDP/VP-16 Cisplatin, Etoposide CEF Cyclophospharnide, Epirubicin, Fluorouracil CEPP(B) Cyclophospharnide, Etoposide, Prednisone, with or t/ Bleomycin CEV Cyclophospharnide, Etoposide, Vincristine CF Cisplatin, Fluorouracil or Carboplatin Fluorouracil 26 WO 2013/078123 PCT/US2012/065816 Name Therapeutic agents CHAP hosphamide or Cyclophosphamide, Altretamine, Doxorubicin, Cisplatin ChlVPP Chlorambucil, Vinblastine, Procarbazine, Prednisone CHOP Cyclophosphamide, Doxorubicin, stine, Prednisone CHOP-BLEO Add Bleomycin to CHOP CISCA Cyclophosphamide, Doxorubicin, tin CLD-BOMP Bleomycin, Cisplatin, Vincristine, Mitomycin CMF Methotrexate, Fluorouracil, Cyclophospharnide CMFP Cyclophosphamide, Methotrexate, Fluorouracil, Prednisone CMFVP Cyclophosphamide, Methotrexate, Fluorouracil, Vincristine, Prednisone CMV Cisplatin, Methotrexate, Vinblastine CNF Cyclophosphamide, Mitoxantrone, Fluorouracil CNOP Cyclophosphamide, Mitoxantrone, Vincristine, Prednisone COB Cisplatin, Vincristine, Bleomycin CODE Cisplatin, Vincristine, Doxorubicin, Etoposide COMLA Cyclophosphamide, stine, Methotrexate, Leucovorin, Cytarabine COMP Cyclophosphamide, stine, Methotrexate, Prednisone Cooper Regimen Cyclophosphamide, Methotrexate, uracil, Vincristine, Prednisone COP Cyclophosphamide, Vincristine, sone COPE Cyclophosphamide, Vincristine, Cisplatin, Etoposide COPP hosphamide, Vincristine, Procarbazine, Prednisone CP(Chronic Chlorambucil, Prednisone lymphocytic leukemia) CP (Ovarian Cancer) Cyclophosphamide, Cisplatin CT Cisplatin, Paclitaxel CVD tin, Vinblastine, Dacarbazine CVI Carboplatin, Etoposide, Ifosfamide, Mesna 27 WO 2013/078123 PCT/US2012/065816 Name Therapeutic agents CVP Cyclophospharnide, Vincristine, Prednisorne CVPP Lornustine, bazine, Prednisone CYVADIC Cyclophospharnide, Vincristine, Doxorubicin, Dacarbazine DA Daunorubicin, Cytarabine DAT Daunorubicin, Cytarabine, Thioguanine DAV Daunorubicin, Cytarabine, Etoposide DCT Daunorubicin, Cytarabine, Thioguanine DHAP Cisplatin, Cytarabine, Dexarnethasone DI Doxorubicin, Ifosfarnide amoxifen Dacarbazine, Tamoxifen DVP Daunorubicin, Vincristine, Prednisone EAP Etoposide, Doxorubicin, Cisplatin EC Etoposide, Carboplatin EFP Etoposie, Fluorouracil, Cisplatin ELF Etoposide, Leucovorin, Fluorouracil EMA 86 Mitoxantrone, Etoposide, Cytarabine EP Etoposide, Cisplatin EVA Etoposide, Vinblastine FAC Fluorouracil, Doxorubicin, Cyclophospharnide FAM Fluorouracil, Doxorubicin, Mitornycin FAMTX rexate, Leucovorin, Doxorubicin FAP Fluorouracil, Doxorubicin, Cisplatin F-CL Fluorouracil, Leucovorin FEC Fluorouracil, hospharnide, Epirubicin FED Fluorouracil, Etoposide, tin FL Flutarnide, lide FZ Flutarnide, Goserelin acetate implant HDMTX Methotrexate, Leucovorin Hexa-CAF arnine, Cyclophospharnide, Methotrexate, Fluorouracil 28 WO 2013/078123 PCT/US2012/065816 Name Therapeutic agents ICE-T Ifosfarnide, Carboplatin, Etoposide, Paclitaxel, Mcsna IDMTX/6-MP Mcthotrcxatc, topurinc, Lcucovorin IE Ifosfarnide, Etoposie, Mcsna IfoVP rnide, Etoposidc, Mcsna IPA Ifosfarnide, Cisplatin, Doxorubicin M-2 Vincristinc, tinc, Cyclophospharnidc, Prcdnisonc, Mclphalan MAC-III Mcthotrcxatc, Lcucovorin, Dactinornycin, hospharnide MACC Mcthotrcxatc, Doxorubicin, Cyclophospharnidc, Lornustinc MACOP-B Methotrcxatc, Leucovorin, Doxorubicin, Cyclophospharnidc, Vincristinc, Blcomycin, Prcdnisone MAID Mesna, Doxorubicin, Ifosfarnidc, Dacarbazinc m—BACOD cin, Doxorubicin, Cyclophosphamide, Vincristinc, Dcxarnethasonc, Methotrcxate, Lcucovorin MBC Methotrcxatc, Blcornycin, Cisplatin MC Mitoxantronc, Cytarabine MF Mcthotrcxatc, Fluorouracil, Lcucovorin MICE Ifosfarnide, Carboplatin, Etoposidc, Mcsna MINE Mesna, rnidc, Mitoxantronc, idc mini-BEAM Carmustinc, Etoposidc, binc, Mclphalan MOBP Blcomycin, Vincristinc, Cisplatin, Mitornycin MOP Mcchloretharninc, Vincristinc, Procarbazinc MOPP Mcchloretharninc, Vincristinc, Procarbazine, Prednisone MOPP/ABV Mcchloretharninc, Vincristinc, bazine, Prcdnisonc, Doxorubicin, Blcornycin, Vinblastinc MP (multiple Mclphalan, Prednisonc myclorna) MP (prostate cancer) Mitoxantronc, Prcdnisonc MTX/6-MO Methotrcxate, Mcrcaptopurinc 29 WO 2013/078123 PCT/US2012/065816 Name Therapeutic agents MTX/6-MP/VP Methotrexate, Mercaptopurine, Vincristine, Prednisone MTX-CDDPAdr Methotrexate, Leucovorin, Cisplatin, Doxorubicin MV (breast cancer) cin, Vinblastine MV (acute myelocytic Mitoxantrone, Etoposide leukemia) M-VAC Methotrexate Vinblastine, Doxorubicin, tin MVP Mitornycin Vinblastine, Cisplatin MVPP Mechloretharnine, Vinblastine, Procarbazine, Prednisone NFL Mitoxantrone, uracil, Leucovorin NOVP Mitoxantrone, Vinblastine, Vincristine OPA Vincristine, Prednisone, Doxorubicin OPPA Add bazine to OPA.
PAC Cisplatin, Doxorubicin PAC-I Cisplatin, Doxorubicin, Cyclophospharnide PA-CI Cisplatin, bicin PC Paclitaxel, Carboplatin or axel, Cisplatin PCV Lornustine, Procarbazine, Vincristine PE Paclitaxel, Estrarnustine PFL Cisplatin, Fluorouracil, Leucovorin POC sone, Vincristine, Lornustine ProMACE Prednisone, Methotrexate, Leucovorin, Doxorubicin, Cyclophospharnide, Etoposide ProMACE/cytaBOM Prednisone, Doxorubicin, Cyclophospharnide, Etoposide, bine, Bleornycin, Vincristine, Methotrexate, Leucovorin, Cotrirnoxazole PRoMACE/MOPP Prednisone, Doxorubicin, Cyclophospharnide, Etoposide, Mechlorethamine, Vincristine, Procarbazine, rexate, Leucovorin Pt/VM Cisplatin, Teniposide PVA Prednisone, Vincristine, Asparaginase PVB Cisplatin, stine, Bleomycin 30 WO 2013/078123 2012/065816 Name Therapeutic agents PVDA Prednisone, Vincristine, Daunorubicin, Asparaginase SMF ozocin, Mitomycin, Fluorouracil TAD Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, Prednisone TCF Paclitaxel, Cisplatin, Fluorouracil TIP axel, Ifosfarnide, Mesna, Cisplatin TTT Methotrexate, Cytarabine, Hydrocortisone Topo/CTX Cyclophospharnide, Topotecan, Mesna VAB-6 Cyclophospharnide, Dactinomycin, Vinblastine, Cisplatin, Bleomycin VAC Vincristine, Dactinomycin, Cyclophosphamide VACAdr Vincristine, Cyclophospharnide, Doxorubicin, Dactinomycin, stine VAD Vincristine, Doxorubicin, thasone VATH Vinblastine, Doxorubicin, Thiotepa, Flouxymesterone VBAP Vincristine, Carmustine, Doxorubicin, Prednisone VBCMP Vincristine, Carmustine, Melphalan, Cyclophosphamide, Prednisone VC Vinorelbine, Cisplatin VCAP Vincristine, Cyclophospharnide, Doxorubicin, Prednisone VD Vinorelbine, Doxorubicin VelP Vinblastine, Cisplatin, rnide, Mesna VIP Etoposide, Cisplatin, rnide, Mesna cin, Vinblastine Vincristine, Melphalan, Cyclophospharnide, Prednisone Etoposide, Cisplatin Etoposide, Thioguanine, Daunorubicin, Cytarabine bine, Daunorubicin, Mitoxantrone Cytarabine with/, Daunorubicin or Idarubicin or Mitoxantrone Methylprednisolone, Vincristine, Lornustine, 31 WO 2013/078123 PCT/US2012/065816 bazine, Hydroxyurea, Cisplatin, Cytarabine, Dacarbazine The proliferation of cancer cells requires lipid sis. Normally, acetyl- coA used for lipid synthesis is formed from a mitochondrial pool of pyruvate that is derived from glycolysis. Yet under hypoxic conditions, such as those ly found in a tumor environment, the sion of pyruvate to acetyl-coA within the mitochondria is downregulated. Recent studies from Metallo et al. (2011) and Mullen et al. (2011) revealed that under such hypoxic conditions, cells instead largely switch to using a pathway involving the reductive carboxylation of alpha-ketoglutarate to make acetyl-coA for lipid synthesis. The first step in this pathway involves converting glutamine to ate via glutaminase enzymes. Subsequently, glutamate is 10 converting to alpha-ketoglutarate, and the resulting alpha-ketoglutarate is ted to rate in a reductive carboxylation step mediated by the isocitrate dehydrogenase enzymes. A switch to this reductive carboxylation y also occurs in some renal oma cell lines that contain either impaired mitochondria or an impaired signal for induction of the enzyme responsible for converting glycolytic pyruvate to acetyl- 15 coA (Mullen et al 2011). A similar switch occurs in cells exposed to mitochondrial respiratory chain inhibitors such as metformin, rotenone, and antimycin (Mullen at al. 2011). Therefore, in some ments of this invention, we propose using combinations of mitochondrial respiratory chain inhibitors and glutaminase inhibitors to simultaneously increase cancer cells’ dependence on glutaminase-dependent 20 pathways for lipid synthesis while inhibiting those very pathways.
The sed dependence on glycolysis in tumor cells is likely because the hypoxic tumor nment impairs mitochondrial respiration. Furthermore, depletion of glucose s apoptosis in cells transformed with the MYC oncogene.
These findings suggest that inhibiting glycolysis would have a therapeutic value in 25 preventing cancer cell proliferation. There are currently many documented ytic inhibitors (Pelicano et al. 2006). However, as pointed out by Zhao et al. (2012), “available glycolytic inhibitors are generally not very potent, and high doses are required, which may cause high levels of systemic toxicity.” Since cancer cells typically use both glucose and glutamine at higher levels than normal cells, impairing 32 WO 2013/078123 PCT/US2012/065816 utilization of each of those metabolites will likely have a synergistic effect.
Therefore, in some embodiments of this invention, we e using combinations of glycolytic pathway inhibitors and glutaminase inhibitors. Such glycolytic inhibitors include 2-deoxyglucose, lonidamine, 3-bromopyruvate, ib, oxythiamine, rapamycin, and their pharmacological equivalents. Glycolysis can be inhibited indirectly by ing NAD+ via DNA damage induced by DNA alkylating agents through a pathway activated by poly(ADP-ribose) polymerase (Zong et al. 2004).
Therefore, in one embodiment of this ion, we propose using a combination of DNA alkylating agents and glutaminase inhibitors. Cancer cells use the pentose 10 phosphate pathway along with the ytic y to create metabolic intermediates derived from glucose. Therefore, in another embodiment of this ion, we propose using a combination of pentose phosphate inhibitors such as 6- aminonicotinamide along with glutaminase inhibitors.
In certain embodiments, a compound of the invention may be conjointly 15 administered with non-chemical methods of cancer treatment. In n embodiments, a compound of the invention may be conjointly administered with radiation therapy. In certain embodiments, a compound of the invention may be conjointly administered with surgery, with thermoablation, with focused ound therapy, with cryotherapy, or with any combination of these. 20 In certain embodiments, different compounds of the invention may be conjointly administered with one or more other compounds of the invention.
Moreover, such combinations may be conjointly administered with other therapeutic agents, such as other agents suitable for the treatment of cancer, logical or neurological es, such as the agents identified above. 25 In certain embodiments, the present invention provides a kit comprising: a) one or more single dosage forms of a compound of the invention; b) one or more single dosage forms of a chemotherapeutic agent as mentioned above; and c) instructions for the administration of the compound of the ion and the chemotherapeutic agent. 30 The present ion provides a kit comprising: a) a pharmaceutical formulation (e. g., one or more single dosage forms) comprising a compound of the invention; and 33 WO 2013/078123 PCT/US2012/065816 b) instructions for the administration of the pharmaceutical formulation, e.g., for treating or preventing any of the conditions discussed above.
In certain embodiments, the kit further ses instructions for the administration of the ceutical formulation comprising a compound of the invention conjointly with a chemotherapeutic agent as mentioned above. In n embodiments, the kit fiarther comprises a second pharmaceutical formulation (e.g., as one or more single dosage forms) comprising a chemotherapeutic agent as mentioned above.
Definitions 10 The term “acyl” is art-recognized and refers to a group represented by the general formula hydrocarble(O)—, preferably alkle(O)-.
The term “acylamino” is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarble(O)NH-. 15 The term “acyloxy” is art-recognized and refers to a group represented by the general formula hydrocarble(O)O-, preferably alkle(O)O-.
The term “alkoxy” refers to an alkyl group, preferably a lower alkyl group, having an oxygen attached thereto. Representative alkoxy groups include methoxy, ethoxy, y, tert—butoxy and the like. 20 The term “alkoxyalkyl” refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O-alkyl.
The term “alkenyl”, as used herein, refers to an aliphatic group containing at least one double bond and is intended to include both "unsubstituted alkenyls" and "substituted alkenyls", the latter of which refers to alkenyl moieties having 25 substituents replacing a hydrogen on one or more carbons of the l group. Such substituents may occur on one or more carbons that are included or not included in one or more double bonds. Moreover, such tuents include all those contemplated for alkyl groups, as discussed below, except where stability is prohibitive. For example, substitution of alkenyl groups by one or more alkyl, 30 carbocyclyl, aryl, heterocyclyl, or aryl groups is contemplated.
An “alkyl” group or “alkane” is a ht chained or branched omatic arbon which is completely saturated. lly, a straight chained or branched alkyl group has from 1 to about 20 carbon atoms, preferably from 1 to about 10 unless 34 WO 2013/078123 PCT/US2012/065816 otherwise . Examples of straight chained and branched alkyl groups include methyl, ethyl, yl, iso-propyl, n-butyl, sec-butyl, utyl, pentyl, hexyl, pentyl and octyl. A C1-C6 straight chained or branched alkyl group is also referred to as a "lower alkyl" group.
Moreover, the term "alkyl" (or "lower alkyl") as used throughout the specification, examples, and claims is intended to include both "unsubstituted " and "substituted ", the latter of which refers to alkyl moieties haVing tuents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents, if not otherwise specified, can include, for e, a 10 halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a , or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, 15 or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the arbon chain can themselves be substituted, if appropriate. For instance, the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, 20 sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), -CF3, -CN and the like. ary substituted alkyls are bed below. Cycloalkyls can be further substituted with alkyls, alkenyls, s, alkylthios, aminoalkyls, carbonyl- substituted alkyls, -CF3, -CN, and the like. 25 The term “CH” when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain. For example, the term “Cx_yalkyl” refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that n from x to y carbons in the chain, 30 including haloalkyl groups such as trifluoromethyl and tirfiuoroethyl, etc. C0 alkyl indicates a hydrogen where the group is in a terminal position, a bond if internal.
The terms “C2_yalkenyl” and “C2_yalkynyl” refer to substituted or unsubstituted 35 WO 78123 PCT/US2012/065816 unsaturated aliphatic groups analogous in length and possible tution to the alkyls described above, but that contain at least one double or triple bond respectively.
The term “alkylamino”, as used herein, refers to an amino group substituted with at least one alkyl group.
The term “alkylthio”, as used herein, refers to a thiol group substituted with an alkyl group and may be ented by the general formula alkylS-.
The term “alkynyl”, as used herein, refers to an aliphatic group containing at least one triple bond and is intended to include both "unsubstituted alkynyls" and "substituted alkynyls", the latter of which refers to alkynyl moieties having 10 tuents replacing a hydrogen on one or more carbons of the alkynyl group. Such substituents may occur on one or more carbons that are included or not included in one or more triple bonds. Moreover, such substituents include all those contemplated for alkyl groups, as sed above, except where stability is prohibitive. For example, substitution of alkynyl groups by one or more alkyl, carbocyclyl, aryl, 15 heterocyclyl, or heteroaryl groups is contemplated.
The term “amide”, as used , refers to a group 0 A /R10 \ N \R’IO wherein each R10 independently represent a hydrogen or hydrocarbyl group, or two R10 are taken together with the N atom to which they are attached complete a 20 heterocycle having from 4 to 8 atoms in the ring structure.
The terms “amine” and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by R10 R10 / / _N\ _N{_R10 R10 01' R10 25 n each R10 independently represents a en or a hydrocarbyl group, or two R10 are taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
The term “aminoalkyl”, as used herein, refers to an alkyl group substituted with an amino group. 36 WO 2013/078123 PCT/US2012/065816 The term “aralkyl”, as used herein, refers to an alkyl group substituted with an aryl group.
The term “aryl” as used herein include tuted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. Preferably the ring is a 5- to 7-membered ring, more preferably a 6-membered ring. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more s are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Aryl groups e benzene, naphthalene, 10 phenanthrene, phenol, aniline, and the like.
The term “carbamate” is cognized and refers to a group O O HKOAN’R“) or RLNAO’R“) R9 R9 wherein R9 and R10 independently ent hydrogen or a hydrocarbyl group, such as an alkyl group, or R9 and R10 taken together with the intervening atom(s) complete a 15 heterocycle haVing from 4 to 8 atoms in the ring structure.
The terms “carbocycle”, and cyclic”, as used herein, refers to a saturated or unsaturated ring in which each atom of the ring is . The term carbocycle includes both aromatic carbocycles and non-aromatic carbocycles. Non- aromatic carbocycles include both cycloalkane rings, in which all carbon atoms are 20 ted, and cycloalkene rings, which contain at least one double bond.
“Carbocycle” includes 5-7 membered monocyclic and 8-12 membered bicyclic rings.
Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated and aromatic rings. Carbocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings. The term “fused carbocycle” refers to a 25 bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring. Each ring of a fused carbocycle may be selected from saturated, unsaturated and aromatic rings. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated and 30 aromatic bicyclic rings, as valence permits, is included in the tion of carbocyclic. Exemplary “carbocycles” include entane, cyclohexane, 37 WO 2013/078123 PCT/US2012/065816 bicyclo[2.2. ane, l ,5-cyclooctadiene, l ,2,3 ,4-tetrahydronaphthalene, bicyclo[4.2.0]octene, naphthalene and adamantane. Exemplary fused ycles include decalin, naphthalene, l,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-lH-indene and bicyclo[4. l .0]heptene. “Carbocycles” may be susbstituted at any one or more positions capable of bearing a hydrogen atom.
A alkyl” group is a cyclic hydrocarbon which is completely saturated.
“Cycloalkyl” includes clic and bicyclic rings. Typically, a monocyclic lkyl group has from 3 to about 10 carbon atoms, more typically 3 to 8 carbon atoms unless ise defined. The second ring of a bicyclic cycloalkyl may be 10 selected from saturated, unsaturated and aromatic rings. Cycloalkyl includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings.
The term “fused cycloalkyl” refers to a bicyclic cycloalkyl in which each of the rings shares two adjacent atoms with the other ring. The second ring of a fused bicyclic lkyl may be selected from saturated, unsaturated and aromatic rings. A 15 “cycloalkenyl” group is a cyclic hydrocarbon containing one or more double bonds.
The term “carbocyclylalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.
The term nate” is art-recognized and refers to a group -OCOz-R10, wherein R10 represents a hydrocarbyl group. 20 The term “carboxy”, as used herein, refers to a group represented by the formula -C02H.
The term “ester”, as used herein, refers to a group -C(O)OR10 wherein R10 represents a hydrocarbyl group.
The term “ether”, as used herein, refers to a hydrocarbyl group linked through 25 an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O-. Ethers may be either rical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O- cycle and aryl-O-heterocycle. Ethers include “alkoxyalkyl” groups, which may be represented by the l formula alkyl-O-alkyl. 30 The terms “halo” and “halogen” as used herein means halogen and includes chloro, fluoro, bromo, and iodo.
The terms “hetaralkyl” and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group. 3 8 WO 2013/078123 PCT/US2012/065816 The term "heteroalkyl", as used herein, refers to a saturated or unsaturated chain of carbon atoms and at least one heteroatom, wherein no two heteroatoms are adjacent.
The terms “heteroaryl” and “hetaryl” e substituted or unsubstituted aromatic single ring ures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring ures include at least one atom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms “heteroaryl” and “hetaryl” also include polycyclic ring systems haVing two or more cyclic rings in which two or more carbons are common to two adjoining rings 10 wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. aryl groups include, for e, pyrrole, filran, thiophene, imidazole, e, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
The term “heteroatom” as used herein means an atom of any element other 15 than carbon or hydrogen. red heteroatoms are nitrogen, oxygen, and sulfur.
The terms “heterocyclyl”, “heterocycle”, and “heterocyclic” refer to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10- membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably 20 one or two heteroatoms. The terms “heterocyclyl” and “heterocyclic” also include polycyclic ring systems haVing two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Heterocyclyl groups e, 25 for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
The term “heterocyclylalkyl”, as used , refers to an alkyl group substituted with a heterocycle group.
The term “hydrocarbyl”, as used herein, refers to a group that is bonded 30 through a carbon atom that does not have a =0 or =S substituent, and lly has at least one carbon-hydrogen bond and a primarily carbon backbone, but may optionally include heteroatoms. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered to be hydrocarbyl for the purposes of this application, 39 WO 2013/078123 PCT/US2012/065816 but substituents such as acetyl (which has a =0 substituent on the linking carbon) and ethoxy (which is linked through oxygen, not carbon) are not. Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocyclyl, alkyl, l, alkynyl, and combinations thereof.
The term “hydroxyalkyl”, as used herein, refers to an alkyl group substituted with a hydroxy group.
The term “lower” when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer non-hydrogen atoms in the substituent, preferably six or fewer. 10 A “lower alkyl”, for example, refers to an alkyl group that contains ten or fewer carbon atoms, preferably six or fewer. In certain embodiments, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy tuents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower , whether they appear alone or in combination with other substituents, such as in the recitations 15 hydroxyalkyl and l (in which case, for example, the atoms within the aryl group are not d when counting the carbon atoms in the alkyl substituent).
The terms “polycyclyl”, “polycycle”, and “polycyclic” refer to two or more rings (e. g., lkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls) in which two or more atoms are common to two adjoining rings, e. g., 20 the rings are “fiJsed rings”. Each of the rings of the polycycle can be substituted or unsubstituted. In certain embodiments, each ring of the polycycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.
The term “silyl” refers to a silicon moiety with three hydrocarbyl moieties attached thereto. 25 The term “substituted” refers to moieties having tuents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or ituted with” includes the implicit proviso that such tution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not 30 spontaneously o transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to e all permissible substituents of organic compounds. In a broad aspect, the permissible substituents e acyclic and cyclic, branched and unbranched, carbocyclic and 40 WO 2013/078123 PCT/US2012/065816 heterocyclic, aromatic and non-aromatic substituents of c compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have en substituents and/or any permissible substituents of organic nds described herein which y the valences of the heteroatoms.
Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a rmate), an alkoxyl, a oryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an 10 amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that tuents can themselves be substituted, if appropriate. Unless specifically stated as “unsubstituted,” references to chemical moieties herein are tood to 15 include substituted variants. For example, reference to an “aryl” group or moiety implicitly includes both substituted and unsubstituted variants.
The term “sulfate” is art-recognized and refers to the group -OSOgH, or a pharmaceutically acceptable salt thereof.
The term namide” is art-recognized and refers to the group represented 20 by the general formulae R10 9 IR10 S—fi—N‘ O\\S’\ or R9 §__N, ‘O O \R9 wherein R9 and R10 independently represents hydrogen or hydrocarbyl, such as alkyl, or R9 and R10 taken together with the intervening atom(s) complete a heterocycle having from 4 to 8 atoms in the ring ure. 25 The term “sulfoxide” is cognized and refers to the group -S(O)-R10, wherein R10 represents a hydrocarbyl.
The term “sulfonate” is art-recognized and refers to the group SOgH, or a pharmaceutically acceptable salt f.
The term “sulfone” is art-recognized and refers to the group -S(O)2-R10 , 30 wherein R10 represents a hydrocarbyl. 4l WO 2013/078123 2012/065816 The term “thioalkyl”, as used herein, refers to an alkyl group substituted with a thiol group.
The term “thioester”, as used herein, refers to a group -C(O)SR10 or -SC(O)R10 wherein R10 represents a hydrocarbyl.
The term “thioether”, as used , is equivalent to an ether, wherein the oxygen is replaced with a sulfilr.
The term “urea” is art-recognized and may be ented by the general formula 0 :‘iNilfi’Rm R9 R9 10 wherein R9 and R10 independently represent hydrogen or a arbyl, such as alkyl, or either occurrence of R9 taken together with R10 and the ening ) complete a heterocycle having from 4 to 8 atoms in the ring structure.
“Protecting group” refers to a group of atoms that, when attached to a reactive functional group in a molecule, mask, reduce or prevent the reactivity of the 15 functional group. Typically, a protecting group may be selectively removed as desired during the course of a synthesis. Examples of protecting groups can be found in Greene and Wuts, Protective Groups in Organic try, 3rd Ed., 1999, John Wiley & Sons, NY and Harrison et al., dium ofSynthetic Organic Methods, Vols. 1- 8, 1971-1996, John Wiley & Sons, NY. Representative nitrogen protecting groups 20 include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (“CBZ”), tert-butoxycarbonyl ), trimethylsilyl (“TMS”), 2- trimethylsilyl-ethanesulfonyl (“TES”), trityl and substituted trityl groups, xycarbonyl, enylmethyloxycarbonyl (“FMOC”), nitroveratryloxycarbonyl (“NVOC”) and the like. Representative hydroxylprotecting 25 groups include, but are not limited to, those where the hydroxyl group is either acylated (esterif1ed) or alkylated such as benzyl and trityl ethers, as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers (e. g., TMS or TIPS groups), glycol ethers, such as ethylene glycol and propylene glycol derivatives and allyl ethers. 30 The term "healthcare providers" refers to individuals or organizations that provide healthcare services to a person, community, etc. Examples of "healthcare 42 WO 2013/078123 PCT/US2012/065816 ers" include doctors, hospitals, continuing care retirement communities, skilled nursing facilities, subacute care ties, clinics, multispecialty clinics, freestanding ambulatory centers, home health agencies, and HMO's.
As used herein, a therapeutic that nts” a disorder or ion refers to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.
The term “treating” includes prophylactic and/or therapeutic treatments. The 10 term “prophylactic or therapeutic” treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the ed condition (e.g., disease or other unwanted state of the host animal) then the ent is prophylactic (i.e., it protects the host against developing the unwanted condition), whereas if it is 15 administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, rate, or stabilize the existing unwanted condition or side s thereof).
The term “prodrug” is intended to encompass compounds which, under physiologic conditions, are converted into the therapeutically active agents of the 20 present invention (e.g., a compound of formula I). A common method for making a g is to include one or more selected moieties which are hydrolyzed under logic ions to reveal the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of the host animal. For example, esters or carbonates (e. g., esters or carbonates of alcohols or carboxylic acids) are preferred 25 prodrugs of the present invention. In certain embodiments, some or all of the compounds of a I in a formulation represented above can be replaced with the corresponding suitable g, e.g., wherein a hydroxyl in the parent compound is presented as an ester or a carbonate or carboxylic acid present in the parent compound is presented as an ester. 30 Pharmaceutical Compositions The itions and s of the present invention may be utilized to treat an individual in need thereof In certain embodiments, the individual is a mammal such as a human, or a non-human mammal. When administered to an 43 WO 2013/078123 PCT/US2012/065816 animal, such as a human, the composition or the compound is ably administered as a pharmaceutical composition comprising, for example, a compound of the invention and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters. In a red embodiment, when such pharmaceutical compositions are for human administration, particularly for invasive routes of administration (i.e., routes, such as injection or implantation, that circumvent transport or diffilsion through an epithelial barrier), the 10 aqueous solution is pyrogen-free, or substantially n-free. The excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in dosage unit form such as tablet, capsule (including sprinkle capsule and gelatin capsule), granule, lyophile for reconstitution, powder, on, syrup, suppository, injection or 15 the like. The composition can also be t in a transdermal delivery system, e. g., a skin patch. The composition can also be present in a solution suitable for topical administration, such as an eye drop.
A pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, se lity or to se the 20 absorption of a nd such as a compound of the invention. Such physiologically acceptable agents e, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low lar weight proteins or other stabilizers or excipients. The choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent, 25 depends, for example, on the route of administration of the composition. The preparation or pharmaceutical composition can be a selfemulsifying drug delivery system or a icroemulsifying drug ry system. The pharmaceutical composition (preparation) also can be a liposome or other polymer matrix, which can have incorporated therein, for example, a nd of the invention. Liposomes, for 30 example, which comprise phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer. 44 WO 2013/078123 PCT/US2012/065816 The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The phrase "pharmaceutically able carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the 10 formulation and not injurious to the t. Some examples of materials which can serve as ceutically acceptable rs include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) ed tragacanth; (5) malt; (6) gelatin; (7) talc; (8) 15 ents, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (l l) polyols, such as in, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (l3) agar; (l4) buffering agents, such as magnesium hydroxide and aluminum ide; (15) 20 alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible nces employed in pharmaceutical formulations.
A pharmaceutical composition (preparation) can be administered to a subject by any of a number of routes of administration including, for example, orally (for 25 example, drenches as in aqueous or non-aqueous solutions or suspensions, s, capsules ding sprinkle capsules and gelatin capsules), boluses, powders, es, pastes for application to the tongue); absorption through the oral mucosa (e.g., sublingually); anally, ly or vaginally (for e, as a pessary, cream or foam); parenterally (including intramuscularly, intravenously, subcutaneously or 30 intrathecally as, for example, a sterile solution or suspension); nasally; intraperitoneally; subcutaneously; transdermally (for example as a patch applied to the skin); and topically (for example, as a cream, nt or spray applied to the skin, or as an eye drop). The compound may also be ated for inhalation. In certain 45 WO 2013/078123 PCT/US2012/065816 embodiments, a nd may be simply dissolved or suspended in sterile water.
Details of appropriate routes of administration and compositions suitable for same can be found in, for example, US. Pat. Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, as well as in patents cited therein.
The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier 10 material to e a single dosage form will generally be that amount of the nd which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 t to about ninety-nine percent of active ient, preferably from about 5 percent to about 70 t, most preferably from about 10 percent to about 30 percent. 15 Methods of preparing these formulations or compositions include the step of bringing into association an active compound, such as a compound of the invention, with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by mly and intimately bringing into ation a compound of the present invention with liquid carriers, or finely d solid 20 carriers, or both, and then, if necessary, shaping the product.
Formulations of the invention suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), lyophile, powders, granules, or as a solution or a suspension in an aqueous or non- 25 aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each ning a ermined amount of a compound of the present invention as an active ingredient. Compositions or compounds may also be administered as a bolus, ary or paste. 30 To prepare solid dosage forms for oral administration (capsules (including le capsules and n capsules), tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more ceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: 46 WO 2013/078123 PCT/US2012/065816 (l) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) on retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium nds; (7) wetting , such as, for example, cetyl alcohol and glycerol earate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, ium stearate, solid polyethylene 10 glycols, sodium lauryl sulfate, and mixtures thereof; (10) xing agents, such as, ed and fied cyclodextrins; and (ll) coloring agents. In the case of capsules (including sprinkle capsules and gelatin capsules), tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a r type may also be employed as fillers in soft and hard-filled gelatin 15 capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, 20 preservative, disintegrant (for example, sodium starch ate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
The tablets, and other solid dosage forms of the pharmaceutical compositions, 25 such as dragees, capsules (including sprinkle capsules and gelatin capsules), pills and granules, may ally be scored or prepared with coatings and , such as enteric coatings and other coatings well known in the pharmaceutical-formulating art.
They may also be formulated so as to provide slow or controlled e of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying 30 proportions to provide the desired release proflle, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by orating izing agents in the form of sterile solid compositions that can be ved in sterile water, or some other sterile 47 WO 2013/078123 PCT/US2012/065816 inj ectable medium immediately before use. These itions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed . Examples of embedding compositions that can be used e polymeric substances and waxes. The active ient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, 10 suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, cyclodextrins and tives thereof, solubilizing agents and emulsifiers, such as ethyl l, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, l,3-butylene glycol, oils (in 15 particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, fying and suspending agents, sweetening, flavoring, 20 coloring, perfiaming and preservative agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, rystalline cellulose, aluminum metahydroxide, bentonite, agar- agar and tragacanth, and mixtures thereof 25 Formulations of the pharmaceutical compositions for rectal, vaginal, or urethral administration may be presented as a suppository, which may be ed by mixing one or more active compounds with one or more suitable itating excipients or carriers sing, for example, cocoa , polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at 30 body temperature and, therefore, will melt in the rectum or vaginal cavity and e the active compound.
Formulations of the pharmaceutical compositions for administration to the mouth may be presented as a mouthwash, or an oral spray, or an oral ointment. 48 WO 2013/078123 PCT/US2012/065816 Alternatively or additionally, itions can be formulated for delivery via a er, stent, wire, or other intraluminal device. Delivery via such devices may be especially useful for delivery to the bladder, urethra, ureter, rectum, or intestine.
Formulations which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such rs as are known in the art to be appropriate.
Dosage forms for the topical or transdermal administration include s, , ointments, pastes, creams, lotions, gels, solutions, patches and nts. The active nd may be mixed under sterile conditions with a pharmaceutically 10 acceptable carrier, and with any preservatives, s, or propellants that may be required.
The ointments, pastes, creams and gels may contain, in addition to an active compound, ents, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, hylene glycols, silicones, bentonites, 15 silicic acid, talc and zinc oxide, or mixtures thereof Powders and sprays can contain, in addition to an active compound, ents such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted 20 hydrocarbons, such as butane and propane.
Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the active compound in the proper medium.
Absorption enhancers can also be used to increase the flux of the nd across 25 the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention. Exemplary ophthalmic formulations are described in US. Publication Nos. 2005/0080056, 2005/0059744, 30 2005/0031697 and 2005/004074 and US. Patent No. 6,583,124, the contents of which are orated herein by reference. If desired, liquid ophthalmic formulations have ties similar to that of lacrimal fluids, aqueous humor or vitreous humor or are compatable with such fluids. A preferred route of administration is local 49 WO 2013/078123 PCT/US2012/065816 administration (e.g., topical administration, such as eye drops, or stration via an implant).
The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical stration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion. ceutical compositions suitable for parenteral administration comprise 10 one or more active compounds in combination with one or more pharmaceutically acceptable e isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile inj ectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the 15 intended recipient or suspending or thickening agents.
Examples of suitable aqueous and nonaqueous carriers that may be employed in the ceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene , and the like), and suitable mixtures f, ble oils, such as olive oil, and injectable organic esters, such 20 as ethyl oleate. Proper fluidity can be maintained, for example, by the use of g als, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of 25 microorganisms may be ensured by the inclusion of various cterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In on, prolonged absorption of the inj ectable pharmaceutical form may be brought about by the inclusion of agents that 30 delay absorption such as um earate and gelatin.
In some cases, in order to g the effect of a drug, it is desirable to slow the tion of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material 50 WO 78123 PCT/US2012/065816 having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form.
Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Inj ectable depot forms are made by forming microencapsulated matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide.
Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. es of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot inj e 10 formulations are also ed by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
For use in the methods of this invention, active compounds can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in ation with a pharmaceutically 15 acceptable carrier.
Methods of introduction may also be provided by rechargeable or radable s. Various slow release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinacious biopharmaceuticals. A variety of biocompatible polymers (including 20 hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a compound at a particular target site.
Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, 25 composition, and mode of stration, without being toxic to the patient.
The selected dosage level will depend upon a variety of factors including the activity of the particular nd or ation of compounds employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound(s) being employed, the duration of the 30 treatment, other drugs, compounds and/or als used in combination with the particular compound(s) employed, the age, sex, weight, condition, general health and prior medical y of the patient being d, and like factors well known in the medical arts. 51 WO 2013/078123 PCT/US2012/065816 A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the therapeutically effective amount of the pharmaceutical ition required. For example, the physician or veterinarian could start doses of the pharmaceutical ition or compound at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. By “therapeutically effective amount” is meant the concentration of a compound that is sufficient to elicit the desired therapeutic effect.
It is generally understood that the ive amount of the compound will vary according to the weight, sex, age, and l history of the subject. Other factors 10 which influence the effective amount may include, but are not limited to, the severity of the t's condition, the disorder being treated, the stability of the compound, and, if desired, another type of therapeutic agent being stered with the compound of the invention. A larger total dose can be delivered by multiple administrations of the agent. Methods to determine efficacy and dosage are known to 15 those skilled in the art bacher et al. (1996) Harrison’s Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated by reference).
In general, a suitable daily dose of an active compound used in the compositions and methods of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will 20 generally depend upon the factors described above.
If desired, the effective daily dose of the active compound may be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate als throughout the day, optionally, in unit dosage forms. In certain ments of the present invention, the active compound may be 25 administered two or three times daily. In preferred embodiments, the active compound will be administered once daily.
The patient ing this treatment is any animal in need, including primates, in particular humans, and other mammals such as s, cattle, swine and sheep; and poultry and pets in general. 30 In certain embodiments, compounds of the invention may be used alone or conjointly administered with another type of therapeutic agent. As used herein, the phrase “conjoint administration” refers to any form of stration of two or more ent therapeutic compounds such that the second compound is administered while 52 WO 2013/078123 2012/065816 the previously administered therapeutic compound is still effective in the body (e.g., the two compounds are simultaneously ive in the patient, which may include istic effects of the two compounds). For example, the different therapeutic compounds can be administered either in the same formulation or in a separate formulation, either concomitantly or sequentially. In certain embodiments, the different therapeutic nds can be administered within one hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, or a week of one another. Thus, an individual who receives such treatment can benefit from a ed effect of different therapeutic compounds. 10 This invention includes the use of pharmaceutically acceptable salts of compounds of the invention in the compositions and methods of the present ion.
In certain embodiments, contemplated salts of the invention include, but are not limited to, alkyl, dialkyl, trialkyl or alkyl ammonium salts. In certain embodiments, plated salts of the invention include, but are not limited to, L- 15 arginine, benenthamine, benzathine, betaine, calcium hydroxide, e, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N—methylglucamine, hydrabamine, lH-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, l-(2- hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts. In 20 certain ments, contemplated salts of the invention include, but are not limited to, Na, Ca, K, Mg, Zn or other metal salts.
The pharmaceutically acceptable acid addition salts can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, and the like.
Mixtures of such solvates can also be ed. The source of such solvate can be 25 from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent.
Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, e agents, coating agents, sweetening, flavoring and perfilming agents, preservatives and idants can also 30 be t in the compositions.
Examples of pharmaceutically acceptable idants include: (1) water- soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as 53 WO 2013/078123 PCT/US2012/065816 ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
In certain embodiments, the invention relates to a method for conducting a pharmaceutical business, by manufacturing a formulation of a compound of the ion, or a kit as described herein, and marketing to healthcare providers the s of using the formulation or kit for treating or preventing any of the diseases or conditions as described herein. 10 In certain embodiments, the invention relates to a method for conducting a ceutical ss, by providing a distribution network for selling a formulation of a compound of the invention, or kit as bed herein, and providing instruction material to patients or physicians for using the formulation for treating or preventing any of the diseases or conditions as described herein. 15 In certain ments, the ion ses a method for conducting a pharmaceutical ss, by determining an appropriate formulation and dosage of a compound of the invention for treating or preventing any of the diseases or conditions as described herein, conducting therapeutic profiling of identified formulations for efficacy and toxicity in animals, and providing a distribution network for selling an 20 identified preparation as having an acceptable therapeutic profile. In certain embodiments, the method further includes providing a sales group for marketing the ation to healthcare providers.
In certain embodiments, the invention s to a method for conducting a pharmaceutical business by determining an appropriate ation and dosage of a 25 nd of the invention for treating or preventing any of the disease or conditions as described herein, and licensing, to a third party, the rights for further development and sale of the formulation.
Examples Example 1: Synthetic Protocols 30 Synthesis OZ linker cores: 5 ,5'-(butane- l l)-bis(l ,3 ,4-thiadiazolamine) (1001) 54 WO 2013/078123 PCT/US2012/065816 N//M\\N S + JL HZNKSMSfNHZ H2N NHNH2 N’N N1N 1001 A mixture of adiponitrile (8.00 g, 73.98 mmol) and thiosemicarbazide (13.48 g, 147.96 mmol) in trifluoroacetic acid (TFA) (75 mL) was heated at 80 0C for 17 hours.
The on was cooled to room temperature and poured into a mixture of ice and water. Sodium hydroxide pellets were added to the mixture until it was basic (pH 14).
The white precipitate was collected by suction filtration, rinsed with water and dried to provide 5,5'-(butane-1,4-diyl)-bis(1,3,4-thiadiazolamine) (1001, 13.07 g). 1H NMR (300 MHz, DMSO-d6) 8 7.00 (s, 4H), 2.84 (bs, 4H), 1.68 (bs, 4H).
Synthesis of 5,5'-(thiobis(ethane-2,1-diyl))bis(1,3,4-thiadiazolamine) (1002) 10 Compound 1002 was prepared as described in US/2002/0115698 A1 5 ,5 '-(2-methylbutane- 1 ,4-diyl)-bis(1 ,3 ,4-thiadiazolamine) (1 003) HOmOH 8 S S + 1 «M? H2N NHNH2 N/N N\N 1003 A mixture of 3-methyl adipic acid (5.00 g, 31.22 mmol) and thiosemicarbazide (5.69 15 g, 62.43 mmol) in POC13 (45 mL) was heated at 90 0C for 4 h. The reaction was cooled to room temperature and poured into a mixture of ice and water. Sodium hydroxide pellets were added to the mixture until it was basic (pH 14). The white itate was ted by suction ion, rinsed with water and dried to e 5,5'-(2-methylbutane-1,4-diyl)-bis(1,3,4-thiadiazolamine) (1003, 8.97 g). 1H NMR 20 (300 MHz, DMSO-d6) 8 7.00 (s, 4H), 2.89—2.81 (m, 3H), 2.89—2.81 (m, 3H), 2.69 (dd, J: 7.6, 7.6 Hz, 1H), 1.89—1.46 (m, 3H), 0.94 (d, J: 6.6 Hz, 3H). 5 ,5'-(propane-1,3-diyl)-bis(1,3 ,4-thiadiazolamine) (1004) 55 WO 2013/078123 2012/065816 A mixture of glutaronitrile (5.00 g, 53.13 mmol) and thiosemicarbazide (9.68 g, 106.26 mmol) in TFA (50 mL) was heated at 85 0C for 4 h. The reaction was cooled to room temperature and poured into a mixture of ice and water. Sodium hydroxide pellets were added to the mixture until it was basic (pH l4).The white precipitate was collected by suction filtration, rinsed with water and dried to provide 5,5'-(propane- 1,3-diyl)-bis(1,3,4-thiadiazolamine) (1004, 13.72 g). 1H NMR (300 MHz, DMSO- d6) 5 7.06—7.03 (s, 4H), 2.87 (t, J: 7.5 Hz, 4H), 2.02 — 1.95 (m, 2H). 5 2-(5 -amino- 1 ,3 ,4-thiadiazolyl)ethyl)amino)ethyl)-1 ,3 adiazolamine 10 (1005) H H s s N s N/V \/\\NN + H N\<N’NI W NH / \ HZNJLNHNHZ 2 \ N‘N>’/ 2 1005 A mixture of 3,3’-iminodipropionitrile (1.50 g, 12.18 mmol) and thiosemicarbazide (2.22 g, 24.36 mmol) in TFA (10 mL) was heated at 85 for 4.5 h. The reaction was cooled to room temperature and poured into a mixture of ice and water. Sodium 15 hydroxide pellets were added to the mixture until it was basic (pH 14). The white precipitate was collected by suction filtration, rinsed with water and dried to provide 5 -(2-((2-(5 -amino- 1 ,3 adiazolyl)ethyl)amino)ethyl)-1 ,3 ,4-thiadiazolamine (1005, 1.47 g). 1H NMR (300 MHz, DMSO-d6) 8 6.95 (s, 4H), 2.90 (d, J: 6.0 Hz, 4H), 2.83 (d, J: 6.3 Hz, 4H).
LiOH.H20 NaN NHZNHCSNHZ , \ POCI3 N,Nfi/VS\/ks>\NH2 (Ls NH2 20 1006 56 WO 2013/078123 PCT/US2012/065816 To a solution of methyl 3-((2-methoxyoxoethyl)thio)propanoate (5.0 g, 26 mmol) in THF/MeOH/water (60mL, 4:1 :1) was added lithium hydroxide monohydrate (4.375 g, 101 mmol). The resulting mixture was stirred at room temperature ght before it was concentrated under reduced pressure. The residue ed was diluted with water (~100mL) and the resulting solution was acidified with 6N HCl. The mixture was partitioned between water and ethyl acetate. The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated to afford 3- ((carboxymethyl)thio)propanoic acid , 85%) as a white solid. 1H NMR (300MHz, DMSO-d6) 8 ppm 2.55-2.57 (t, 2H) 2.75-2.79 (t, 2H) 3.27 (s, 2H) 12.41 (s, 10 2H) To a mixture of 3-((carboxymethyl)thio)propanoic acid (3.64g, 22.2 mmol) and thiosemicarbazide (4.1g, 45 mmol) was added phosphorus oxychloride (25mL) slowly. The resulting mixture was stirred at 90°C for 3hr before it was poured over crushed ice slowly. The solid ted was filtered and the filtrate was basified to 15 pH~13 by solid sodium hydroxide. The solid separated was filtered, washed with water and dried at 45°C under vacuum overnight to afford 1006 (~3 g, 50%) as a tan solid. 1H NMR (300MHz, DMSO-d6) 5 ppm 2.79-2.83 (t, 2H) 3.06-3.10 (t, 2H) 3.99 (s, 2H) 7.04 (s, 2H) 7.16 (s, 2H) O O S N‘N N’N HOJK/SdkOH + HNHZ HzNT<S)\/S\/&S>TNH2/ \ 1007 20 A mixture of 2,2’-Thiodiacetic acid (5.00 g, 33.3 mmol) and thiosemicarbazide (6.07 g, 66.6 mmol) in POC13 (40 mL) was heated at 90 0C for 5 h. The on was cooled to room temperature and carefully poured it onto a mixture of ice and water. Sodium hydroxide pellets were added to the mixture until it was basic (pH 14). The white precipitate was collected by n filtration, rinsed with water and dried to afford 25 1007. 1H NMR (300 MHz, DMSO-d6) 5 7.18 (s, 4H), 3.96 (s, 4H).
S [NmN N H2N NHNH2 )/3 S\/( 57 WO 2013/078123 2012/065816 A mixture of 1,5-dicyanopentane (1.00 g, 8.19 mmol) and thiosemicarbazide (1.5 g, 16.40 mmol) in TFA (3 mL) was heated at 85 0C for 5 h. The reaction was cooled to room temperature and poured into a mixture of ice and water. Sodium hydroxide pellets were added to the mixture until it was basic (pH l4).The white precipitate was collected by suction filtration, rinsed with water and dried to afford 1008. 1H NMR (300 MHz, DMSO-d6) 8 6.98 (s, 4H), 2.81 (t, 4H), 1.67 (m, 4H), 1.20 (m, 2H).
Acylatz'on OZ diaml'no core: Method A: Via acid chloride N,N'-[5 ,5'-(butane-1,4-diyl)-bis(1,3 ,4-thiadiazole-5 ,2-diyl)]-bis(2-phenylacetamide) 10 (21) s S O O s N»N ‘N C I HN\<\M fNH N’N N‘N 1001 21 To a suspension of 1001 (8.00 g, 31.21 mmol) in ylpyrrolidinone (NMP) 100 mL) at 0 0C was added phenylacetyl chloride (10.25 mL, 77.54 mmol) dropwise.
The resulting mixture was stirred at 0 0C for 1 h before it was quenched by addition of 15 water (~200 mL). The white itate was collected by suction filtration, rinsed with water and dried to provide N,N-[5,5'-(butane-1,4-diyl)-bis(1,3,4-thiadiazole-5,2- diyl)]-bis(2-phenylacetamide) (21, 14.02 g). 1H NMR (300 MHz, DMSO-d6) 5 12.66 (s, 2H), 7.34 (m, 10H), 3.81 (s, 4H), 3.01 (bs, 4H), 1.76 (bs, 4H).
ELI/(NASMS/ N14 N’N N~N 43 20 Compound 43 was prepared following Method A using yacetyl chloride. 1H NMR (300 MHz, DMSO-d6) 8 12.68 (s, 2H), 7.35—7.30 (m, 4H), 6.99—6.97 (m, 6H), 4.90 (s, 4H), 3.05 (bs, 4H), 1.79 (bs, 4H). 58 WO 2013/078123 2012/065816 PVC S 8 ovox HMMw N’ ‘N 100 Compound 100 was prepared following Method A. 1H NMR (300 MHz, DMSO-d6) 8 12.42 (s, 2H), 3.64 (t, J: 5.6 Hz, 4H), 3.24 (s, 6H), 3.01 (bs, 4H), 2.72 (t, J: 6.2 Hz, 4H), 1.79 (bs, 4H). 0 O *ofirNxS O N— Compound 5 was prepared according to Method A: 1H NMR (300 MHz, DMSO-d6) 8 12.66(s, 4H), 3.27(t, J=6.99 Hz, 4H), 2.95(t, J=7.02 Hz, 4H), 2.12(s, 6H).
O O 1001 o O Ti, )T HN\<\ />’NH o N4N N~N 0 173 TN 0 —’ s 3 09 HO HNKMfNH OH N’N N~N 174 To a suspension of 1001 (200 mg, 0.78 mmol) in NMP (2 mL) at 0 0C was added 0- 10 acetylmandelic acid chloride (0.44 mL, 1.95 mmol) dropwise. The resulting mixture was stirred at 0 0C for 1.5 h before it was ed by addition of water (~10 mL).
The white precipitate was collected by suction filtration, rinsed with more water and dried. The crude material was d by recrystallization with a mixture of DMSO and MeOH to afford 173. 15 A flask was charged with 173 and 2N ammonia in MeOH (3 ml) and the resulting e was stirred at room temperature for 6 h. The solvent was removed and the resulting material was dried in the oven to afford 174. 1H NMR (300 MHz, DMSO- d6) 8 12.42 (s, 2H), 7.53-7.31 (m, 10H), 6.35 (s, 2H), 5.34 (d, .1: 1.14 Hz, 2H), 3.01 (bs, 4H), 1.76 (bs, 4H). 20 Compound 306 was prepared according to the procedure for compound 174 above. 59 WO 2013/078123 PCT/US2012/065816 S S H2N~<\M />’NH2 +©\)l\ —> O N'N N~N _ 1001 0Y GigMW\Ms/>’NH O NaN N‘N O;( H O 0 —> § S\r/\¥_J/\W/sI \ />’NH 0“ N~N To a suspension of 1001 (400 mg, 1.56 mmol) in NMP (4 mL) at 0 0C was added (R)—(-)-O-formylmandeloyl chloride (0.61 mL, 3.90 mmol) dropwise. The resulting mixture was stirred at 0 0C for 1.5 h before it was quenched by addition of water (~10 mL). The white precipitate was collected by suction filtration, rinsed with more water and dried. The crude material was purified by recrystallization with a mixture of DMSO and MeOH to afford 68.
A flask was charged with 68 and 2N ammonia in MeOH (5 ml) and the resulting mixture was stirred at room temperature for 2 h. The solvent was removed and the 10 resulting material was dried in the oven to afford 80. 1H NMR (300 MHZ, 6) 5 7.53-7.31 (m, 10H), 6.34 (s, 2H), 5.33 (s, 2H), 3.01 (bs, 4H), 1.75 (bs, 4H).
HZNYNsm:\/\(slYNH2+Ej/ijI 4» mfR/NHZ To a sion of 1002 (544 mg, 1.89 mmol) in NMP (13 mL) at -l5°C was added phenylacetyl chloride (0.249 mL, 1.89 mmol) dropwise. The resulting mixture was 15 stirred at 0°C for l h and quenched by the addition of water (54 mL). The white precipitate was collected by suction filtration, rinsed with water (27 mL) and ethyl acetate (3x27 mL). The te was basif1ed to pH 11 using 2.5M NaOH. The layers were separated and the aqueous layer ted with romethane (3x54 mL).
The combined organic layers were dried over magnesium sulfate and concentrated to 20 afford N—(5 -(2-((2-(5-amino- 1 ,3 ,4-thiadiazolyl)ethyl)thio)ethyl)-l ,3 ,4-thiadiazol yl)phenylacetamide (17, 56 mg) 1H NMR (300 MHz, DMSO-d6) 5 l2.7l(s, 1H), 7.32(s, 5H), 3.8l(s, 2H), 3.25(t, J=7.61 Hz, 2H) 3.06(t, J=7.25 Hz, 2H), 2.92(t, J=6.90 Hz, 2H), 2.85(t, J=6.86 Hz, 2H) 60 WO 2013/078123 PCT/US2012/065816 HN S s 8 2 \« W \/\« YNH2 > CI O O N‘“ N‘“ + O \_’/< + 1002 0 CI 0 H H N S s S N O N—N N—N O 26 Phenylacetyl chloride (0.134 mL, 1.01 mmol) and acetoxyacetyl chloride (0.109 mL, 1.01 mmol) were mixed together in NMP (0.5 mL). This mixture was slowly added to a suspension of 1002 (292 mg, 1.01 mmol) in NMP (7 mL) at RT. The resulting mixture was stirred at RT for 1 h and quenched by the addition of water (20 mL). The white precipitate was collected by suction filtration, rinsed with water and dried under high vacuum. The crude material was purified by preparative HPLC. Compound 26: 1H NMR (300 MHz, DMSO-d6) 5 12.69(s, 2H), , 5H), , 2H), 3.82(s, 2H), 2.96(bs, 4H), 2.14(s, 3H). 10 Compound 44 was prepared following the procedure for compound 21 described previously. 1H NMR (300 MHz, DMSO-d6) 8 12.66 (s, 2H), 7.34—7.28 (m, 10H), 3.81 (s, 4H), 3.05—3.00 (m, 3H), 2.87 (dd, J: 7.9, 8.2 Hz, 1H), 1.95—1.77 (m, 3H), 0.94 (d, J: 6.5 Hz, 3H). s s W.MW . or N’N N‘N CI 1004 ; O O ; S S —, HN~<\M >/NH N’N N‘N 15 72 nd 72 was prepared following the procedure for compound 21 described previously. To a suspension of diamine 1004 (0.70 g, 3.07 mmol) in NMP (15 mL) at 0 0C was added phenylacetyl chloride (811 uL, 6.13 mmol) dropwise. The resulting mixture was stirred at 0 0C for 1 h before it was quenched by addition of water. The 20 white itate was ted by n filtration, rinsed with water and dried to 61 WO 78123 PCT/US2012/065816 provide N,N-[5,5'-(propane-l,3-diyl)-bis(1,3,4-thiadiazole-5,2-diyl)]-bis(2- phenylacetamide) (72, 1.37 g). 1H NMR (300 MHZ, DMSO-d6) 5 12.68 (s, 2H), .27 (m, 10H), 3.82 (s, 4H), 3.06 (t, J: 7.2 Hz, 4H), 2.17—2.12 (m, 2H). 0 o H2N\<\NJ\JSWHWS[\LrNHz _> s T s H2N\<\W W />/NH2 1005 N’” N‘N 1009 To a suspension of compound 1005 (100 mg, 0.37 mmol) in DMF (12 mL) at room temperature was added a solution of (t—Boc)20 (88 mg, 0.41 mmol) in DMF (2 mL).
The mixture was stirred at room temperature for 24 h. To this reaction e was added NMP (2 mL) and followed by addition of phenylacetyl de (97 uL, 0.74 mmol). The reaction was stirred for 1 h before it was poured into a mixture of ice- 10 water. The solid was collected by suction filtration, rinsed with water and dried to provide 1010 (180 mg).
The above product 1010 (160 mg, 0.26 mmol) in a mixture of TFA (1.5 mL) and CH2CH2 (10 mL) was stirred at room temperature for 4 h before it was concentrated.
The residue was re-taken up in CHzClz (3 X) and concentrated to provide N,N'-(5,5'- 15 (azanediyl-bis(ethane-2,1-diyl))—bis(1,3 ,4-thiadiazole-5 ,2-diyl))-bis(2- phenylacetamide) trifluoroacetic acid (149, 122 mg). 1H NMR (300 MHz, DMSO-d6) 8 12.81 (s, 2H), 8.75 (bs, 2H), 7.38—7.27 (m, 10H), 3.84 (s, 4H), 3.45 (d, J: 2.9 Hz, 4H), 3.39 (d, J: 6.0 Hz, 4H). owS O {NMs/stw N‘N o 199 62 WO 2013/078123 2012/065816 To a suspension of 1006 (0.274g, 1mmol) in NMP (5mL) was added phenyl acetyl chloride mL, 2mmol) dropwise. The mixture was stirred at room temperature for 1hr and afterwards it was diluted with water. Solid separated was filtered, washed with more water and dried. The crude material was d by prep HPLC to afford 199 as a white solid. 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 2.87-2.91 (t, 2H) 3.25-3.29 (t, 2H) 3.82 (s, 4H) 4.19 (s, 2H) 7.26-7.33 (m, 10H) 12.71-12.72 (br s, 2H).
Method B: via acid using peptide coupling ts o O AM /\/& k HO H2N s S s NH2 HBTu,HOBt,DIEA 1002 DMF o o N—N N—N o (\o K,N\)LN/Qs‘ sA/stNJk/NQ H H 12 10 To a flask containing 5,5'-(thiobis(ethane-2,1-diyl))bis(1,3,4-thiadiazolamine) (1002) (0.69 mmol, 0.20 g, 1.0 ) was added 2-morpholinoacetic acid (1.52 mmol, 0.22 g, 2.2 equiv.), O-(Benzotriazol-l-yl)-N,N,N’,N’-tetramethyluronium hexafiuorophosphate (HBTU) (2.20 mmol, 0.83 g, 3.2 equiv.), 1- Hydroxybenzotriazole (HOBT) (2.2 mmol, 0.29 g, 3.2 equiv.) 5 mL ofDMF followed 15 by N,N-Diisopropylethylamine (DIEA) (5.52 mmol, 0.71 g, 0.960 mL, 8.0 equiv.).
The mixture was stirred overnight at room temperature and then diluted with 15 mL water. The mixture was extracted with EtOAc and the organic layers combined, washed with water, brine and dried over Na2S04. The Na2S04 was removed by filtration and the volatiles removed under reduced pressure to give 0.04 g of 20 compound 12. 1HNMR (300 MHz, CDClg) Compound 12: 8 3.80 (broad multiplet, 4H), 3.34 (dd, 4H, J: 7.2 Hz), 3.28 (s, 4 H), 3.00 (dd, 4H, J: 7.1 Hz), 2.63 (broad multiplet, 4H).
Hom5 N—N _ g AW8 O i_ NHBOC [ll HZN HZN S \ >7’ 8 MS NH2 S (8) N‘N 1) HBTU,HOBt,D|EA H \ / DMF NH2 N~N o 1001 187 2) 4M HCI / dioxane 63 WO 2013/078123 PCT/US2012/065816 To a flask containing 5,5'-(butane-1,4-diyl)bis(1,3,4-thiadiazolamine) (1101) (3.9 mmol, 1.0 g, 1.0 equiv.) was added (S)—2-((tert-butoxycarbonyl)amino) phenylacetic acid (8.58 mmol, 2.15 g, 2.2 equiv.), HBTU (12.48 mmol, 4.73 g, 3.2 equiv.), HOBt (12.48 mmol, 1.69 g, 3.2 equiv.) 25 mL ofDMF followed by DIEA (31.2 mmol, 4.03 g, 5.43 mL, 8.0 equiv.). The mixture was stirred overnight and poured into 150 mL water. The white solids that formed were collected by vacuum filtration, washed with water and dried under vacuum giving 2.47 g of the bis-Boc protected intermediate.
To a slurry of the bis-Boc protected intermediate (2.76 mmol, 2.0 g, 1.0 equiv.) in 20 10 mL of dichloromethane (DCM) was added 4 M HCl in e (40 mmol, 10 mL) with vigorous stirring. The mixture briefly became clear and homogeneous then a white precipitate formed. The mixture was stirred overnight and diluted with 20 mL l ether. The solids were collected by vacuum filtration washed with additional diethyl ether and dried under vacuum giving 0.9 g 187. 1HNMR (300 MHz , DMSO, 15 d6) Compound 187: 8 9.13 (s, 4H), 7.61 (m, 4H), 7.48 (m, 6H), 6.2 (broad singlet, 4H), 5.32 (s, 2H), 3.04 (broad multiplet, 4H), 1.77 (broad multiplet, 4H). 0 OH Home. l S S O 0 HMMMHZ+m + )4 N’N N‘N HO F OH 0 1001 1011 F F HO 0% o 0 0H 0 o>’< V 0 s s >— z <— s s “HMNH HMMNH N— 152 ‘N To a solution of 2,2-bis(hydroxymethyl)propionic acid (5.00 g, 37.28 mmol) in e (80 mL) at room temperature was added 2,2-dimethoxypropane (6.88 mL, 20 55.92 mmol) and 'HzO (0.36 g, 1.86 mmol). The on was stirred for 2 h before it was quenched with Et3N (0.30 mL). The organic volatile was removed 64 WO 2013/078123 2012/065816 under reduced pressure. The e was partitioned between EtOAc and water. The organic layer was washed with brine, dried (MgSO4) and concentrated to provide the desired product 1011 (5.17 g) as a white solid.
To a suspension of diamine 1001 (500 mg, 1.95 mmol), 3-fluorophenylacetic acid (361 mg, 2.34 mmol) and acid 1011 (442 mg, 2.54 mmol) in DMF (20 mL) at 0 0C was added HOBt (791 mg, 5.85 mmol) and followed by N—(3-Dimethylaminopropyl)- N’-ethylcarbodiimide hloride (EDC) (l . 12 g, 5.85 mmol). The mixture was stirred from 0 0C to room temperature over 18 h before it was d with water. The precipitate was collected by suction filtration, washed with water and dried. The 10 crude product was purified by silica gel chromatography eluting with l—10% MeOH in CHzClz to e N—(5-(4-(5-(2-(3-fluorophenyl)acetamido)-l,3,4-thiadiazol yl)butyl)- l ,3 ,4-thiadiazolyl)-2,2,5-trimethyl- l ,3-dioxanecarboxamide (1012, 208 mg).
The above product 1012 (87 mg, 0.16 mmol) and TFA (2 mL) in a mixture of THF (8 15 mL) and water (2 mL) was heated at 50 0C for 5 h before it was concentrated under reduced pressure. The crude e was purified by HPLC to provide N,N'-(5-(4-(5- (2-(3 -fluorophenyl)acetamido)-l ,3 ,4-thiadiazolyl)butyl)-l ,3 ,4-thiadiazolyl)-3 - hydroxy(hydroxymethyl)methylpropanamide (152). 1H NMR (300 MHz, DMSO-d6) 5 12.68 (s, 1H), 11.77 (s, 1H), 7.04—7.38 (m, 1H), 7.18—7.09 (m, 4H), 4.98 20 (s, 2H), 3.86 (s, 2H), 3.62 (dd, J: 10.7, 29.0 Hz, 4H), 3.03 (bs, 4H), 1.77 (bs, 4H), 1.14 (s, 3H). 1 F HO OH F O><O O 0W0 Q MS S S Owo HN\<\S l N 4N To a suspension of diamine 1001 (400 mg, 1.56 mmol), 3-fluorophenylacetic acid (3 13 mg, 2.03 mmol), (R)-(—)-2,2-dimethyloxo-l,3-dioxolaneacetic acid (353 25 mg, 2.03 mmol) and Eth (200 uL) in DMF (20 mL) at 0 0C was added HOBt (633 mg, 4.68 mmol) and followed by EDC (897 mg, 4.68 mmol). The mixture was stirred 65 WO 2013/078123 PCT/US2012/065816 from 0 0C to room temperature over 18 h before it was diluted with water. The precipitate was collected by n filtration and washed with water. The solid was filrther rinsed with a e of hot MeOH-THF. The ed filtrate was concentrated and purified by silica gel chromatography g with 1—10% MeOH in CHzClz to provide (R)-N—(5-(4-(5-(2-(3-fluorophenyl)acetamido)-1,3,4-thiadiazol yl)butyl)-1,3,4-thiadiazolyl)-3,4-dihydroxybutanamide (1013, 93 mg).
The above product 1013 (87 mg, 0.16 mmol) and TFA (2 mL) in a mixture of THF (8 mL) and water (2 mL) was heated at 50 0C for 5 h before it was concentrated under reduced pressure. The crude residue was purified by HPLC to provide (R)-N—(5-(4- 10 (5 -(2-(3 -fluorophenyl)acetamido)- 1 ,3 ,4-thiadiazolyl)butyl)- 1 ,3 ,4-thiadiazolyl)- 3,4-dihydroxybutanamide (153). 1H NMR (300 MHZ, DMSO-d6) 5 12.67 (s, 1H), 12.43 (s, 1H), 7.41—7.38 (m, 1H), 7.20—7.12 (m, 4H), 4.45—4.40 (m, 1H), 3.86 (s, 2H), 3.03 (bs, 4H), 2.85—2.77 (m, 2H), 1.78 (bs, 4H). 15 To a suspension of (S)-(+)-O-acetylmandelic acid (666 mg, 3.43 mmol) and O-(7- Azabenzotriazol-l-yl)-N,N,N’,N’-tetramethyluronium orophosphate (HATU) (1.47 g, 3.86 mmol) in DMF (4 mL) was added DIEA (0.672 ml, 3.86 mmol) followed by 1001 (400 mg, 1.56 mmol). The resulting mixture was stirred at room temperature overnight before it was quenched by addition of water (~10 mL). The 20 white precipitate was collected by suction filtration, rinsed with more water and dried.
The crude material was purified by recrystallization with a mixture ofDMSO and MeOH to afford 66.
A flask was charged with 66 and 2N ammonia in MeOH (5 ml) and the resulting e was stirred at room temperature for 6 h. The solvent was removed and the 66 WO 78123 PCT/US2012/065816 resulting material was dried in the oven to afford 92. 1H NMR (300 MHZ, DMSO-d6) 5 12.42 (s, 2H), 7.53-7.31 (m, 10H), 6.35 (s, 2H), 5.33 (s, 2H), 3.01 (bs, 4H), 1.76 (bs, 4H).
GHZQWSMWHO S 69 A flask was charged with 1001 (200 mg, 0.78 mmol), DLphenyllactic acid (285 mg, 1.716 mmol), and HOBT (527 mg, 3.9 mmol) in DMF (3 ml) was added EDC (897 mg, 4.68 mmol) followed by triethylamine (0.87 ml, 6.24 mmol). The resulting e was stirred at room temperature overnight before it was ed by addition of water (~5 mL). The mixture was partitioned between water and EtOAc. The 10 organic extract was washed with water, dried over sodium sulfate, filtered and evaporated. The crude material was purified by silica gel chromatography eluting with 0-6% MeOH in CHzClz to afford 69. 1H NMR (300 MHZ, DMSO-d6) 5 12.20 (s, 2H), 7.24 (m, 10H), 5.75 (d, J: 6.87 Hz, 2H), 4.43 (m, 2H), 3.10 (m, 6H), 2.89-2.81 (m, 2H), 1.80 (bs, 4H).
N~ - Ho HN’<’W \>~ S 8 15 A flask was d with 1001 (200 mg, 0.78 mmol), D-(+)phenyllactic acid (285 mg, 1.716 mmol), and HOBt (464 mg, 3.43 mmol) in DMF (3 ml) was added EDC (822 mg, 4.28 mmol) followed by triethylamine (0.718 ml, 5.15 mmol). The resulting mixture was stirred at room temperature overnight before it was quenched by addition 20 of water (~5 mL). The mixture was partitioned between water and EtOAc. The organic extract was washed with water, dried over sodium e, filtered and evaporated. The crude material was purified by silica gel chromatography eluting with 0-6% MeOH in CHZClz to afford 169. 1H NMR (300 MHz, DMSO-d6) 5 12.20 (s, 2H), 7.24 (m, 10H), 5.75 (d, .1: 6.87 Hz, 2H), 4.43 (m, 2H), 3.03 (m, 6H), 2.89- 25 2.81 (m, 2H), 1.80 (bs, 4H). 67 WO 2013/078123 PCT/US2012/065816 mo N‘N N—N \ I 8%”Wa5 HO HN’<SW OH 146 A flask was charged with 1001 (200 mg, 0.78 mmol), L-(-)phenyllactic acid (285 mg, 1.716 mmol), and HOBt (464 mg, 3.43 mmol) in DMF (3 ml) was added EDC (822 mg, 4.28 mmol) followed by ylamine (0.718 ml, 5.15 mmol). The resulting mixture was stirred at room temperature overnight before it was quenched by on of water (~5 mL). The mixture was partitioned between water and EtOAc. The organic extract was washed with more water, dried over sodium sulfate, filtered and ated. The crude material was purified by silica gel chromatography eluting with 0-6% MeOH in CHzClz to afford 146. 1H NMR (300 MHz, DMSO-d6) 8 12.27 10 (s, 2H), 7.31 (m, 10H), 5.78 (m, 2H), 4.44 (m, 2H), 3.05 (m, 6H), 2.87 (m, 2H), 1.79 (bs, 4H). 0 O N~N N’N 'IIIIOH HMWH 8 S OH 127 To a suspension of (R)-(+)—3-hydroxyphenylpropionic acid (285 mg, 1.72 mmol) and HATU (719 mg, 1.89 mmol) in DMF (3 mL) was added DIEA (0.329 ml, 1.89 15 mmol) followed by 1001 (200 mg, 0.78 mmol). The resulting mixture was stirred at room temperature overnight before it was quenched by on of water (~10 mL).
The white precipitate was collected by suction filtration, rinsed with more water and dried. The crude material was purified by recrystallization with DMSO and MeOH to afford 127. 1H NMR (300 MHz, DMSO-d6) 8 12.38 (s, 2H), 7.34 (m, 10H), 5.56 (m, 20 2H), 5.10 (m, 2H), 3.04 (bs, 4H), 2.80 (m, 4H), 1.80 (bs, 4H). 68 WO 2013/078123 PCT/US2012/065816 To a suspension of (R)hydroxyphenylbutyric acid (310 mg, 1.72 mmol) and HATU (719 mg, 1.89 mmol) in DMF (3 mL) was added DIEA (0.329 ml, 1.89 mmol) followed by 1001 (200 mg, 0.78 mmol). The resulting mixture was stirred at room temperature overnight before it was quenched by addition of water (~10 mL). The crude material was d by HPLC to afford 143. 1H NMR (300 MHz, DMSO-d6) 5 7.61 (d, .1: 7.65 Hz, 4H), 7.34 (m, 6H), 2.99 (bs, 4H), 2.26 (m, 2H), 2.10 (m, 2H) 1.74 (bs, 4H), 0.80 (t, 6H).
W O s s N'NMXBH‘g s o H2N~<\M />/NH2 >’\ + O HN N‘N N‘N 64 O OH o 1001 N—N O I N >~NH N,\ s >\,s o OH HN O 94 OH To a suspension of 3-Oxoindancarboxylic acid (604 mg, 3.43 mmol) and HATU 10 (1 .47g, 3.86 mmol) in DMF (5 mL) was added DIEA (0.672 ml, 3.86 mmol) ed by 1001 (400 mg, 1.56 mmol). The resulting mixture was stirred at room temperature overnight before it was quenched by on of water (~10 mL). The light brown precipitate was collected by suction filtration, rinsed with water and dried. The crude material was purified by recrystallization with a mixture ofDMSO and MeOH to 15 afford 64.
To a suspension of 64 (100 mg, 0.175 mmol) in EtOH (20 ml) at 0 0C was added NaBH4 (15 mg, 0.384 mmol) and the resulting mixture was stirred for 1 h before it was quenched by 1N HCl. The mixture was ioned between 1N HCl and EtOAc, the organic t was dried over sodium sulfate, filtered and evaporated. The crude 20 material was purified by silica gel chromatography eluting with 0-6% MeOH in CHZClz and further purified by recrystallization with a mixture ofDMSO and MeOH to afford 94. 1H NMR (300 MHz, DMSO-d6) 5 12.81 (s, 2H), 7.34 (m, 8H), 5.56 (m, 69 WO 2013/078123 PCT/US2012/065816 2H), 5.11 (t, 2H), 4.15 (t, 2H), 3.05 (bs, 4H), 2.70 (m, 2H), 2.15 (m, 2H), 1.80 (bs, 4H). 1014 | o o s s N~N N’N H2N M\<\N’N N‘N/>’NH2 + 01 /W\ O —> HN/<S S>\HN (1 0 203 SO 1001 0H OZ /0 o\ 1014 To a solution of DL-mandelic acid (1 g, 6.57 mmol) in DMF (10 ml) at 0 0C was added NaH ( 700 mg, 19.7 mmol) and allowed the e to stir for 20 minutes before 2-bromoethyl methyl ether (1.24 ml, 13.1 mmol) was added dropwise. The resulting mixture was d at 0 0C and slowly warmed up to room temperature overnight before it was quenched by 1N HCl. The mixture was partitioned between 1N HCl and EtOAc, the organic extract was washed with water, dried over sodium 10 sulfate, ed and evaporated to afford 1014.
To a suspension of 1014 (500 mg, 2.37 mmol) and HATU (995 mg, 2.62 mmol) in DMF (3 mL) was added DIEA (0.456 ml, 2.62 mmol) followed by 1001 (277 mg, 1.08 mmol). The ing mixture was stirred at room temperature overnight before it was quenched by addition of water (~6 mL). The mixture was partitioned between 15 water and EtOAc. The organic extract was washed with water, dried over sodium sulfate, filtered and evaporated. The crude material was purified by HPLC to afford 203. 1H NMR (300 MHz, DMSO-d6) 8 12.58 (s, 2H), 7.49-7.37 (m, 10H), 5.22 (s, 2H), 3.66-3.54 (m, 8H), 3.27 (s, 6H), 3.01 (bs, 4H), 1.75 (bs, 4H). 70 WO 2013/078123 2012/065816 HzNfiNMKNHZs s I \ N (:1? SW8\ H {3 + O ’9 N 63 N To a suspension of 2-(4-Boc-piperazinyl)phenylacetic acid (1.1 g, 3.43 mmol) and HATU (1.47g, 3.86 mmol) in DMF (5 mL) was added DIEA (0.672 ml, 3.86 mmol) followed by 1001 (400 mg, 1.56 mmol). The resulting mixture was stirred at room ature overnight before it was ed by on of water (~10 mL).
The white precipitate was collected by suction filtration, rinsed with water and dried.
The crude material was purified by recrystallization with DMSO and MeOH to afford 63.
A flask was charged with 63 and 4N HCl in 1,4-dioxane (6 ml) and the resulting 10 mixture was stirred at room temperature for 3 h. The precipitation was collected by filtration, rinse with EtOAc/CHgClz and dried to afford 77. 1H NMR (300 MHZ, DMSO-d6) 5 9.10 (bs, 4H), 7.51-7.41 (m, 10H), 4.90 (bs, 2H), 4.62 (s, 2H), 3.15 (bs, 8H), 3.03 (bs, 4H), 2.73 (bs, 8H), 1.76 (bs, 4H).
N'NWSWN‘N N,N\\’/\/s\/\r/N\ 9H 0 >\,s s\/< N E HN NH \ 8% + , H2N ‘ 1002 NH2 126 15 To a suspension of (R)-(+)hydroxyphenylpropionic acid (254 mg, 1.53 mmol) and HATU (640 mg, 1.68 mmol) in DMF (3 mL) was added DIEA (0.292 ml, 1.68 mmol) followed by 1002 (200 mg, 0.693 mmol). The resulting mixture was stirred at room temperature overnight before it was quenched by addition of water (~10 mL).
The white precipitate was collected by suction filtration, rinsed with water and dried. 20 The crude material was purified by tallization with a mixture ofDMSO and MeOH to afford 126. 1H NMR (300 MHz, DMSO-d6) 8 12.40 (s, 2H), 7.38 (m, 10H), 5.55 (m, 2H), 5.09 (m, 2H), 3.27 (t, 4H), 2.95 (t, 4H), 2.82 (m, 4H). 71 WO 2013/078123 PCT/US2012/065816 Boc NNYVSWr/N‘N o 8% + r”) w + m N HZN NH; O 1002 OH N\ S /N\ ,N S N # HN NH + HN NH 70 76 A flask was d with 1002 (200 mg, 0.693 mmol), 2-(4-Boc-piperazinyl) phenylacetic acid (244 mg, 0.763 mmol), and HOBt (187 mg, 1.39 mmol) in DMF (3 ml) was added EDC (332 mg, 1.73 mmol) followed by triethylamine (0.290 ml, 2.08 mmol). The resulting mixture was d at room temperature overnight before phenylacetyl chloride (0.037 ml, 0.277 mmol) was added dropwise at 0 0C and stirred for l h before it was quenched by addition of water (~10 mL). The white precipitate was collected by suction filtration, rinsed with water and dried. The crude al was purified by HPLC to afford 70 and 76. of HNJ:m HCI 10 73 A flask was charged with 70 and 4N HCl in 1,4-dioxane (6 ml) and the resulting mixture was stirred at room temperature for 3 h. The precipitation was collected by filtration, rinse with EtOAc/CH2C12 and dried to afford 78. 1H NMR (300 MHZ, DMSO-d6) 5 12.70 (s, 2H), 8.97 (bs, 2H), 7.50-7.29 (m, 10H), 4.72 (bs, 1H), 4.59 (s, 15 1H), 3.82 (s, 2H), 3.27 (t, 4H), 3.15 (bs, 4H), 2.92 (t, 4H), 2.70 (bs, 4H). 72 WO 2013/078123 PCT/US2012/065816 N'NYVSVYN‘N *8 8% HN NH 79 A flask was charged with 76 and 4N HCl in 1,4-dioxane (6 ml) and the resulting mixture was d at room temperature for 3 h. The precipitation was collected by filtration, rinse with EtOAc/CHgClz and dried to afford 79. 1H NMR (300 MHZ, DMSO-d6) 5 12.87 (s, 2H), 9.03 (bs, 4H), 7.50-7.40 (m, 10H), 4.67 (bs, 2H), 4.59 (s, 2H), 3.28 (t, 4H), 3.14 (bs, 8H), 2.97 (t, 4H), 2.71 (bs, 8H).
Amide Coupling General Procedure (used for following examples): To a 0.2 molar concentration suspension of ylic acid (2 lents) in DMF was added HATU (2 equivalents) and stirred till reaction mixture is clear followed by the 10 addition of an amine (1 equivalent) and DIPEA(4 equivalents). The resulting mixture was stirred at room temperature overnight before it was quenched by the addition of water. The solid separated was filtered, washed with water and dried. 39: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.89-2.01 (m, 6H) .29 15 (m, 2H) 2.95-3 (m, 4H) 3.79-3.86 (m, 2H) 3.94-4.02 (m, 2H) 4.55-46 (m, 2H) 12.29 (brs, 2H). 73 WO 2013/078123 PCT/US2012/065816 N’N N O \ S | \ go 0:0 C; 41: 1H NMR (300MHz, Dimethylsulfoxide-dé) 5 ppm 2.93-2.98 (m, 4H) 3.27—3.32 (m, 4H), 4.46 (s, 4H), 5.18-5.2 (br s, 2H) 6.88-7.03 (m, 8H) 12.87-12.92 (br s, 2H). 0 O H O N S/<NH\ YWN'NS O N‘N 5 51: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.78 (br s, 4H) 3.05-3.06 (br s, 4H), 3.38-3.40 (m, 2H) 3.54-3.63 (m, 2H) .50 (m, 2H) .26 (m, 8H) 12.78 (br s, 2H). 54: 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.92-2.03 (m, 10H) 2.17-2.28 10 (m, 2H) 3.05 (br s, 4H) 3.79-3.85 (m, 2H) 3.94-4.01 (m, 2H) 4.55-4.59 (m, 2H) 12.27(br s, 2H).
/N\N NH H O IW’N N‘N N 74 WO 2013/078123 PCT/US2012/065816 60: 1H NMR (300MHz, ylsulfoxide-d6) 8 ppm 1.77 (br s, 4H) 3.04 (br s, 4H) 5.20 (s, 4H) 6.31 (br s, 2H) 7.49 (br s, 2H) 7.79 (br s, 2H) 12.80 (br s, 2H).
H WN S S/<NH 85: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 0.20-0.21 (br s, 4H) 0.48-0.50 5 (br s, 4H) 1.79 (br s, 4H) .38 (br s, 4H) 3.04 (br s, 4H) 12.32 (br s, 2H).
/ / S O NH mNYS\ H S/\< 87: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.78 (br s, 4H) 3.03 (br s, 4H) 4.05 (s, 4H) 6.99 (br s, 4H) 7.42-7.44 (m, 2H) 12.68 (br s, 2H). 4 O 0=( N >4 O H O)7’N/3/7rN S s,<NH\N 10 114: 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.01-1.12 (m, 4H) 1,40 (s, 18H) 1.61-1.65 (m, 4H) 1.78 (br s, 4H) 1.95 (br s, 2H) 3.84 (m, 4H) 2.65-2.75 (m, 4H) 3.03 (br s, 4H) 3.89-3.93 (m, 4H) 12.39 (br s, 2H). 75 WO 78123 PCT/US2012/065816 123: 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.43 (s, 6H) 1.79—1.94 (m, 10H) 2.22—2.31 (m, 2H) 3.05 (br s, 4H) 3.85-4.01 (m, 4H) 11.85 (br s, 2H). 0/: 0 O NH H N S/\< o N|\N/>\/\S/\/L\N'N 133: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 2.92-2.97 (m, 4H) 3.26-3.30 (m, 4H) 4.61-4.87 (m, 6H) 6.83-6.89 (m, 4H) .21 (m, 2H) 7.36-7.38 (m, 2H) 12.95 (br s, 2H). 135: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.77 (br s, 4H) 3.03 (br s, 4H) 4.60-4.87 (m, 6H) 6.83-6.89 (m, 4H) 7.16-7.22 (m, 2H) 7.36-7.38 (m, 2H) 12.92 (br s, 2H). 76 WO 2013/078123 PCT/US2012/065816 114: 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.01-1.12 (m, 4H) 1,40 (s, 18H) 1.61-1.65 (m, 4H) 1.78 (br s, 4H) 1.95 (br s, 2H) 3.84 (m, 4H) .75 (m, 4H) 3.03 (br s, 4H) 3.89-3.93 (m, 4H) 12.39 (br s, 2H). 5 323: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.76 (brs, 4H) 3.01(brs, 4H) 4.02 (s, 4H) 6.56 (s, 2H) 6.94-7.05 (m, 4H) 7.31-7.33 (m, 4H) 11.12 (brs, 2H) 12.69 (s, 2H).
N‘N HN’</ \ N s ‘N o | / NH 0\ o 0/ 397: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.75 (brs, 4H) 2.90 (brs, 2H) 10 3.02 (brs, 2H) 3.67-3.82 (m, 10H) 6.85-7.03 (m, 4H) 7.26-7.36 (m, 5H) 7.55-7.58 (d, 1H)8.18-8.21(d, 1H) 11.26 (s, 1H) 12.65 (brs, 1H).
N~N HN’</ \ N\ NH O O O/ 398: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm ppm 1.75 (brs, 4H) 2.90 (brs, 2H) 3.02 (brs, 2H) 3.72-3.78 (m, 10H) 6.42-6.51 (m, 4H) 7.36 (m, 5H) 7.54-7.58 (d, 15 1H)8.18-8.21(d,1H)11.26(s,1H)12.65(brs,1H). 77 WO 2013/078123 PCT/US2012/065816 HN’</ ‘ N\ S ‘N o | / NH 0 O 399: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.48 (s, 9H) 1.75 (brs, 4H) 2.90 (brs, 2H) 3.02 (brs, 2H) 3.74-3.78 (m, 4H) 6.92-6.94 (m,1H) 7.20-7.36 (m, 7H) 7.51-7.58 (m, 2H) .21 (d, 1H) 9.34 (s, 1H) 11.26 (s, 1H) 12.65 (brs, 1H).
OHN’Q‘JJWL/kN\ 400: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.48 (s, 9H) 1.75 (brs, 4H) 2.90 (brs, 2H) 3.02 (brs, 2H) .78 (m, 4H) 7.18-7.42 (m, 9H) 7.54-7.58 (m, 2H) 8.18-8.21 (d, 1H) 9.34 (s, 1H) 11.26 (s, 1H) 12.65 (brs, 1H).
NNM O): )V 10 324: 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.39 (s, 18H) 1.76 (brs, 4H) 3.01(brs, 4H) 3.79 (s, 4H) 4.11-4.13 (brs, 4H) 7.13-7.38 (m, 8H) 12.65 (s, 2H).
Method C: Via aluminum amide coupling with esters/lactones 78 WO 2013/078123 PCT/US2012/065816 1002 HN O“ N‘N “H1A _. s—\< o S S/\/L\N,N OH 181 To a suspension of 1002 (288 mg, 1.00 mmol) in toluene (9 mL) was added 3- isochromanone (311 mg, 2.10 mmol) ed by hyl aluminum (2M in toluene, 1.0 mL, 2.00 mmol). The resulting mixture was stirred at 75°C for 15 h, cooled to room temperature and diluted with ethyl acetate (50 mL). The organic layer was washed with water (3X20 mL), 10% sodium chloride solution (10 mL), dried (magnesium sulfate) and concentrated under reduced pressure. The crude product was purified by HPLC to afford N,N'-(5,5'-(thiobis(ethane-2,l-diyl))bis(l ,3,4- thiadiazole-5,2-diyl))bis(2-(2-(hydroxymethyl)phenyl)acetamide) (181, 78 mg). 1H 10 NMR (300 MHz, DMSO-d6) 5 7.42(d, J=6.84 Hz, 2H), 7.26(bs, 6H), 4.57(s, 4H), 3.90(s, 4H), 3.27(t, J=6.62 Hz, 4H), 2.94(t, J=6.44 Hz, 4H) —N N’N HZNJLSWQ‘NHZ + mo 1001 To a suspension of 1001 (256 mg, 1.00 mmol) in toluene (8 mL) was added 3- isochromanone (311 mg, 2.10 mmol) followed by hyl aluminum (2M in toluene, 15 1.0 mL, 2.00 mmol). The resulting mixture was stirred at 75°C 15 h, cooled to room ature and diluted with ethyl acetate (50 mL). The c layer was washed with water (3X20 mL), 10% sodium chloride solution (10 mL), dried (magnsesium sulfate) and concentrated under reduced pressure. The crude t was purified by HPLC to afford N,N'-(5,5'-(thiobis(ethane-2,l-diyl))bis(l ,3,4-thiadiazole-5,2- 20 diyl))bis(2-(2-(hydroxymethyl)phenyl)acetamide) (208, 62 mg). 1H NMR (300 MHz, DMSO-d6) 5 7.4l(s, 2H), 7.26(s, 6H), 4.56(s, 4H), 3.01(bs, 4H), l.76(bs, 4H) 79 WO 2013/078123 PCT/US2012/065816 CCI4 B NBS 2-Methyl imidazole \[>/\Coome—>Benzoylperoxide COOMe Acetone N/LN/\©/\COOM6 \J 1015 1015 1017 N S N' \ \ NHz Wys 1001 N~[\%>’ . D'PEA COOH W’s\ LIOH.HZO N)’\N NeN —’ \7’ O HN o 1018 (E? To a solution of 1015 (3.2g, l9.5mmol) in carbon tetrachloride (l50mL) was added N—bromosuccinimide (3.47g, l9.6mmol) and benzoyl peroxide (10mg, catalytic). The resulting mixture was refluxed ght before it was filtered hot. The filtrate was concentrated under reduced pressure and the residue obtained was purified by silica gel chromatography eluting with 20% ethylacetate/hexane to afford 1016 (2g, 42% yield) as an oil. 1H NMR z, form—d) 8 ppm 3.66 (s, 2H) 3.74 (s, 3H) 4.5 l(s, 2H) 7.35 (m, 4H).
To a solution of 1016 (0.243 g, lmmol) in acetone (lOmL) was added 2-methyl 10 imidazole (0.41 g, 5mmol). The resulting mixture was refluxed overnight before it was concentrated under reduced pressure and the residue obtained was diluted with water (~100mL). The resulting solution was partitioned between water and ethyl acetate.
The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel 15 chromatography eluting with ichloromethane to afford 1017 (0. 17g, 69% yield) as an oil. 1H NMR (300MHz, Chloroform—d) 8 ppm 2.37 (s, 3H) 3.63 (s, 2H) 3.72 (s, 3H) 5.07 (s, 2H) 6.87 (s, 1H) 6.96-7.02 9m, 2H) .33 (m, 3H) To a solution of 1017 (0. l7g, 0.69mmol) in OH/Water (lOmL, 2mL, 2mL) was added lithium hydroxide monohydrate (0.06g, l.42mmol). The resulting mixture 20 was stirred at room temperature overnight before it was trated under reduced pressure. The residue obtained was d with water (~20mL) and the resulting solution was acidified with acetic acid. The aqueous layer was concentrated and the 80 WO 2013/078123 PCT/US2012/065816 product was isolated by prep HPLC. The residue obtained was dissolved in water (5 mL) and concentrated hloric acid (83 uL) was added to it before it was concentrated and dried to afford 1018 (0. 15gm) as a hloride salt.
To a suspension of carboxylic acid 1018 (105mg, 0.39mmol) in DMF (3mL) was added HATU (150mg, 0.39mmol) and stirred till reaction mixture is clear followed by the addition of an amine 1001 (50.5mg, 0.197mmol) and DIPEA (0.14mL, 0.8mmol).
The resulting mixture was stirred at room temperature overnight before it was ed by the addition of water. The solid separated was filtered, washed with water and dried to afford 296 (112mg, 83%). 1H NMR (300MHz, Dimethylsulfoxide- 10 d6) 8 ppm 1.76 (brs, 4H) 2.38 (s, 6H) rs, 4H) 3.82 (s, 4H) 5.25 (s, 4H) 7.09- 7.38 (m, 12H) 12.64-12.67 (brs, 2H).
Br/\/// I N: I Nc l/N % / / N“N | IN:N NH NC/\/ + |/ NH / 0 NH2 1021 O 1019 1020 1022 N\ No N, N ‘N \ I H2N’</ N 3 / “N NH I / —> —. NH o 1023 1024 o N~N HN’</ \ s N‘” —. | / NH 0 295 To a suspension of 1019 (1.5 g, 6.8 mmol) in CHzClz (15 mL) at 0 0C was added Et3N (1.9 ml, 13.6 mmol) se followed by phenyl acetyl chloride (1.07 ml, 8.1 mmol) 15 dropwise. The resulting mixture was stirred at 0 0C and then slowly warmed up to room temperature for 2 days. The crude material was purified by silica gel chromatography eluting with 0-25% EtOAc in hexane to afford 1020. 8 1 WO 2013/078123 PCT/US2012/065816 To a solution of obutyne (7 g, 53 mmol) in DMSO (30 ml) at 0 0C was added NaI (7.94 g, 53 mmol). The mixture was stirred at room temperature for 2 h before it was cooled to 0 0C and followed by addition ofNaCN (5.2 g, 106 mmol).
The resulting mixture was heated at 80 0C for 2.5 h and then d at room temperature overnight. The mixture was partitioned between water and EtOAc. The organic extract was washed with water, dried over sodium sulfate, filtered and evaporated to afford 1021.
To a mixture of 1020 (400 mg, 1.18 mmol), PdC12(PPh3)2 (41 mg, 0.059 mmol) and CuI (11 mg, 0.059 mmol) in Et3N (3 ml) and THF (6 ml) under argon atmosphere was 10 added 1021 (187 mg, 2.36 mmol), then heated at 60 0C overnight. After removal of the t, the residue was purified by silica gel chromatography eluting with 0-60% EtOAc in Hexane to afford 1022.
To a solution of 1022 (118 mg, 0.406 mmol) in the mixture of EtOAc (60 ml) and EtOH (15 ml) was added Pd(OH)2/C (50 mg, 0.356 mmol). Hydrogen was bubbled 15 through the resulting mixture and stirred for 1 h. The Pd catalyst was filterd off and the filtrate was concentrated to afford 1023.
A mixture of 1023 (127 mg, 0.431 mmol) and thiosemicarbazide (51 mg, 0.561 mmol) in TFA (3 mL) was heated at 85 0C for 5 h. The reaction was cooled to room temperature and poured onto a mixture of ter. The mixture was ed with 20 NaOH s (pH 10). The crude material was purified by silica gel tography eluting with 0-6% MeOH in CHZClz to afford 1024.
To a solution of 1024 (38.4 mg, 0.104 mmol) in NMP (1 mL) at 0 0C was added phenyl acetyl chloride (0.017 mL, 0.125 mmol) dropwise. The resulting mixture was stirred at 0 0C for 1.5 h before it was quenched by addition of water (~10 mL). The 25 e was partitioned between water and EtOAc. The organic extract was washed with water, dried over sodium sulfate, filtered and evaporated. The crude material was purified by silica gel chromatography eluting with 0-6% MeOH in CHzClz to afford 295. 1H NMR (300 MHz, DMSO-d6) 8 12.65 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, .1: 8.82 Hz, 1H), 7.58-7.54 (d, .1: 9.72 Hz, 1H), 7.36-7.28 (m, 10H), 3.81-3.78 30 (d, .1: 8.43 Hz, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 82 W0 2013/078123 2012/065816 Compound 1024 can also be prepared according to the following procedure: H CI H2N N, N N\ ~ N ~ N + I —> | o / o / CI CI 1042 Ban(CH2)4CN H N N:N —> I O / —> CN 1024 NH2 To a solution of 3-aminochloropyridazine (11.14 g, 86.0 mmol) in NMP (279 mL) at 19°C was added phenylacetyl chloride (18.2 mL, 137.6 mmol) dropwise over 5 minutes with the internal temperature of the solution maintained T;- S 28 °C. The resulting mixture was stirred at 19°C for 90 minutes and poured into ice water (557 mL). The white precipitate was ted by n filtration, rinsed with water (2X110 mL) and diethyl ether (110 mL). The product was dried overnight under high vacuum to afford N—(6-chloropyridazinyl)phenylacetamide (XXX, 18.8 g). 1H 10 NMR (300 MHz, DMSO-d6) 8 ll.57(s, 1H), 8.40(d, J=9.636 Hz, 1H), , J=9.516 Hz, 1H), 7.36(m, 5H) 3.82(s, 2H) A 1000 mL three-neck flask fitted with internal temperature probe and on funnel was flushed with Aug). Under positive Argon pressure obutylzinc bromide (0.5M in THF, 500mL, 250 mmol) was charged into the addition funnel then added to 15 the reaction vessel at room temperature. Solid N—(6-chloropyridazin-3 -yl) phenylacetamide (20.6 g, 83.3 mmol) was added to the stirred solution at RT under Ar(g) flow, followed by the addition ofNiClz(dppp) (4.52 g, 8.33 mmol). The resulting mixture was stirred at 19°C for 240 minutes and then quenched with ethanol (120 mL). Water (380mL) added to the stirred red solution, giving a thick itate. 20 Ethyl acetate (760 mL) added and d well for 30 minutes. The solids were removed by filtration through a pad of celite. The mother liquor was then transferred to a separatory funnel and the organic layer was washed with H20 (3 80mL), 0.5% ethylenediaminetetraacetic acid solution (380 mL) and again with H20 (3 80mL). The 83 WO 2013/078123 PCT/US2012/065816 c layer was concentrated by rotoevaporation. ing red oil was redissolved in EtOAc (200 mL) and 1M HCl (380 mL) was added to the well stirred flask. After 30 minutes the mixture was transferred to separatory funnel and the aqueous layer collected. The organic layer was extracted with 1M HCl (2x3 80mL). The aqueous layer’s pH was then adjusted to ~7 using 7.5% sodium bicarbonate solution and the pale yellow precipitate was collected by suction filtration, rinsed with water (200 mL) and diethyl ether (2x200mL). The solid was dried overnight under high vacuum to afford 4-cyanobutyl)pyridazinyl)- 2-phenylacetamide (1023, 14.76 g). 1H NMR (300 MHz, DMSO-d6) 5 ll.29(s, lH), 8.23(d, J=9.036 Hz, 1H), 7.59(d, 10 J=9.246 Hz, 1H), 7.32(m, 5H), , 2H), 2.90(t, .1: 7.357 Hz, 2H), 2.56(t, .1: 7.038 Hz, 2H), l.79(t, J: 7311 Hz, 2H), l.63(t, J: 7.01 Hz, 2H) N—(6-(4-cyanobutyl)pyridazinyl)phenylacetamide (14.7 g, 50.2 mmol) was charged into a 250 mL round bottom flask fitted with an open top reflux condenser.
To the flask was added thiosemicarbazide (5.03 g, 55.2 mmol) and trifluoroacetic acid 15 (88 mL). The reaction slurry was heated in a 65°C bath for 2 h. After cooling to RT, H20 (150 mL) was added and stirred for 30 minutes. The mixture was then slowly erred to a stirred 7.5% sodium bicarbonate solution (l400mL) cooled in a 0°C bath. The precipitate was collected by suction filtration, rinsed with water (2x200 mL), diethyl ether (2x200mL) and dried under high vacuum overnight. The off-white 20 solid was slurried in DMSO (200 mL) and heated in an 80°C bath until the internal temperature reached 65°C. DMSO (105 mL) was used to rinse sides of flask. H20 (120 mL) was slowly added until the solution became slightly cloudy and then the e was d from heat bath and allowed to cool to ambient temperature while stirring. The pale green precipitate was collected by suction tion, rinsed 25 with water (200 mL) and diethyl ether (2x200mL). The solid was dried overnight under high vacuum to provide N—(6-(4-(5-amino-l ,3,4-thiadiazol yl)butyl)pyridazinyl)phenylacetamide (1024, 15.01 g). 1H NMR (300 MHz, DMSO-d6) 5 ll.28(s, lH), 8.23(d, J=8.9l6 Hz, 1H), , J=8.826 Hz, 1H), 7.36(m, 5H), 7.07(s, 2H), 3.78(s, 2H), 2.87(t, .1: 6.799 Hz, 4H), l.69(bm, 4H) 30 84 WO 2013/078123 PCT/US2012/065816 0 M60MOW HZNNHZ HNNH2 MeOH NHNH2 O N—N m, A \ o NH MeOH,0°C-RT H2N O \ y N—N 1025 To a solution of yl adipate (28.7 mmol, 5.0 g, 4.7 mL, 1.0 equiv.) in 20 mL of MeOH was added anhydrous hydrazine (229.6 mmol, 7.36 g, 7.51 mL, 8.0 equiv.) and the mixture heated to 50°C, giving a white precipitate. The e was heated for one hour and then allowed to cool to room temperature. The white solid was collected by ion and washed with onal MeOH then dried under high vacuum giving 4.6 g of adipohydrizide. 1HNMR (300 MHz, DMSO-d6) 8 8.91 (s, 2H), 4.14 (s, 4H), 2.00 (br s, 4H), 1.46 (br s, 4H).
To a 0°C cooled slurry of adipohydrizide (12.49 mmol, 4.0 g, 1.0 equiv.), potassium 10 bicarbonate (15.61 mmol, 1.56 g, 1.25 equiv.) in 25 mL ofMeOH was added solid cyanogen bromide (13.74 mmol, 1.44 g, 1.1 equiv.) in one portion. This mixture was stirred at 0°C and allowed to warm to RT over one hour and then stirred overnight.
The volatiles were removed under reduced pressure and the solids diluted with water.
The pH was adjusted to 12 with 2.5 N NaOH and the solids collected by filtration. 15 The white solid was washed with water and dried under high vacuum to give 1.73 g of oxadiazole 1025. 1HNMR (300 MHz, 6) 5 6.85 (s, 4H), 2.68 (s, 4H), 1.68 (s, 4H). 0 1025 o HN‘<\O\,/\/\/“\O\>\NHI To a suspension of oxadiazole 1025 (181 mg, 0.81 mmol) in NMP (9 mL) was added 20 triethylamine (0.564 mL, 4.05 mmol) and the mixture warmed to 70°C. The mixture was allowed to stir for 30 minutes followed by the addition of phenylacetyl chloride (0.234 mL, 1.77 mmol). The reaction temperature was held at 70°C for 15 hours then allowed to cool to room temperature. The crude reaction mixture was purified by 85 WO 2013/078123 PCT/US2012/065816 reverse phase HPLC giving 305 (0.015 g). 1HNMR (300 MHz, 6) 8 11.74(s, 2H), 7.33(s, 10H), 3.74(s, 4H), 2.85(s, 4H), 1.76(s, 4H).
Functionalizatz'on 0 diac lated cores: CO 0&3 SCM533 HN\<\N’WN/\_/\r\ 8,),NH HNfiSM )rNH\ N‘N N’N N‘N To a suspension of 21 (2.25 g, 4.57 mmol) in a mixture of THF (250 mL) and H20 (20 mL) at room temperature was added NaOH (1.83 g, 45.67 mmol) and formaldehyde solution (37% in water, 14.83 mL, 182.70 mmol). The resulting mixture was heated at 60 0C for 7 h before it was cooled to 0 0C and acidified to pH 7 with aq. HCl solution. The white precipitate was collected by n filtration, rinsed 10 with water and dried to provide N,N-[5,5'-(butane-1,4-diyl)-bis(1,3,4-thiadiazole-5,2- -bis(3-hydroxyphenylpropanamide) (36, 624 mg). The 211d itation from the filtrate provided additional product (1.29 g). 1H NMR (300 MHZ, DMSO-d6) 5 12.65 (bs, 2H), 7.35—7.30 (m, 10H), 5.09 (bs, 2H), 4.10—4.02 (m, 4H), 3.61 (d, J: 8.1 Hz, 2H), 3.02 (bs, 4H), 1.76 (bs, 4H).
GAMMA/«Mk0 @firNiM/VUMEL/O 15 To a suspension 9 (300 mg, 0.572 mmol)in a mixture of THF2(50 mL) and MeOH (5 ml) was added potassium carbonate (158 mg, 1.144 mmol) and formaldehyde solution (37% in water, 2 mL). The resulting mixture was stirred at room temperature for 48 h before it was cooled to 0 0C and acidified to pH 7 with aq. 20 HCl solution. The white precipitate was collected by suction filtration, rinsed with water and dried. The crude al was purified by HPLC to afford 29. 1H NMR (300 MHz, DMSO-d6) 5 7.34—7.26 (m, 10H), 4.13-4.02 (m, 2H), 3.81 (s, 2H), 3.62 (m, 2H), 3.24 (t, 4H), 2.93 (t, 4H).
QQLAMA/ka’x/Q@fiAMMXkEQ OH 199 25 To a suspension of 199 (2.0 g, 3.81 mmol)in a mixture of THF (250 mL) and MeOH 86 WO 78123 PCT/US2012/065816 (20 ml)H20 (20 mL) at room temperature was added 1N NaOH (20 ml) and formaldehyde solution (37% in water, 15 mL). The resulting mixture was heated at 50 0C overnight before it was cooled to 0 0C and acidified to pH 7 with aq. HCl solution. The white precipitate was collected by suction filtration, rinsed with water and dried. The crude material was purified by HPLC to afford 24. 1H NMR (300 MHz, DMSO-d6) 8 12.67 (bs, 2H), 7.36—7.30 (m, 10H), 5.10 (bs, 2H), 4.10—4.02 (m, 4H), 3.61 (d, 2H), 3.27 (t, 4H), 2.95 (t, 4H).
Prodrugs.‘ O N—N N—N O KSMS/VKSXNJk/Ph 0 k k 0 O 8 o N—N N—N o /\ M 0 M0 M0 Ph\)LN/KSJ\/\S/\/&SJ\NJ\/Ph —.Cl H H K2C03, DMF O 1 N—N N—N O PhQLNASMSA/QSXNJk/Ph H 7 k0 MO 10 To a flask containing N,N'-(5,5'-(thiobis(ethane-2,1-diyl))bis(1,3,4-thiadiazole-5,2- diy1))bis(2-phenylacetamide) (1) (9.4 mmol, 5.0 g, 1.0 equiv.) was added 100 mL DMF, K2C03 (20.98 mmol, 2.89 g, 2.2 equiv.), and chloromethyl butyrate (20.98 mmol, 2.86 g, 2.62 mL, 2.2 equiv.). The mixture stirred at room temperature for 15 hours then diluted with 200 mL water and 200 mL EtOAc. The layers were separated 15 and the aqueous layer extracted with EtOAc (2 x 100 mL) and the organic layers combined, washed with water, brine and dried over Na2S04. The Na2S04 was removed by filtration and the volatiles removed under reduced re. The nds were purified by reverse phase chromatography (MeCN, H20) giving 0.235 g of nd 8 and 0.126 g of compound 7. 20 1HNMR (300 MHz, DMSO, d6) Compound 8: 8 7.31 (m, 10H), 6.18 (s, 4H), 3.82 (s, 4H), 3.17 (dd, 2H, J=6.8 Hz), 2.92 (dd, 2H, J=6.8 Hz), 2.93 (m, 4H), 2.32 (dd, 2H, J=7.2 Hz), 1.54 (dt, 2H, J=7.2, 7.4 Hz), 0.87 (t, 3H, J: 7.4Hz). 1HNMR (300 MHz, DMSO, d6) Compound 7: 8 12.68 (s, 1H), 7.32 (m, 10H), 6.18 (s, 2H), 3.82 (s, 4H), 3.26 (dd, 2H, J=7.0 Hz), 3.17 (dd, 2H, J=6.8 Hz), 2.93 (m, 4H), 25 2.32 (dd, 2H, J=7.2 Hz), 1.54 (dt, 2H, J=7.2, 7.4 Hz), 0.87 (t, 3H, J: 7.4Hz). 87 WO 2013/078123 PCT/US2012/065816 HN\<\ \ )rNH L/ o N’N N~N 0 Nu NaN N‘N 188 36 o o —> + + o o o OflN OH m U 0 N HN‘<\5M5’ \ ‘HCI >’NH To a suspension of 3-morpholinyl-propionic acid hydrochloride (500 mg, 2.56 mmol) in DMF (20 mL) at 0 0C was added N—(3-dimethylaminopropyl)-N’- ethylcarbodiimide hydrochloride (534 mg, 2.79 mmol). The resulting mixture was stirred at 0 0C for 40 min and followed by addition of diol 36 (642 mg, 1.16 mmol) and 4-DMAP (454 mg, 3.72 mmol). The resulting mixture was stirred from 0 0C to room temperature over a period of 3.5 h before it was diluted with EtOAc and cold water. The organic layer was ted and washed with water (3 ><50 mL), brine, 10 dried (MgSO4) and concentrated. The crude product was purified by silica gel chromatography g with 10—25% MeOH in EtOAc to e {[5,5'-(butane-l,4- diyl)-bis(l ,3 ,4-thiadiazole-5 ,2-diyl)] -bis(azanediyl)} -bis(3 -oxophenylpropane-3 , l - diyl)-bis(3-morpholinopropanoate) (188, 340 mg) and a less polar product, 3-((5-{4- [5 -(3 -hydroxyphenylpropanamido)- l ,3 adiazolyl]butyl} - l ,3 ,4-thiadiazol 15 yl)amino)oxophenylpropyl holinopropanoate (228, 103 mg). 188: 1H NMR (300 MHz, DMSO-d6) 8 12.80 (s, 2H), 7.39 (m, 10H), 4.62 (t, J: 9.6 Hz, 2H), 4.33—4.27 (m, 4H), 3.48 (bs, 8H), 3.02 (bs, 4H), 2.45 (bs, 8H), 2.25 (bs, 8H), 1.76 (bs, 4H). 228: 1H NMR (300 MHz, MeOD-d4) 5 7.43—7.37 (m, 10H), 4.71 (t, .1: 10.5 Hz, 1H), 20 4.41 (m, 1H), 4.30—4.24 (m, 2H), 4.06—4.03 (m, 1H), 3.80—3.76 (m, 1H), 3.62 (bs, 4H), 3.11 (bs, 4H), 2.63—2.52 (m, 4H), 2.40 (bs, 4H), 1.90 (bs, 4H). 88 W0 2013/078123 2012/065816 1. LAH o o \ %IL 2.Mscl,pyridine,DCM MsO/W“‘“\OMS NaCN,DMSO -““ Eto oEt—. —> \\CN 1039 1040 8 JL HZN NHNH2 O O 6%“W XwN’NS _.\\\ S s 9» s H2N\<\W \W fNHZ N‘N N’N N‘N 1035 1041 To a solution of diethyl 1,2-cyclopropanedicarboxylate (5.00 g, 26.85 mmol) in THF (20 mL) at 0 0C was added a solution ofLAH (67.13 mL, 1.0 M in THF, 67.13 mmol) dropwise. The resulting mixture was stirred at 0 0C for 1.5 h before it was quenched with H20 (20 mL), 2N aq. NaOH (20 mL) and H20 (20 mL). The mixture was stirred vigorously for 1 h at room temperature before it was filtered through a plug of celite. The filtrate was dried (MgSO4) and concentrated to provide the desired diol (2.73 g) as a colorless oil.
A e of the diol (2.00 g, 19.58 mmol) in CH2Cl2 (75 mL) at 0 0C was added 10 ne (6.34 mL, 78.33 mmol) and followed by MsCl (3.33 mL, 43.08 mmol) dropwise. The resulting mixture was stirred 0 0C for 1 h before it was warmed up to room temperature. The reaction was quenched with H20 and diluted with ether. The organic layer was washed with brine, dried (MgSO4) and concentrated to provide 1039. This crude product was dissolved in DMSO (75 mL), and added NaCN (2.88 g, 15 58.75 mmol) and NaI (294 mg, 1.96 mmol). The resulting mixture was heated at 45 0C for 8 h before it was allowed to cool to room temperature and diluted with EtOAc and H20. The organic layer was separated, washed with brine, dried (MgSO4) and concentrated to provide the crude product 1040 which was used in the following step without purification. 20 A mixture of 1040 and thiosemicarbazide (3.75 g, 41.12 mmol) in trifluoroacetic acid (TFA) (20 mL) was heated at 80 0C for 5 h. The reaction was cooled to room temperature and poured into a mixture of ice and water. Sodium hydroxide pellets were added to the e until it was basic (pH 14). The white precipitate was ted by suction filtration, rinsed with water, ether and dried to provide 1041 (472 25 mg). 89 WO 2013/078123 PCT/US2012/065816 To a suspension of 1041 (70 mg, 0.26 mmol) in 1-Methylpyrrolidinone (NMP) (5 mL) at 0 0C was added phenylacetyl chloride (72 uL, 0.55 mmol) dropwise. The resulting mixture was stirred at 0 0C for 1 h before it was quenched by addition of water (~3 mL). The white itate was collected by suction filtration, rinsed with water and dried to provide 1035 (37 mg). 1H NMR (300 MHz, DMSO-d6) 8 12.65 (s, 2H), 7.34—7.27 (m, 10H), 3.82 (s, 4H), 3.04 — 2.75 (m, 4H), 1.14—1.12 (m, 2H), 0.63— 0.59 (m, 2H). 0 1. Pd catalyst, Cul, Et3N HN—<—>—|_ | 2, K2C03, MeOH HN + :—Si— —> _(=>__ 1H; — N—N | o o o o HNW—NH_ _ Pd(OH)2/C, H2 _ _ <— HN \ : , : \ / NH N—N N-N N—N N—N 1038 1037 10 To a solution of 1020 (1.50 g, 4.42 mmol), ethynyltrimethylsilane (813 uL, 5.75 mmol), PdClz(PPh3)2 (310 mg, 0.44 mmol) and CuI (59 mg, 0.31 mmol) in THF (20 mL) under argon atmosphere at room temperature was added Eth (6.16 mL, 44.23 mmol). The resulting mixture was heated at 50 0C for 5 h before it was allowed to cool to room temperature and filtered through a plug of celite. The filtrate was 15 concentrated and the crude residue was purified by flash column chromatography over silica gel eluting with 10—50% EtOAc in hexanes to e the desired t (1.21 g) as a solid.
A mixture of the foregoing ediate (1.07 g, 3.48 mmol) and K2C03 (0.40 g, 2.90 mmol) in MeOH (100 mL) was stirred at room temperature for 5 h before it was 20 concentrated under d pressure. The residue was re-dissolved in a mixture of EtOAc and H20, and was neutralized with 1N aq. HCl solution to pH 7. The organic layer was separated, washed with brine, dried (MgSO4) and concentrated. The crude e was purified by flash column chromatography over silica gel g with 10— 50% EtOAc in hexanes to provide the desired alkyne 1036 (0.48 g) as a white solid. 90 WO 2013/078123 PCT/US2012/065816 To a solution of alkyne 1036 (52 mg, 0.22 mmol) in pyridine (5 mL) at room temperature was added CuCl (4.3 mg, 0.04 mmol). The ing mixture was stirred under a stream of air for 40 min as all of the starting material was consumed. The reaction mixture was diluted with saturated aq. NH4Cl solution (~2 mL). The off- 5 white precipitate was collected by n filtration, washed with H20 and dried. This crude bis-acetylene product 1037 (52 mg) was used in the following step without further purification.
A mixture of 1037 (52 mg) and 2/C (100 mg) in a mixture of DMF (5 mL) and THF (10 mL) was stirred at room temperature under 1 atmosphere of H2 for 3 h as all 10 of the ng material was consumed. The palladium catalyst was filtered off and the filtrate was concentrated. The crude residue was purified by column chromatography over silica gel eluting with 1—10% MeOH in CHzClz to provide the desired product 1038 (18 mg) as a solid. 1H NMR (300 MHz, DMSO-d6) 8 11.26 (s, 2H), 8.20 (d, .1: 8.97 Hz, 2H), 7.56 (d, .1: 8.77 Hz, 2H), 7.36—7.24 (m, 10H), 3.78 (s, 4H), 2.90 (bs, 15 4H), 1.73 (bs, 4H). 8 HZNJLN .NH2 wCI H N—N /N /WN lW/ _> N / / TFA, 70°C HZN’kS NMP 1081 i O H2N N_N N ”MHz QQL Wm W’”“20 S AW N S °C fl 3 N—N 1082 1083 F HOY\©:O\ F 0 H N—N s O N F w ’W O\ / —. fl 3 N—N o F EDC, HOBt, DIEA, DMF 1084 F 0 i—ws NYUOHH BBrg, DCM, RT \ / _ N S N_N H O F 346 To a solution of adiponitrile (19.02 g, 175.8 mmol) in TFA (50 mL) was added thiosemicarbazide (16.02 g, 175.8 mmol) and the mixture heated to 70°C for 4 hours 91 WO 2013/078123 PCT/US2012/065816 under an atmosphere of Argon. The mixture was allowed to cool to room temperature and the volatiles removed under reduced re. The e was diluted with water (200 mL) and the pH adjusted to 7 with solid NaOH giving a white precipitate that was collected by filtration and washed with water. The solids were dried under high vacuum giving 9.22 g of 1081. 1HNMR (DMSO, d6): 8 7.02 (br s, 2H) 2.84 (m, 2H), 2.55 (m, 2H), 1.67 (m, 4H).
To a solution of 1081 (0.625 g, 2.87 mmol) in NMP (12.5 mL) was added phenylacetyl chloride (0.487 g, 0.42 mL, 3.15 mmol) dropwise and the mixture stirred at room temperature for one hour under an atmosphere of Argon. The mixture was 10 poured into water (100 mL) and the solids collected by filtration. The solids were washed with water and dried under high vacuum to give 0.805 g of 1082. 1HNMR (DMSO, d6): 8 12.65 (s, 1H) 7.31 (m, 5H), 3.80 (s, 2H), 3.00 (t, 2H, J: 7.3 Hz), 2.53 (t, 2H,.]= 7.1 Hz), 1.78 (dq, 2H,J= 7.3,7.1Hz), 1.61 (dq, 2H, J: 7.3, 7.1 Hz).
To a solution of 1082 (0.49 g, 1.33 mmol) in TFA (10 mL) was added 15 thiosemicarbazide (0.23 g, 1.46 mmol) and the mixture heated at 70°C overnight under an atmosphere of Argon. The mixture was allowed to cool to room temperature and the volatiles removed under reduced pressure. The residue was diluted with water (50 mL) and the pH adjusted to 7 with solid NaOH giving a white itate that was collected by filtration and washed with water. The solids were dried under high 20 vacuum giving 0.367 g of 1083. 1HNMR (DMSO, d6): 8 12.70 (s, 1H) 7.34 (br s, 5H), 7.16 (s, 2H), 3.82 (s, 2H), 3.01 (s, 2H), 2.84 (S, 2H), 1.71 (br s, 4H).
To a solution of 1083 (0.10 g, 0.267 mmol), 2,4-difiuoromethoxyphenylacetic acid (0.058 g, 0.267 mmol), EDC (0.127 g, 0.667 mmol), HOBt (0.090 g, 0.667 mmol) in DMF (4 mL) was added DIEA (0.171 g, 0.231 mL, 1.335 mmol) and the e 25 stirred overnight under an atmosphere of Argon. The mixture was poured into water (20 mL) and the solids formed were collected by filtration, washed with water and dried under high vacuum. The crude 1084 was used in the following step without purification. To a on of 1084 (0.050 g, 0.091 mmol) in dichloromethane (1 mL) was added BBr3 (1.0 mL, 1 mmol, 1.0 M in romethane) and the mixture stirred 30 for 4 hours at room temperature under an atmosphere of Argon. The volatiles were removed under reduced pressure and the e diluted with dichloromethane (5 92 WO 2013/078123 PCT/US2012/065816 mL). The volatiles were removed under reduced pressure and the residue diluted with water (15 mL) and the pH adjusted to 12. The aqueous layer was washed with dichloromethane (4 x 5 mL) and the pH adjusted to 4. The solids were collected by ion, washed with water and dried under high vacuum giving 0.029 g of 346. 1HNMR (DMSO, d6): 8 12.66 (s, 2H), 10.12 (s, 1H), 7.33 (s, 5H), 7.00 (m, 1H), 6.80 (m, 1H), 3.84 (s, 2H), 3.81 (s, 2H), 3.02 (br s, 4H), 1.76 (br s, 4H). m 0 0 H s o HVQVK IW YNHZ >r I OH N—N 1083 EDC, HOBt, DIEA, DMF N H 375 Mick0 To a solution of 1083 (0.05 g, 0.133 mmol), Bocaminomethyl-phenylacetic acid (0.035 g, 0.133 mmol), EDC (0.064 g, 0.332 mmol), HOBt (0.045 g, 0.332 mmol) in 10 DMF (8 mL) was added DIEA (0.086 g, 0.115 mL, 0.665 mmol) and the mixture stirred overnight under an atmosphere of Argon. The mixture was poured into water (20 mL) and the solids formed were collected by filtration, washed with water and dried under high vacuum to give 0.023 g of 375. 1HNMR (DMSO, d6): 8 12.66 (s, 2H), 7.27 (m, 10H), 4.11 (br s, 2H), 3.81 (s, 2H), 3.79 (s, 2H), 3.01(br s, 4H), 1.76 (br 15 s, 4H), 1.39 (s, 9H). 0 HO HN’<N‘N/ \ / NH 314 O A flask was charged with 1024 (100 mg, 0.27 mmol), tropic acid (54 mg, 0.326 mmol) in DMF (2 ml) at 0 0C was added HOBT (88 mg, 0.652 mmol) followed by EDCI (156 mg, 0.815 mmol). The resulting mixture was slowly warmed up to room 20 temperature and stirred for 3 h before it was quenched by addition of water (~10 mL).
The white itate was collected by n filtration, rinsed with more water and dried to afford 314. 1H NMR (300 MHz, DMSO-d6) 5 12.65 (s, 1H), 11.26 (s, 1H), 93 WO 2013/078123 PCT/US2012/065816 8.22-8.19 (d, .1: 8.82 Hz, 1H), 7.58-7.54 (d, .1: 9.72 Hz, 1H), 7.36-7.28 (m, 10H), 4.10—4.05 (m, 2H), 3.78 (s, 3H), 3.65 (s, 1H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
O 1024 315 0 /’\O 0 “u 0 334 ] 5 A flask was d with 1024 (500 mg, 1.36 mmol), delic acid (248 mg, 1.63 mmol) in DMF (10 ml) at 0 0C was added HOBT (441 mg, 3.26 mmol) followed by EDCI (781 mg, 4.08 mmol). The resulting mixture was stirred at 0 0C for 10 minutes then warmed up to room temperature and d for 10 minutes before it was quenched by addition of water (~50 mL) at 0 0C. The white precipitate was collected 10 by suction filtration, rinsed with more water and dried to afford 315. 1H NMR (300 MHz, DMSO-d6) 8 12.65 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, .1: 8.82 Hz, 1H), 7.58- 7.50 (m, 3H), 7.36-7.28 (m, 8H), 6.35 (s, 1H), 5.32 (s, 1H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
To a suspension of holinyl-propionic acid hydrochloride (209 mg, 1.07 15 mmol) in DMF (10 ml) was added EDCI (308 mg, 1.61 mmol). The resulting mixture was stirred at 0 0C for 1 hour and followed by addition of 315 (447 mg, 0.889 mmol) and 4-DMAP (261 mg, 2.14 mmol). The resulting mixture was stirred from 0 0C to room temperature over a period of 6 h before it was quenched by addition of ice water (~5OmL). The white itate was collected by suction filtration, rinsed with more 20 water. The crude material was purified by silica gel chromatography eluting with 0— 6% MeOH in EtOAc to afford 334. 1H NMR (300 MHZ, DMSO-d6) 5 12.95 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, .1: 9.45 Hz, 1H), 7.58-7.26 (m, 11H), 6.14 (s, 1H), 3.78 (s, 2H), 3.54 (bs, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 2.63 (bs, 4H), 2.38 (bs, 4H), 1.73 (bs, 4H). 94 WO 2013/078123 PCT/US2012/065816 O HO HN4N7? s N~‘N O I / / 0 317 Compound 317 was prepared according to the ure above for compound 315. 1H NMR (300 MHz, DMSO-d6) 8 12.40 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, J: 9.03 Hz, 1H), 7.58-7.54 (d, J: 9.72 Hz, 1H), 7.36-6.87 (m, 9H), 6.35 (bs, 1H), 5.30 (s, 5 1H), 3.78 (m, 5H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
HO 0 HN4”?“ s N‘N CI | / NH 04 3 318 Compound 318 was prepared according to the procedure above for compound 315. 1H NMR (300 MHz, DMSO-d6) 8 12.50 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, J: 9.43 Hz, 1H), 7.60-7.27 (m, 10H), 6.51 (bs, 1H), 5.35 (s, 1H), 3.78 (s, 2H), 3.01 (bs, 2H), 10 2.90 (bs, 2H), 1.73 (bs, 4H). 0 NM HN’</ \ N s ~‘N | / NH Cl 335 o A flask was charged with 1024 (50 mg, 0. 135 mmol), 3-chlorophenylacetic acid (28 mg, 0.163 mmol) in DMF (1 ml) at 0 0C was added HOBT (44 mg, 0.326 mmol) followed by EDCI (78 mg, 0.408 mmol). The resulting mixture was slowly warmed 15 up to room temperature and stirred for l h before it was quenched by addition of water (~5 mL). The white precipitate was ted by suction ion, rinsed with more water and ether then dried to afford 335. 1H NMR (300 MHZ, DMSO-d6) 5 12.65 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, .1: 8.82 Hz, 1H), 7.58-7.54 (d, .1: 9.72 Hz, 95 WO 2013/078123 PCT/US2012/065816 1H), 7.36-7.28 (m, 9H), 3.84 (s, 2H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs,4H).
O N~N HN’</ \ N\ s ‘N I / NH OH 0 337 Compound 337 was prepared according to the procedure above for compound 335. 5 1H NMR (300 MHz, DMSO-d6) 8 12.65 (s, 1H), 11.26 (s, 1H), 9.38 (s, 1H), 8.22-8.19 (d, J: 8.37 Hz, 1H), 7.58-7.54 (d, J: 9.63 Hz, 1H), .09 (m, 6H), 6.75-6.65 (m, 3H), 3.78 (s, 2H), 3.70 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
/ / H N \ HN,< \ 2 ’<8 N°N S N“N I I / / NH _. H NH 0 1024 04 3 O)” >L 339 o? O O N-N /N~N HN’</ \ HN’< ‘ N, S S IN:N ‘N I / / NH _. NH NH2 —> H o O O TFA E] (2; 7 341 382 339, 341, 382: A flask was d with 1024 (100 mg, 0.27 mmol), Boc 10 aminomethyl-phenylacetic acid (86 mg, 0.325 mmol) in DMF (2 ml) at 0 0C was added HOBT (88 mg, 0.65 mmol) followed by EDCI (156 mg, 0.812 mmol). The resulting mixture was stirred at 0 0C for 5 minutes then warmed up to room temperature and stirred for 1.5 h before it was quenched by addition of water (~10 mL) at 0 0C. The white precipitate was collected by suction filtration, rinsed with 15 more water and ether then dried to afford 339. 1H NMR (300 MHZ, DMSO-d6) 5 12.65 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, .1: 8.82 Hz, 1H), 7.58-7.54 (d, .1: 9.42 Hz, 1H), .13 (m, 9H), 4.13-4.11 (d, .1: 10.62, 2H), 3.78 (s, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H), 1.38 (s, 9H). 96 WO 78123 PCT/US2012/065816 To a suspension of 339 (50 mg, 0.081 mmol) in dichloromethane (2 ml) was added TFA (2 ml) at 0 0C. The resulting mixture was stirred at room temperature for 20 minutes before it was evaporated under vacuo to dryness. Ether was added and the white precipitate was collected by suction filtration, rinsed with more ether and romethane then dried to afford 341. 1H NMR (300 MHZ, DMSO-d6) 5 12.65 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, J: 8.82 Hz, 1H), 8.14-8.11 (bs, 2H), 7.58-7.54 (d, J = 9.42 Hz, 1H), 7.36-7.13 (m, 9H), 4.06-4.03 (m, 2H), 3.84 (s, 2H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
To a on of 341 (10 mg, 0.0159mmol) in DMF (1 ml) at 0 0C was added 10 triethylamine (4.4 ul, 0.0317 mmol) drop wise followed by ethyl formate (1.8 ul, 0.0191 mmol) drop wise. The resulting mixture was slowly warmed up to room temperature and stirred for 30 minutes before it was quenched by addition of water (~1 mL) at 0 0C. The mixture was partitioned n water and EtOAc. The organic extract was washed with water, dried over sodium sulfate, filtered and 15 evaporated. The crude material was purified by silica gel chromatography eluting with 0-6% MeOH in CHZClz to afford 382. 1H NMR (300 MHZ, DMSO-d6) 5 12.65 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, J: 8.82 Hz, 1H), 7.67-7.58 (bs, 1H), .54 (d, J: 9.42 Hz, 1H), 7.36-7.13 (m, 9H), 4.18-4.16 (m, 2H), 4.06-4.0 (q, 2H), 3.78 (s, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H), 1.19-1.13 (t, 3H). 0 HN,qN‘NSW\ H / NH N 760 O 431 20 Compound 431 was prepared according to the procedure above for compound 382 with the appropriate reagents. 1H NMR (300 MHz, DMSO-d6) 5 12.65 (s, 1H), 11.26 (s, 1H), 8.35 (s, 1H), 8.22-8.19 (d, J: 8.88 Hz, 1H), 7.57-7.54 (d, J: 9.51 Hz, 1H), 7.38-7.15 (m, 9H), 4.25-4.24 (d, J: 5.64 Hz, 2H), 3.76 (s, 4H), 3.01 (bs, 2H), 2.90 25 (bs, 2H), 1.87 (s, 3H), 1.73 (bs, 4H). 97 WO 2013/078123 PCT/US2012/065816 0 NM / HN’<SA\/\/\ENJ\I\\ H / NH N 60 o 432 Compound 432 was prepared according to the procedure above for compound 382 with the appropriate reagents. 1H NMR (300 MHz, DMSO-d6) 5 12.63 (s, 1H), 11.26 (s, 1H), 9.04-9.01 (m, 1H), 8.22-8.19 (d, J: 8.91 Hz, 1H), 7.93-7.89 (d,.]= 9.51 Hz, 2H), 7.58-7.25 (m, 13H), 4.50-4.48 (d, J: 5.91 Hz, 2H), 3.78 (s, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 HN’<S)\/\/UM H / NH i0 o 433 Compound 433 was ed ing to the procedure above for compound 382 with the appropriate reagents. 1H NMR (300 MHz, DMSO-d6) 5 12.63 (s, 1H), 11.26 10 (s, 1H), 8.31-8.21 (m, 1H), 8.20-8.19 (d, J: 9.57 Hz, 1H), .54 (d, J: 8.73 Hz, 1H), 7.35-7.13 (m, 9H), 4.26-4.24 (d, J: 5.52 Hz, 2H), 3.78 (s, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 2.0 (s, 3H), 1.73 (bs, 4H), 0.86-0.85 (d, J: 3.99 Hz, 6H). 0 o N HN’<S / ‘N \ NtN HIV/<3/ \ I NsN / —> I / To a solution of 341 (70 mg, 0.111mmol) in DMF (1 ml) at 0 0C was added 15 triethy1amine (31 ul, 0.22 mmol) drop wise followed by 5-bromovaleryl chloride (12 ul, 0.122 mmol) drop wise. The resulting mixture was slowly warmed up to room ature and stirred for 1h. Potassium tert-butoxide (50 mg, 0.445 mmol) was 98 WO 2013/078123 PCT/US2012/065816 then added to the reaction mixture at 0 0C. The resulting mixture was slowly warmed up to room temperature and stirred for overnight before it was quenched by addition of water (~2 mL) at 0 0C. The mixture was partitioned between water and EtOAc.
The organic extract was washed with water, dried over sodium sulfate, filtered and ated. The crude material was d by silica gel chromatography eluting with 0-6% MeOH in CHzClz to afford 476. 1H NMR (300 MHZ, DMSO-d6) 8 12.65 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, .1: 8.82 Hz, 1H), 7.58-7.54 (d, .1: 9.42 Hz, 1H), 7.36-7.13 (m, 9H), 4.50 (s, 2H), 3.78 (s, 4H), 3.35 (bs, 2H), 3.20 (bs, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 2.30 (bs, 2H), 1.68-1.80 (d, 6H). 0 HO N\N ’ (R)HN \ N s ~‘N I / NH CI 340 0 10 nd 340 was prepared according to the procedure above for compound 315 with the appropriate reagents. 1H NMR (300 MHz, DMSO-d6) 5 12.50 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, J: 9.24 Hz, 1H), 7.60-7.27 (m, 10H), 6.51 (bs, 1H), 5.35 (s, 1H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
HO 0 N (R) ‘N HN’</ \ N s \‘N | / NH 349 0 15 nd 349 was prepared according to the procedure above for compound 315 with the appropriate reagents. 1H NMR (300 MHz, DMSO-d6) 5 12.41 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, J: 8.76 Hz, 1H), 7.58-7.27 (m, 11H), 6.36 (s, 1H), 5.34 (s, 1H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 99 WO 2013/078123 PCT/US2012/065816 Hg 0 6 N (S)‘ ‘N HN’</ \ S / NH 0 350 Compound 350 was prepared according to the procedure above for nd 315 with the riate reagents. 1H NMR (300 MHz, DMSO-d6) 5 12.41 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, J: 8.67 Hz, 1H), 7.58-7.27 (m, 11H), 6.34 (s, 1H), 5.34 (s, 1H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
HO 0 HN4N7” F SW\ / NH F 351 0 Compound 351 was prepared according to the procedure above for compound 315 with the appropriate reagents. 1H NMR (300 MHz, DMSO-d6) 5 12.50 (s, 1H), 11.26 (s, 1H), 8.21-8.18 (d, J: 8.67 Hz, 1H), 7.58-7.54 (d, J: 9.72 Hz, 1H), 7.36-7.23 (m, 10 8H), 6.67 (s, 1H), 5.40 (s, 1H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 “flu/(NT N s ~‘N | / NH 0 352 To a solution of 1024 (50 mg, 0.136 mmol) in DMF (1 ml) at 0 0C was added triethylamine (38 ul, 0.271 mmol) drop wise ed by benzyl isocyanate (20 ul, 15 0.163 mmol) drop wise. The resulting mixture was slowly warmed up to room temperature and stirred for 40 minutes before it was quenched by addition of water ~5 mL at 0 0C. The white precipitate was collected by suction filtration, rinsed with 100 WO 2013/078123 PCT/US2012/065816 more water. The crude al was purified by silica gel chromatography eluting with 0—6% MeOH in CHzClz to afford 352. 1H NMR (300 MHz, DMSO-d6) 5 11.26 (s, 1H), 10.82 (s, 1H), 8.22-8.19 (d, J: 9.42 Hz, 1H), 7.58-7.54 (d, J: 8.79 Hz, 1H), 7.36-7.31 (m, 10H), 7.06 (bs, 1H), 4.37-4.35 (d, J: 5.22 Hz, 2H), 3.78 (s, 2H), 2.99- 2.90 (m, 4H), 1.73 (bs, 4H). 0 NM HN’</ \ N S °N o l / / 0 353 Compound 353 was prepared according to the procedure above for the preparation of compound 335. 1H NMR (300 MHz, DMSO-d6) 8 12.57 (s, 1H), 11.26 (s, 1H), 8.22- 8.19 (d, J: 9.45 Hz, 1H), 7.57-7.54 (d, J: 9.48 Hz, 1H), 7.36-7.25 (m, 6H), 6.91- 10 6.84 (m, 3H), 3.76 (m, 7H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
N~N N~N MAJ/(SW/ \ 615Nf<3/ \ N¢N I / —> \ / / NH NH O o 1024 354 A flask was charged with 1024 (50 mg, 0.135 mmol), 2-pyridine acetic acid hydrochloride (27 mg, 0.156 mmol) in DMF (1 ml) at 0 0C was added propylphosphonic anhydride solution (91 ul) followed by triethylamine (54 ul, 0.39 15 mmol). The resulting e was slowly warmed up to room temperature and stirred for 1 h before it was quenched by addition of water (~5 mL). The white itate was ted by suction filtration, rinsed with more water and ether then dried to afford 354. 1H NMR (300 MHz, DMSO-d6) 5 12.65 (s, 1H), 11.26 (s, 1H), 8.51 (s, 1H), 8.22-8.19 (d, J: 8.97 Hz, 1H), 7.81-7.76 (m, 1H), 7.58-7.54 (d, J: 9.06 Hz, 20 1H), 7.42-7.26 (m, 7H), 4.02 (s, 2H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 101 WO 2013/078123 PCT/US2012/065816 o d4 ’(SN~N/HN \ N“” N\/ | / NH 0 355 Compound 355 was prepared according to the procedure above for the preparation of compound 354. 1H NMR (300 MHz, DMSO-d6) 8 12.70 (s, 1H), 11.26 (s, 1H), 8.53- 8.49 (m, 1H), 8.22-8.19 (d, J: 9.0 Hz, 1H), 7.77-7.73 (d, J: 8.46 Hz, 1H), 7.58-7.54 (d, J: 9.48 Hz, 1H), .26 (m, 7H), 3.88 (s, 2H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
Compounds 309 and 310 were prepared according to the procedure above for the preparation of nd 354.
CCH4 NBS Br 2-Methyl imidazole Benzoyl de. Acetone COOMe COOMe —, —> 1 043 1 044 N>\N COOMe a LIOH-Hzo_ L/ N/\©/\COOH N ““““” \za 1 045 1046 H2N4”'\ S NN I/ N‘N 1024 NH HN’</ \ N O S ‘N O I HATU / NH DIPEA —> §=N O m) 380 10 To a solution of 1043 (3.2g, 19.5mmol) in carbon tetrachloride (150mL) was added N—bromosuccinimide (3.47g, 19.6mmol) and benzoyl peroxide (10mg, catalytic). The resulting mixture was refluxed overnight before it was filtered hot. The filtrate was concentrated under d pressure and the residue ed was purified by silica gel chromatography eluting with 20% ethylacetate/hexane to afford 1044 (2g, 42% 102 WO 2013/078123 PCT/US2012/065816 yield) as an oil. 1H NMR (300MHz, Chloroform-d) 8 ppm 3.66 (s, 2H) 3.74 (s, 3H) 4.51(s, 2H) 7.35 (m, 4H) To a solution of 1044 (0.243 g, lmmol) in acetone (10mL) was added 2-methyl imidazole (0.41 g, 5mmol). The resulting mixture was refluxed overnight before it was concentrated under reduced pressure and the residue obtained was diluted with water (~100mL). The ing solution was partitioned n water and ethyl acetate.
The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and ated. The residue obtained was purified by silica gel chromatography eluting with MeOH/dichloromethane to afford 1045 (0.17g, 69% 10 yield) as an oil. 1H NMR (300MHz, Chloroform—d) 8 ppm 2.37 (s, 3H) 3.63 (s, 2H) 3.72 (s, 3H) 5.07 (s, 2H) 6.87 (s, 1H) 6.96-7.02 9m, 2H) .33 (m, 3H) To a solution of 1045 (0. 17g, 0.69mmol) in THF/MeOH/Water (lOmL, 2mL, 2mL) was added lithium ide monohydrate (0.06g, 1.42mmol). The resulting mixture was stirred at room temperature overnight before it was concentrated under reduced 15 pressure. The residue obtained was diluted with water ) and the resulting solution was acidified with acetic acid. The aqueous layer was concentrated and the product was ed by prep HPLC. The residue obtained was dissolved in water (mL) and concentrated hydrochloric acid (mL) was added to it before it was concentrated and dried to afford 1046 (0. 15gm) as a hydrochloride salt. 20 To a suspension of carboxylic acid 1046 (41.8mg, 0.157mmol) in DMF (3mL) was added HATU (61 .3mg, 0. l6lmmol) and d till reaction e is clear followed by the addition of an amine 1024 (52.5mg, 0.142mmol) and DIPEA (50ul, 0.29mmol). The resulting mixture was stirred at room temperature overnight before it was quenched by the addition of water. The resulting solution was partitioned 25 between water and ethyl acetate. The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The e obtained was triturated with ether. The solid separated was filtered, washed with ether and dried to afford 380 (40mg, 48%). 1H NMR (300MHz, ylsulfoxide-d6) 5 ppm 1.74 (brs, 4H) 2.91-3.02 (brs, 4H) 3.78-3.83 (m, 4H) 5.34 (s, 2H) 7.16-7.57 (m, 12H) 30 8.19-8.22 (d, 1H) 11.26 (s, 1H) l2.65 (brs, lH) 103 WO 2013/078123 PCT/US2012/065816 O/—\N_/—C| \—/ 1050 DMF MeOH HO\©/\COOH HO 80012 COOMe K2003 (\NNO COOMe —> —> 0 (DA 1048 1°49 1°51 N-N H N4 \ 2 S INN 1024 HN’< s .
O N O I LIOH.H20. / /\/0 HATU {\N NH COOH DIPEA l/\o 1052 OXNQ To an ice cold solution of 1048(5 g, 0.033mol) in methanol (50mL) was added l chloride (0.2mL) and the resulting mixture was d at room temperature overnight before it was concentrated under reduced pressure. The residue obtained was dried at high vacuum overnight to afford 1049 (5gm) as an oil and was used as such for the next step. 1H NMR (300MHz, Chloroform-d) 5 ppm 3.62 (s, 2H) 3.74 (s, 3H) 6.76- 6.87 (m, 3H) .21(m, 1H).
To a solution of 1049 (lg, 6mmol) in DMF (20mL) was added ium carbonate (2.08g, lSmmol), 1050 (l.225g, 6.62mmol) and sodium iodide (10mg). The resulting 10 mixture was stirred at 80 0C overnight before it was diluted with water (~100mL).
The resulting solution was partitioned between water and ethyl acetate. The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with MeOH/dichloromethane to afford 1051 (lg, 60% yield) as an oil. 1H 15 NMR (300MHz, Chloroform-d) 8 ppm 2.61 (s, 4H) 2.83 (t, 2H) 3.62 (s, 2H) 3.63 (s, 3H) 3.73-3.77 (m, 4H) 4.14 (t, 2H) .91 (m, 3H) 7.26-7.29 (m, 1H) To a solution of 1051 (lg, 3.57mmol) in OH/Water (30mL, SmL, SmL) was added lithium ide monohydrate (0.3g, 7.14mmol). The resulting mixture was stirred at room temperature overnight before it was concentrated under reduced 20 pressure. The residue obtained was diluted with water (~50mL) and the resulting solution was acidified with 1N hydrochloric acid. The aqueous layer was concentrated and the product was ed by prep HPLC. The residue obtained was dissolved in 104 WO 2013/078123 PCT/US2012/065816 water (mL) and trated hydrochloric acid (mL) was added to it before it was concentrated and dried to afford 1052 as a hydrochloride salt.
To a suspension of carboxylic acid 1052 (47.4mg, 0.157mmol) in DMF (3mL) was added HATU (61 .3mg, 0.161mmol) and stirred till reaction mixture is clear ed by the addition of an amine 1024 (52.5mg, 0.142mmol) and DIPEA (50ul, 0.29mmol). The resulting mixture was stirred at room temperature overnight before it was quenched by the addition of water. The resulting solution was partitioned between water and ethyl acetate. The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue obtained 10 was purified by silica gel tography eluting with MeOH/dichloromethane to afford 381 (40mg, 46% yield). 1H NMR z, Dimethylsulfoxide-d6) 5 ppm 1.74 (brs, 4H) 2.72 (t, 2H) 2.89-2.9 (m, 4H) 3.02 (brs, 4H) 3.336 (m, 2H) 3.76-3.78 (m,2H) 4.09 (m, 2H) 6.88-6.93 (m, 3H) 7.24-7.36 (m, 6H) 7.54-7.58 (d, 1H) 8.18- 8.21 (d, 1H) 11.26 (s, 1H) 12.65 (brs, 1H).
Pyrazole Br DMF COOMe K2003 THF GUN4 COOMe —> / —»<2§©W 1044 1053 1054 NaCN N DCM N D / ‘N CI Nal 4 onane SOCI2 9V DMF Q/UACN —> —>Q/\©/\COOHconcHCI —> 1055 1056 1057 N-N H N48 \ 2 INN/ 1024' NH M4 3 NN HATU WNH DIPEA 15 To a solution of 1044 (2.29g, 0.01mol) in DMF (100mL) was added potassium carbonate (1 .3 8g, 0.01mmol) and pyrazole , 0.01mol). The resulting mixture was stirred at 70 0C for 5hr before it was diluted with water (~100mL). The resulting solution was partitioned between water and ethyl acetate. The organic extract was 20 washed with more water, separated, dried over sodium sulfate, filtered and 105 WO 2013/078123 PCT/US2012/065816 evaporated. The residue obtained was purified by silica gel tography g with EtOAc/Hexane to afford 1053 (lg, 50% yield). 1H NMR (300MHz, Chloroform-d) 8 ppm 3.94 (s, 3H) 5.40 (s, 2H) 6.33 (s, 1H) 7.42-7.48 (m, 3H) 7.58 (s, 1H) 7.95 (s, 1H) 8.00-8.02 (m, 1H) To an ice cold solution of 1053 (lg, 4.62mmol) in THF (20mL) was added lithium um hydride (2.5mL, 2M/THF) drop wise and the resulting reaction mixture was stirred at 0 0C for 5hr before it was quenched with saturated le salt solution. The resulting solution was partitioned n water and ethyl acetate. The organic extract was washed with more water, ted, dried over sodium sulfate, 10 filtered and evaporated to afford 1054 (0.8g, 92% yield). 1H NMR (300MHz, Chloroform—d) 8 ppm 4.71 (s, 2H) 5.35 (s, 2H) 6.30 (s, 1H) 7.15-7.43 (m, 5H) 7.58 (s, 1H) To a solution of 1054 (0.8g, 4.2mmol) in dichloromethane (20mL) was added thionyl chloride and the resulting mixture was stirred at room temperature for 5hr before it 15 was trated under the reduced pressure. The residue obtained was dried at high vacuum overnight to afford 1055 (lg, 97% yield) as a HCl salt. 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 4.75 (s, 2H) 5.38 (s, 2H) 6.30 (s, 1H) 7.19-7.50 (m, 5H) 7.86 (s, 1H) ll.49-ll.60 (brs, lH) To a solution of 1055 (lg, 4.lmmol) in DMF (20mL) was added sodium cyanide 20 (0.625 g, l2.7mmol) and sodium iodide (20mg) and the resulting reaction mixture was stirred at 70 0C for 2hr before it was diluted with water. The resulting solution was partitioned between water and ethyl acetate. The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue ed was purified by silica gel chromatography eluting with EtOAc/Hexane to 25 afford 1056 (0.664g, 83% yield). 1H NMR (300MHz, Chloroform-d) 8 ppm 3.76 (s, 2H) 5.38 (s, 2H) 6.35 (s, 1H) 7.19-7.46 (m, 5H) 7.61 (s, 1H) To a solution of 1056 g, 3.3mmol) in dioxane (5mL) was added concentrated hydrochloric acid (5mL) and the resulting reaction mixture was stirred at 90 0C overnight before it was concentrated under the d pressure. The residue ed 30 was purified through prep HPLC and was converted to HCl salt to afford 1057 (0.5g, 106 WO 2013/078123 PCT/US2012/065816 40% . 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 3.55 (s, 2H) 5.33 (s, 2H) 6.29 (s, 1H) 7.14-7.20 (m, 4H) 7.48 (s, 1H) 7.84 (s, 1H) 11.97-11.99 (brs, 1H) To a suspension of carboxylic acid 1057 (19.8mg, 0.0785mmol) in DMF (2mL) was added HATU (30.6mg, 0.08mmol) and stirred till reaction mixture is clear followed by the addition of an amine 1024 (26.25mg, ol) and DIPEA (25ul, 0.15mmol). The resulting mixture was stirred at room temperature ght before it was quenched by the addition of water. The solid separated was filtered, washed with water and dried to afford 395 (18mg, ld). 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.74 (brs, 4H) 2.89-3.04 (m, 4H) 3.78 (s, 4H) 5.33 (s, 10 2H) 6.27-6.28 (s, 1H) 7.09-7.58 (m, 11H) 7.82 (s, 1H) 8.19-8.21 (d, 1H) 11.26 (s, 1H) 12.65 (brs, 1H) Br COOMe_> COOMe \N COOMe BOC 1044 1058 1059 H N—(S \ 2 SW NHN’48/N‘N NH 1024 \N COOH | HATU UOHlbO BOC DPEA BOC _, 1060 396 N‘N N‘N HN’</S\ N HN \ N N DMF Is ~‘ N DCM O | O TEA I TFA / / NH AcercNonde' NH —> —’ o Y0 o ZI N\ 408 445 To a solution of 1044 (lg, 4.1mmol) in L) was added 2M/THF methyl amine solution (2mL) and the resulting reaction mixture was stirred at room temperature 15 overnight before it was concentrated under the reduced pressure. The residue ed was partitioned between water and ethyl acetate. The organic extract was washed with more water, ted, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with MeOH/dichloromethane to afford 1058 (0.26g, 33% yield). 1H NMR (300MHz, 107 WO 2013/078123 PCT/US2012/065816 Chloroform—d) 8 ppm 2.49 (s, 3H) 3.66 (s, 2H) 3.73 (s, 3H) 3.79 (s, 2H) 72-733 (m, 4H).
To a solution of 1058 , 1.35mmol) in romethane (5mL) was added boc anhydride (0.293 g, ol) and the resulting reaction mixture was stirred at room temperature for 4hr before it was purified by silica gel chromatography g with EtOAc/Hexane to afford 1059 (0.3g, 77% . 1H NMR (300MHz, Chloroform-d) 8 ppm 1.5 (s, 9H) 2.84 (s, 3H) 3.66 (s, 2H) 3.73 (s, 3H) 4.44 (s, 2H) 7.17-7.32 (m, 4H).
To an ice cold solution of 1059 (0.3 g, 1.02mmol) in e (3mL) and water (2mL) 10 was added lithium hydroxide monohydrate (0.086g, 2.04mmol) and the resulting reaction mixture was stirred at 0 0C for 3hr before it was acidified with 1N HCl. The resulting solution was partitioned between water and ethyl acetate. The organic extract was washed with more water, separated, dried over sodium e, filtered and evaporated. The residue obtained was dried at high vacuum ght to afford 15 1060 (0.2g, 70%yield). 1H NMR (300MHz, Chloroform-d) 8 ppm 1.5 (s, 9H) 2.84 (s, 3H) 3.66 (s, 2H) 4.43 (s, 2H) 7.17-7.32 (m, 4H) To a suspension of carboxylic acid 1060 (51.1mg, 0.183mmol) in DMF (3mL) was added HATU (69.7mg, 0.183mmol) and stirred till reaction mixture is clear followed by the addition of an amine 1024 (61 .3mg, 0.166mmol) and DIPEA (5 8ul, 20 0.33mmol). The resulting mixture was stirred at room temperature overnight before it was quenched by the addition of water. The resulting solution was partitioned between water and ethyl e. The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with MeOH/dichloromethane to 25 afford 445 (0.06g, 57% yield). 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.37-1.38 (s, 9H) 1.74 (brs, 4H) 2.76 (s,3H) 2.89 (brs, 2H) 3.02 (brs, 2H)3.78-3.80 (m, 4H) 4.36 (s, 2H) .36 (m, 9H) 7.54-7.57 (d, 1H) 8.18-8.21 (d, 1H) 11.26 (s, 1H) 12.65 (brs, 1H).
Prep of 445 via 396 deprotection to 408 and re—acylation: 108 WO 78123 PCT/US2012/065816 HN’</ \ N\ S ‘N o | / NH Y0 0 N\ To an ice cold solution of 408 (26mg, 0.04mmol) in DMF (1mL) was added triethylamine (12.3uL, 0.088mmol) and acetyl chloride (3.16uL, 0.044mmol). The resulting e was stirred at room temperature for 2hr before it was diluted with water. The solid separated was filtered, washed with water and dried at high vacuum overnight to afford 445 (10mg, 48% yield). 1H NMR z, Dimethylsulfoxide- d6) 5 ppm 1.74 (brs, 4H) 2.05 (m, 3H) 2.91-3.02 (m,7H) 3.78-3.82 (m, 4H) 4.49-4.56 (m, 2H) 7.18-7.36 (m, 9H) 7.55-7.58 (d, 1H) 8.18-8.21 (d, 1H) 8.75-8.7 (brs, 2H) 11.26 (s, 1H) 12.65 (brs, 1H).
N~N HN’</ \ N\ S ‘N o | / NH 0 10 Compound 401 was prepared according to the procedure above for the preparation of compound 339. 1H NMR (300MHz, ylsulfoxide-d6) 8 ppm 1.40 (s, 9H) 1.75 (brs, 4H) 2.87 (brs, 2H) 2.89 (brs, 2H) 3.78 (s, 4H) 4.09-4.11 (brs, 2H) 7.18-7.36 (m, 9H) 7.54-7.58 (d, 1H) 8.18-8.21 (d, 1H) 11.26 (s, 1H) 12.65 (brs, 1H) Fgco H N o / I s \ N , O HN‘<\ N I 413 15 N’N Compound 413 was prepared according to the procedure above for the preparation of compound 315. 1H NMR (300 MHz, DMSO-d6) 8 12.68 (bs, 1H), 11.26 (s, 1H), 8.20 109 WO 2013/078123 PCT/US2012/065816 (d, .1: 9.46 Hz, 1H), 7.58—7.26 (m, 10H), 3.90 (s, 2H), 3.78 (s, 2H), 3.02 (bs, 2H), 2.90 (bs, 2H), 1.74 (bs, 4H).
Br S ,N O E j H0 \N HN\<\ N,l1 Compound 415 was prepared according to the procedure above for the preparation of compound 315.: 1H NMR (300 MHz, DMSO-d6) 8 12.48 (s, 1H), 11.26 (s, 1H), 8.20 (d, J: 8.95 Hz, 1H), 7.75 (s, 1H), 7.58—7.26 (m, 9H), 6.52 (m, 1H), 5.35 (m, 1H), 3.78 (s, 2H), 3.02 (m, 2H), 2.90 (m, 2H), 1.74 (bs, 4H).
HN’«N‘N\2 SW / NH 1024 0 HATU EtOOC/\©/\COOEt—>L'0H.H20 EtOOC COOH DIPEA —> 1063 1064 N‘N N‘N HN’</sl|N/\N \ N\ O ‘N o l / LiOH H20 NH —> O COOEt COOH 465 N‘N / HATU HN’<S N¢N DIPEA O | / NH , 0 O N/ | 472 10 To a on of 1063 (6.31g, 24.9mmol) in ethanol was added lithium hydroxide monohydrate (1 .048g, 24.9mmol) and the ing reaction mixture was stirred at room temperature for 3hr before it was concentrated under the reduced pressure. The residue obtained was diluted with water and was acidified with 6N HCl. The solution was extracted with ethyl acetate. The organic extract was washed with more water, 110 WO 2013/078123 PCT/US2012/065816 separated, dried over sodium sulfate, filtered and ated. The residue obtained was purified by silica gel chromatography eluting with EtOAc/hexane to afford 1064 (3g, 53% yield).
To a sion of carboxylic acid 1064 (0.1g, 0.44mmol) in DMF (2mL) was added HATU (0. 17g, 0.44mmol) and stirred till reaction mixture is clear followed by the addition of an amine 1024 (0.l5g, 0.4mmol) and DIPEA L, 0.8mmol). The ing mixture was stirred at room ature overnight before it was quenched by the addition of water. The solid separated was filtered, washed with water and dried to afford 456 (0.2, 86%yield). 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 10 ppm 1.18 (t, 3H) 1.74 (brs, 4H) 2.88-2.90 (m,2H) 3.01-3.04 (m, 2H) 3.66 (s, 2H) 3.78 (s, 4H) 4.05-4.12 (q, 2H) 7.19-7.36 (m, 9H) 7.55-7.58 (m, 1H) 8.18-8.21 (d, 1H) 11.26 (s, 1H) 12.65 (brs, 1H).
To a solution of 456 (0.205 g, 0.358mmol) in Dioxane/Water (20mL/ 6mL) was added m hydroxide monohydrate (0.06g, 1.42mmol). The resulting mixture was stirred 15 at room temperature for 3hr before it was acidified with acetic acid. The solution was concentrated under reduced pressure and the residue obtained was diluted with water.
The solid separated was filtered, washed with water and dried at high vacuum ght. The residue obtained was purified by silica gel chromatography eluting with ichloromethane to afford 465 (0.15 g, 77% yield). 1H NMR (300MHz, 20 Dimethylsulfoxide-d6) 8 ppm 1.74 (brs, 4H) 2.90 (brs, 2H) 3.01 (brs, 2H) 3.5 (s, 2H) 3.78 (s, 4H) 7.19-7.36 (m, 9H) 7.55-7.58 (m, 1H) 8.18-8.21 (d, 1H) 11.26 (s, 1H) 12.32 (brs, 1H) 12.65 (s, 1H).
To a suspension of carboxylic acid 465 (25mg, 0.046mmol) in DMF (1mL) was added HATU (19.2mg, 0.05mmol) and stirred till reaction mixture is clear followed 25 by the addition of an N,N-dimethylamine (2M/THF, 30uL, 0.05mmol) and DIPEA (l6uL, mol). The resulting mixture was stirred at room temperature for 3hr before it was quenched by the addition of water. The solid separated was filtered, washed with water and dried to afford 472 (19mg, 73%yield). 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.74 (brs, 4H) 2.83-2.90 (brs, 6H) 3.01 (brs, 4H) 3.68 30 (s, 2H) 3.78 (s, 4H) 7.14-7.36 (m, 9H) 7.55-7.58 (d, 1H) 8.18-8.21 (d, 1H) 11.26 (s, 1H) 12.65 (brs, 1H). lll WO 2013/078123 2012/065816 HO C COOH COOMe K2003 /S|‘O/\/O COOMe LiOH.H20 HON —> —> 1049 1065 1066 H N4 \ 2 SJ\v/\¢/\E:Ei/ N~N NH 1024 HN/Q \ S ”K \N O I HATU / / NH 8' o / "o/V Ucoom fl,02) 1067 427 To a solution of 1049 (1g, 6mmol) in DMF (20mL) was added potassium carbonate (1 .662g, 12mmol) and , 9mmol). The resulting mixture was stirred at 70 0C overnight before it was diluted with water (~100mL). The resulting solution was partitioned between water and ethyl acetate. The organic t was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with EtOAc/Hexane to afford 1065 (1.78g, 91% yield) as an oil. 1H NMR (300MHz, Chloroform-d) 5 ppm 0.13 (s, 6H) 0.95 (s, 9H) 3.63 (s, 2H) 3.73 (s, 2H) 3.99-4.06 (m, 4H) 6.87 (m, 3H) 7.3 10 (m, 1H).
To a solution of 1065 (1 .78g, 5.5mmol) in THF/MeOH/Water (30mL, 3mL, 3mL) was added lithium hydroxide drate , 10.9mmol). The ing e was stirred at room temperature overnight before it was concentrated under reduced pressure. The residue obtained was diluted with water (~20mL) and the resulting 15 solution was acidified with 6N hydrochloric acid. The solution was partitioned between water and ethyl acetate. The organic extract was washed with more water, separated, dried over sodium sulfate, d and evaporated. The residue obtained was purified by silica gel chromatography eluting with EtOAc/Hexane to afford 1065 and 1066. 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 3.54 (s, 2H) 3.72 (brs, 20 2H) 3.96-3.98 (brs, 2H) 4.85 (brs, 1H) 6.82-6.85 (m, 3H) 70-722 (m, 1H) 12.3 (brs, 1H).
To a suspension of carboxylic acid 1065 (27mg, 0.137mmol) in DMF (2mL) was added HATU (52.2mg, 0.137mmol) and stirred till reaction mixture is clear followed 112 WO 2013/078123 2012/065816 by the addition of an amine 1024 (46mg, 0.125mmol) and DIPEA (44ul, 0.25mmol).
The resulting mixture was stirred at room temperature overnight before it was quenched by the addition of water. The solid ted was filtered, washed with water and dried. The solid obtained was purified by prep HPLC to afford 427 (16mg, 23%yield). 1H NMR z, Dimethylsulfoxide-d6) 5 ppm 1.75 (brs, 4H) 2.90 (brs, 2H) 3.02 (brs, 2H) 3.71-3.78 (m, 6H) 3.98-3.99 (brs, 2H) 4.84-4.87 (brs, 1H) 6.83-6.92 (m,3H) 7.21-7.36 (m, 6H) 7.54-7.58 (d, 1H) 8.2-8.23 (d, 1H) 11.26 (s, 1H) 12.65 (brs, 1H).
N‘N HN’</ \ N s HO O COOMe \ /\/O —> léN 428 1049 o 1075 10 To a solution of 1049 (1g, 6mmol) in acetone (50mL) was added cesium carbonate (2.545 g, 7.83mmol), 2- bromoethyl methyl ether(0.92g, 6.62mmol) and sodium iodide(10mg). The resulting mixture was stirred at 50 0C overnight before it was filtered. The e was evaporated and the residue ed was purified by silica gel chromatography eluting with EtOAc/Hexane to afford 1075 (0.97g, 72% yield) as 15 oil. 1H NMR (300MHz, Chloroform-d) 8 ppm 3.48 (s, 3H) 3.63 (s, 2H) 3.72(brs, 2H) 4.14-4.15 (t, 2H) 6.86-6.9 (m, 3H) 7.26-7.29 (m, 1H).
The remainder of the preparation for compound 428 followed the procedure above for compound 427. 428: 1H NMR (300MHz, ylsulfoxide-d6) 8 ppm 1.75 (brs, 4H) 2.90 (brs, 2H) 3.02 (brs, 2H) 3.32 (s, 3H) 3.66 (brs,2H) 3.78 (brs, 4H) 4.08 (brs, 20 2H) 6.88-6.92 (m,3H) 7.25-7.27 (m, 6H) 7.54-7.58 (d, 1H) 8.2-8.23 (d, 1H) 11.26 (s, 1H) 12.65 (brs, 1H). 113 WO 2013/078123 PCT/US2012/065816 EtOH CDI HOOC/\©/\COOH —>—>EtOOC/\©/\COOE’(socn2 NaBH4 EtOOC CHZOH Methane sulfonyl Ch'or'de EtOOC CHZOMs N3 —> NaN3 EtOOC PPh3 _’ —’ 1070 1071 EtOOC EtOOC OCLiOHH20 HOOC 1072 1073 1074 NN N\N H N48\ N‘N 2 OWN/<8\, INN? OSHN,</ \ 1024 HATU DCM DIPEA TFA N,Boc4 NH2 441 N‘N / DMF TEA OS\HN’< Acetyl chloride —> ”21 454 o To an ice cold solution of 1068 (6g, 30.9mmoL) in ethanol (50mL) was added thionyl chloride (2mL) and the resulting reaction mixture was stirred at room temperature overnight before it was concentrated under the reduced pressure. The residue obtained was partitioned between water and ethyl acetate. The organic t was washed with more water, ted, dried over sodium sulfate, filtered and ated to afford 1063 (6gm).
To a stirred solution of 1063 (3.35 g, 13.4mmol) in THF (50mL) was added CD1 (2.44g, lSmmol)and the resulting mixture was stirred for 2hr followed by the addition 10 of water (l3mL). The reaction e was cooled to 0 0C and sodium borohydride (2.87g, 76mmol) was added nwise. The stirring was continued at room temperature for 3hr before it was diluted with ethyl acetate and acidifed with 6N HCl.
The organic layer was ted, dried over sodium sulfate, filtered and evaporated.
The residue obtained was purified by silica gel chromatography eluting with 15 EtOAc/Hexane to afford 1069 (0.563 g, 20% yield) as an oil. 1H NMR (300MHz, 114 WO 2013/078123 PCT/US2012/065816 Chloroform—d) 5 ppm 1.27—1.31 (q, 3H) .92 (d, 2H) 3.63 (s, 2H) .92 (t, 2H) 4.18-42 (q, 2H) 7.19—7.31 (m, 4H).
To an ice cold solution of 1069 (0.563 g, 2.7mmol) in dichloromethane (40mL) and triethylamine (0.47mL, 3.3mmol) was added methane sulfonylchloride L, 3.3mmol) and the resulting mixture was stirred at 0 0C for 2hr and at room temperature for lhr before it was diluted with saturated aqueous sodium bicarbonate solution. The solution was extracted with ethyl acetate. The organic t was washed with more water, separated, dried over sodium sulfate, filtered and evaporated to afford 1070 (0.78g, 100%yield). 1H NMR (300MHz, Chloroform-d) 5 ppm 1.27- 10 1.31 (q, 3H) 2.87 (s, 3H) 3.08 (t, 2H) 3.63 (s, 2H) 4.l8-4.2 (t, 2H) 4.45 (q, 2H) 7.19- 7.31 (m, 4H).
To a solution of 1070 (0.787g, 2.7mmol) in DMF (6mL) was added sodium azide (0.358g, 5.5mmol) and the resulting reaction mixture was stirred at 60 0C for 3hr before it was partitioned between water and ethyl e. The organic extract was 15 washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue obtained was ed by silica gel tography eluting with EtOAc/Hexane to afford 1071 (0.5g, 78% yield) as an oil. 1H NMR (300MHz, form-d) 5 ppm l.27-l.3l (q, 3H) 2.92 (t, 2H) 3.54 (t, 2H) 3.63 (s, 2H) 4.l8-4.2 (q, 2H) .29 (m, 4H). 20 To a solution of 1071 (0.5g, 2.lmmol) in THF (25mL) was added triphenylphosphine (0.787g, 3mmol) and the reaction mixture was stirred at room temperature under argon for overnight before it was diluted with lmL of water. The reaction was continued at 50 0C for lhr before it was trated under the reduced pressure. The residue was partitioned between saturated sodium bicarbonate solution and 25 dichloromethane. The organic layer was separated, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with MeOH/dichloromethane to afford 1072 (0.43 g, 100% yield) as an oil. 1H NMR (300MHz, Chloroform-d) 8 ppm l.27-l.3l (q, 3H) 2.75-2.79 (t, 2H) 2.98- 3.02 (t, 2H) 3.63 (s, 2H) 4.l8-4.2 (q, 2H) 7.13-7.29 (m, 4H). 30 To a on of 1072 (0.427g, 2mmol) in dichloromethane (30mL) was added di-tert- butyl dicarbonate ( 0.447g, 2mmol) and the reaction mixture was stirred at room 1 l5 WO 2013/078123 PCT/US2012/065816 temperature for 5hr before it was purified by silica gel chromatography eluting with EtOAc/Hexane to afford 1073 (0.577g, 91% yield) as an oil. 1H NMR (300MHz, form-d) 8 ppm 1.27-1.31 (q, 3H) 1.59 (s, 9H) 2.82 (t, 2H) 3.4 (m, 2H) 3.63 (s, 2H) 4.18 (q, 2H) 7.13-7.29 (m, 4H).
To a solution of 1073 (0.577g, 1.8mmol) in Dioxane/Water (10mL/ 3mL) was added lithium hydroxide monohydrate (0. 158g, 3.6mmol). The ing mixture was stirred at room temperature overnight before it was concentrated under reduced re. The residue obtained was diluted with water (~20mL) and the resulting solution was acidified with 1N hydrochloric acid. The solution was ioned between water and 10 ethyl acetate. The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated to afford 1074 (0.35 g, 67%yield). 1H NMR (300MHz, Chloroform-d) 5 ppm 2.82 (m, 2H) 3.4 (m, 2H) 3.63 (s, 2H) 4.6 (brs, 1H) 7.13-7.29 (m, 4H).
To a suspension of carboxylic acid 1074 (43.8mg, 0.157mmol) in DMF (2mL) was 15 added HATU (61 .3mg, 0.161mmol) and stirred till reaction mixture is clear followed by the addition of an amine 1024 g, 0.142mmol) and DIPEA (50ul, 0.287mmol). The resulting mixture was stirred at room temperature overnight before it was ed by the addition of water. The solid ted was filtered, washed with water and dried to afford 429 (60mg, 67%yield). 1H NMR (300MHz, 20 Dimethylsulfoxide-d6) 8 ppm 1.37-1.38 (s, 9H) 1.74 (brs, 4H) 2.69-2.71 (m,2H) 2.87- 2.88 (m, 2H) 29-315 (m, 4H) 3.78 (s, 4H) 7.09 (brs, 1H) 7.12-7.36 (m, 9H) 7.54- 7.57 (d, 1H) 8.18-8.21 (d, 1H) 11.26 (s, 1H) 12.65 (brs, 1H).
To a suspension of 429 (50mg, 79.5mmol) in dichloromethane (5mL) was added TFA (1mL) and the reaction mixture was stirred at room temperature for overnight before 25 it was concentrated under the reduced pressure. The e obtained was triturated with ether. The solid separated was filtered, washed with ether and dried at high vacuum overnight to afford 441 (45mg, 88%yield) as a TFA salt. 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.74 (brs, 4H) 2.86-3.02 (m, 8H) .80 (s, 4H) 7.12-7.36 (m, 8H) 7.58 (d, 1H) 7.78 (brs, 3H) 8.18-8.21 (d, 1H) 11.26 (s, 1H) 30 12.65 (brs, 1H). 116 WO 2013/078123 PCT/US2012/065816 To an ice cold solution of 441 (23mg, 0.035mmol) in DMF (1mL) was added triethylamine (11uL, 0.079mmol) and acetyl chloride (2.8uL, 0.03 8mmol). The resulting mixture was stirred at room temperature for 2hr before it was diluted with water. The solid separated was filtered, washed with water and dried at high vacuum overnight to afford 454 (10mg, 50% yield). 1H NMR (300MHz, Dimethylsulfoxide- d6) 8 ppm 1.75-1.79 (m, 7H) 2.67-2.70 (m, 2H) 2.9 (brs, 2H) 3.00-3.02 (m, 2H) 3.21- 3.26 (m, 2H) 3.78 (s, 4H) .36 (m, 9H) 7.58 (d, 1H) 7.9 (brs, 1H) 8.18-8.21 (d, 1H) 11.26 (s, 1H) 12.65 (brs, 1H).
HN’</ \ N\ S ‘N o | / NH 0 NH2 10 Compound 409 was ed via TFA deprotection of compound 399 according to the procedure above for the preparation of compound 441. 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.75 (brs, 4H) 2.90 (brs, 2H) 3.02 (brs, 2H) 3.78 (brs, 4H) 6.89-6.98 (m,4H) 7.25-7.36 (m, 7H) 7.51-7.58 (d, 1H) 8.2-8.23 (d, 1H) 9.34 (s, 1H) 11.26 (s, 1H) 12.65 (brs, 1H). 15 Compound 457 was prepared by acylation of 409 ing to the amide ng procedure above for the preparation of compound 39. 1H NMR (300MHz, ylsulfoxide-d6) 5 ppm 1.74 (brs, 4H) 2.32 (s, 6H) 2.89 (m, 2H) 3.02 (m, 2H) 3.13 (s, 2H) 3.78 (s, 4H) 7.01-7.04 (m, 1H) 7.25-7.38 (m, 6H) 7.54-7.58 (m, 3H) 20 8.18-8.21 (d, 1H) 9.77 (s, 1H) 11.26 (s, 1H) 12.65 (brs, 1H) 117 WO 2013/078123 PCT/US2012/065816 O HN,qN‘NSW\ / NH2 348 To a suspension of 295 (30 mg, 0.0617 mmol) in MeOH (2 ml) at 0 0C was added 2N NaOH (2 ml) solution. The resulting mixture was stirred at room temperature overnight. The t was evaporated under vacuo and the mixture was acidified 5 with 1N HCl to pH 6. The white precipitate was collected by suction ion, rinsed with more water and dried to afford 348. 1H NMR (300 MHZ, DMSO-d6) 8 7.32-7.24 (m, 5H), 7.15-7.12 (d, J: 9.57 Hz, 1H), 6.72-6.69 (d, J: 9.15 Hz, 1H), 6.09 (s, 2H), 3.77 (s, 2H), 2.99-2.96 (bs, 2H), 2.76-2.70 (bs, 2H), 1.70 (bs, 4H). 366 10 366: 1H NMR (300 MHz, DMSO-d6) 5 12.65 (s, 1H), 11.26 (s, 1H), 8.22-8.19 (d, .1: 8.82 Hz, 1H), 7.58-7.54 (d, .1: 9.32 Hz, 1H), .25 (m, 6H), .82 (m, 3H), 3.81 (s. 3H), 3.75 (s, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 367 0 NH Y 367: A flask was charged with 348 (100 mg, 0.27 mmol), Bocaminomethyl- 15 phenylacetic acid (86 mg, 0.325 mmol) in DMF (2 ml) at 0 0C was added HOBT (88 mg, 0.65 mmol) followed by EDCI (156 mg, 0.812 mmol). The resulting mixture was stirred at 0 0C for 5 minutes then warmed up to room temperature overnight before it was quenched by addition of water (~10 mL) at 0 0C. The white precipitate was 1 18 WO 2013/078123 PCT/US2012/065816 collected by suction ion, rinsed with more water. The crude material was purified by silica gel chromatography eluting with 0—6% MeOH in CHzClz to afford 367.
N‘N HN’</ \ N s N o | / NH o 368 TFA NH2 5 nd 368 was prepared Via the deprotection of nd 367 according to the procedure above for compound 341. 1H NMR (300 MHz, DMSO-d6) 5 12.65 (s, 1H), 11.26 (s, 1H), 8.22-8.16 (m, 3H), 7.58-7.54 (d, J: 9.27 Hz, 1H), 7.40-7.28 (m, 9H), 4.04 (s, 2H), 3.81 (s. 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 /N‘N / NH 383 o / N I \ 10 Compound 383 was prepared from compound 348 according to the procedure above for the preparation of compound 354. 1H NMR (300 MHZ, DMSO-d6) 5 12.65 (s, 1H), 11.26 (s, 1H), 8.51 (s, 1H), 8.22-8.19 (d, J: 9.09 Hz, 1H), 7.81-7.76 (m, 1H), 7.58-7.54 (d, J: 9.12 Hz, 1H), 7.42-7.26 (m, 7H), 4.0 (s, 2H), 3.81 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 405 OANH .5 D To a solution of 348 (56.5 mg, 0.153 mmol) in DMF (1 ml) at 0 0C was added triethylamine (43 ul, 0.306 mmol) drop wise followed by benzyl isocyanate (23 ul, 1 19 WO 2013/078123 PCT/US2012/065816 0.184 mmol) drop wise. The resulting mixture was slowly warmed up to room temperature and stirred for 6 h before it was quenched by addition of water (~5 mL) at 0 0C. The white precipitate was collected by suction filtration, rinsed with more water and ether and dichloromethane then dried to afford 405. 1H NMR (300 MHz, DMSO- d6) 8 12.65 (s, 1H), 9.57 (s, 1H), 8.25 (bs, 1H), 7.74-7.71 (d, .1: 8.61 Hz, 1H), 7.50- 7.47 (d, .1: 9.42 Hz, 1H), .27 (m, 10H), 4.42-4.40 (d, J = 5.46 Hz, 2H), 3.80 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0); 420 To a sion of 339 (1 g, 1.62 mmol) in MeOH (10 ml) at 0 0C was added 2N 10 NaOH (10 ml) solution. The resulting e was stirred at room temperature overnight. The solvent was evaporated under vacuo and the mixture was acidified with 6N HCl to pH 6 at 0 0C. The mixture was triturated with EtOAc and the white precipitate was collected by suction filtration, rinsed with more EtOAc and dried to afford 412. 1H NMR (300 MHz, DMSO-d6) 8 12.66 (s, 1H), 7.29—7.22 (m, 2H), 15 .13 (m, 4H), 6.72 (d, J: 8.86 Hz, 1H), 6.12 (bs, 2H), 4.12 (d, J: 6.09 Hz, 2H), 3.79 (s, 2H), 3.01 (m, 2H), 2.71 (m, 2H), 1.70 (bs, 4H), 1.39 (s, 9H).
To a solution of 412 (60 mg, 0.121 mmol) in DMF (1 ml) at 0 0C was added triethylamine (34 ul, 0.242 mmol) drop wise followed by ethyl isocyanate (11 ul, 0.145 mmol) drop wise. The resulting mixture was slowly warmed up to room 20 temperature and stirred for 6 h before it was quenched by addition of water (~5 mL) at 0 0C. The white precipitate was collected by suction filtration. The crude material was purified by silica gel tography eluting with 0—6% MeOH in CHzClz to afford 420. 1H NMR (300 MHz, DMSO-d6) 12.65 (s, 1H), 11.27 (s, 1H), 9.42 (s, 120 WO 2013/078123 PCT/US2012/065816 1H), 8.22-8.19 (d, .1: 8.61 Hz, 1H), 7.77—7.13 (m, 5H), 6.56-6.53 (bs, 1H),4.12-4.11 (d, 2H), 3.78 (s, 2H), 3.23-3.16 (m, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H), 1.38 (s, 9H), .07 (t, 3H). 0 N~N / HN(<sz\ / NH OH HN 0 >§O o>L 422 CI 5 422: 1H NMR (300 MHz, 6) 8 12.65 (s, 1H), 10.74 (s, 1H), 8.18-8.15 (d,.]= 9.51 Hz, 1H), .12 (m, 9H), 6.62 (s, 1H), 5.33 (s, 1H), 4.13—4.11 (d, .1: 5.58 Hz, 2H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H), 1.38 (s, 9H). 0 N~N MW3 °N I / NH HN 0A 0);0 424 >L To a solution of 412 (40 mg, 0.0804 mmol) in DMF (1 ml) at 0 0C was added 10 triethylamine (17 ul, 0.121 mmol) drop wise followed by acetic anhydride (8 ul, 0.0844 mmol) drop wise. The resulting mixture was slowly warmed up to room temperature and stirred overnight before it was quenched by addition of water (~5 mL) at 0 0C. The mixture was partitioned between water and EtOAc. The organic extract was washed with water, dried over sodium sulfate, filtered and evaporated. 15 The crude material was purified by silica gel chromatography eluting with 0-6% MeOH in CH2C12 to afford 424. 1H NMR (300 MHz, DMSO-d6) 5 12.65 (s, 1H), 11.01 (s, 1H), .20 (d, J: 8.61 Hz, 1H), 7.57-7.55 (d, J: 8.16 Hz,1H),7.38- 7.12 (m, 4H), 4.13-4.11 (d, J = 5.76 Hz, 2H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 2.14 (s, 3H), 1.75 (bs, 4H), 1.39 (s, 9H). 121 WO 2013/078123 PCT/US2012/065816 0 NM / HN’<s \ N,N I / NH HZN TFA 0A 425 To a suspension of 424 (10 mg, 0.018 mmol) in dichloromethane (1 ml) was added TFA (1 ml) at 0 0C. The resulting mixture was stirred at room temperature for 1 h before it was evaporated under vacuo to dryness. Ether was added and the white 5 precipitate was collected by suction ion, rinsed with more ether and dried to afford 425. 1H NMR (300 MHz, DMSO-d6) 5 12.70 (s, 1H), 11.0 (s, 1H), 8.22-8.19 (d, .1: 8.82 Hz, 1H), 8.16-8.08 (bs, 2H), .54 (d, .1: 9.42 Hz, 1H), 7.39-7.30 (m, 4H), 4.06-4.03 (m, 2H), 3.84 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 2.14 (s, 3H), 1.75 (bs, 4H).
NaCN NaBH4 EtOH CN BiCls Water EtOH N02 NC COOH lsoamyl nitrite EtOH KOAC \ 20%NaOH _ N Acetlc anhydrlde \ N, —’ ,N —’ fie H 1079 1080 N-N H2N’q ‘ N S N I / N‘N 1024 NH HN/</ \ N O S 3 N o I HATU / NH DIPEA I \ O ,N N H 512 10 To a solution of 1076(1.8g, 10mmmol) in l/water (40mL/20mL) was added sodium cyanide (0.98g, 20mmol). The resulting mixture was stirred at 90 0C for 4hr before it was cooled to 0 0C. Solid separated was filtered, washed with water and dried at high vacuum overnight to afford 1077(1 .5 g, 85% yield). 122 WO 2013/078123 PCT/US2012/065816 To an ice cold solution of 1077(1g, 5.68mmmol) in ethanol (50mL) was added sodium borohydride (0.86g, 22.72mmol) followed by the on of bismuth de (2g, 6.248mmol) portionwise. The resulting mixture was stirred at room temperature for 3hr before it was d through the celite pad. te was concentrated and the residue obtained was partitioned n aq sodium bicarbonate solution and ethyl acetate. The organic extract was separated, dried over sodium sulfate, ed and evaporated to afford 1078 (0.82g, 100% yield). 1H NMR (300MHz, Chloroform-d) 8 ppm 2.l7(s, 3H) 3.69-3.71 (brs, 4H) 6.71-6.74 (d, 1H) 6.80-6.83(d, 1H) 7.04-7.09 (m, 1H). 10 To a solution of 1078 (0.3g, 2mmmol) in toluene (10mL) was added potassium acetate (0.2g, 2.04mmol) and acetic anhydride (0.55mL, 5.83mmol). The resulting mixture was stirred at 80 0C for 1hr ed by the addition of isoamyl nitrite (0.4mL, 3mmol). Stirring was continued at 80 0C overnight before it was cooled to room temperature. The solution was partitioned between water and ethyl acetate. The 15 c extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with EtOAc/Hexane to afford 1079 (0.22g, 54% yield). 1H NMR (300MHz, Chloroform-d) 8 ppm 2.85(s, 3H) 4.09 (s, 2H) 7.39-7.41 (d, 1H) 7.58-7.63(m, 1H) 8.28 (s, 1H) 8.48-8.51(d, 1H) 20 To a solution of 1079 (0.44g, 2.2lmmmol) in ethanol (5mL) was added 20% aqueous sodium hydroxide (SmL). The resulting mixture was d at 90 ° overnight before it was concentrated. The residue obtained was diluted with water, acidified with acetic acid and extracted with ethyl acetate. The c extract was separated, dried over sodium sulfate, filtered and evaporated to afford 1080 (0.1 g, 51% yield). 1H NMR 25 (300MHz, Dimethylsulfoxide-d6) 8 ppm 3.89 (s, 2H) 6.98-7.0 (d, 1H) 7.27-7.32(m, 1H) 7.43-7.46 (d, 1H) 8.10(s, 1H) 12.3-13.2(broad doublet, 2H) To a suspension of carboxylic acid 1080 (60mg, 0.34mmol) in DMF (2mL) was added HATU (130mg, ol) and stirred till reaction mixture is clear ed by the addition of an amine 1024 (114mg, 0.31mmol) and DIPEA , 0.62mmol). 30 The resulting mixture was stirred at room temperature for 3hr before it was quenched by the addition of water. The solid separated was filtered, washed with water and 123 WO 2013/078123 PCT/US2012/065816 dried. The residue obtained was purified by silica gel chromatography e1uting with MeOH/dichloromethane to afford 512 (14mg, 9%yield). 1H NMR z, Dimethylsulfoxide-d6) 5 ppm 1.74 (brs, 4H) 2.89 (brs, 2H) 2.91 (brs, 2H) 3.78 (s, 2H) 4.13 (s, 2H) 7.05-7.08 (m, 1H) 7.27-7.57 (m, 8H) 8.19 (d, 2H) 11.26 (s, 1H) 12.76- 12.80 (brs, 1H) 13.11 (s, 1H). 389 Compound 389 was prepared according to the procedure above for the preparation of compound 334. 1H NMR (300 MHz, DMSO-d6) 8 12.95 (s, 1H), 11.26 (s, 1H), 8.22- 8.19 (d, J: 8.91 Hz, 1H), .26 (m, 10H), 6.17 (s, 1H), 3.78 (s, 2H), 3.54 (bs, 10 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 2.67-2.62 (m, 4H), 2.38 (bs, 4H), 1.73 (bs, 4H). 404 Compound 404 was prepared according to the procedure above for the ation of compound 334. 1H NMR (300 MHz, DMSO-d6) 8 12.95 (s, 1H), 11.26 (s, 1H), 8.22- 8.19 (d, J: 9.60 Hz, 1H), 7.58-7.54 (d, J: 9.03 Hz, 1H),7.39-7.26 (m, 6H), 7.12 (s, 15 2H), 7.01-6.98 (m, 1H), 6.10 (s, 1H), 3.78 (s, 5H), 3.54 (bs, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 2.64 (bs, 4H), 2.38 (bs, 4H), 1.74 (bs, 4H). 124 WO 2013/078123 PCT/US2012/065816 295 H 0 @Dl—Rl MOACI N s N“N O K2CO3, DMF k0 / 80°, 1,5 hr AA 402 M 0 To a flask was added K2C03 (0.28 g, 2.06 mmol), compound 295 (0.5 g, 1.03 mmol) followed by 25 mL of DMF. The mixture was stirred for 15 s and chloromethyl te (0.17 g, 1.23 mmol) was added and the reaction placed under an atmosphere of argon. The mixture was heated to 80°C for 1.5 hours, allowed to cool to room temperature and poured into 200 ml water. The mixture was transferred to a separatory filnnel, extracted with EtOAc (3x100 mL), the organic layers separated and washed with water (3x50 mL), brine (2x50 ml) and dried over Na2S04. The Na2S04 was removed by filtration and the volatiles removed under reduced pressure. The 10 crude material was d by reverse-phase chromatography giving 0.15 g of compound 402.
H 08MB]Hm O whim \N'N O HO HN\<\:I \NN #0HN\<\SI N—N 318 439 To a solution of318 (100 mg, 0.19 mmol) in CHzClz (5 mL) at 0 0C was added pyridine (300 uL) and followed by addition of a solution of butyryl chloride (43 mL, 15 0.41 mmol) in CHZClz (5 mL) dropwise. The resulting e was d at 0 0C for 1 h before it was partitioned between EtOAc and H20. The organic layer was separated, dried (MgSO4) and concentrated. The residue was d by flash column chromatography over silica gel eluting with 1—10% MeOH in CH2Cl2 to provide the desired product 439 (117 mg). 1H NMR (300 MHz, CDClg) 8 13.01 (bs, 20 1H), 10.12 (s, 1H), 8.49 (d, .1: 9.64 Hz, 1H), 7.77 (s, 1H), 7.57 (d, .1: 7.11 Hz, 1H), 7.40—7.30 (m, 8H), 6.57 (s, 1H), 3.97 (s, 2H), 3.09 (bs, 2H), 3.00 (bs, 2H), 2.48 (m, 2H), 1.91 (bs, 4H), 1.85—1.62 (m, 2H), 0.98 (t, .1: 7.07 Hz, 3H). 125 WO 2013/078123 PCT/US2012/065816 o \0 3:0 K(DACOO'VWDMNaSFMe K[>/\coowle_>MCPBA OWDCM 1016 1085 1086 N~N N‘N \ HN’</ \ H N4 N, 2 3% S N O O I \ l/ 1024 / 3:0 NH / NH LiOH.H20 HATU o COO“ —> DIPEA (3‘ o o —> ’/ S\ 1087 634 To a on of sodium thiomethoxide (0.266g, 3.8mmol) in DMF(lOmL) was added a solution of 1016 (0.65 7g, 2.7mmol) in DMF and the resulting mixture was d at room temperature for overnight. The solution was partitioned between water and ethyl acetate. The organic t was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with EtOAc/Hexane to afford 1085 (0.41 g, 72% yield). 1H NMR (300MHz, Chloroform-d) 8 ppm .04(s, 3H) 3.66-3.73(m, 7H) 7.21- 7.32(m, 4H). 10 To a on of 1085 (0.503 g, 2.39mmol) in dichloromethane was added MCPBA (l .338g, 7.78mmol) and the resulting mixture was stirred at room temperature for 4hr before it was diluted with aq. Sodium lfate solution. Organic layer was separated, washed with saturated aq. Sodium bicarbonate solution and water, dried over sodium sulfate, filtered and concentrated. The residue obtained was purified by 15 silica gel chromatography eluting with EtOAc/Hexane to afford 1086 (0.5g, 86% yield). 1H NMR (300MHz, Chloroform-d) 8 ppm 2.8(s, 3H) 3.7-3.74(m, 5H) 4.27(s, 2H) 7.30-7.4(m, 4H).
To an ice cold solution of 1086 (0.5g, 2.06mmol) in dioxane (lOmL) and water (lOmL) was added lithium hydroxide drate (0.26g, 6.19mmol) and the 20 resulting reaction mixture was stirred at room temperature for overnight before it was concentrated. The residue obtained was diluted with water and was acidified with acetic acid. The resulting solution was partitioned between water and ethyl acetate.
The organic extract was washed with more water, separated, dried over sodium 126 WO 2013/078123 PCT/US2012/065816 sulfate, filtered and evaporated. The residue obtained was triturated with ether. The solid separated was filtered, washed with ether and dried at high vacuum overnight to afford 1087 (0.3g, 64%yield). 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 2.92(s, 3H) 3.61(s, 2H) 4.48(s, 2H) 7.31-7.35(m, 4H) s, 1H).
N~N HN’</ \ N‘ 0 SW NH 0 o 634 0 Compound 634 was prepared using procedures analogous to those above. 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.74 (brs, 4H) 2.91 (brs, 5H) 3.03(brs, 2H) 3.78 (s, 2H) 3.85 (s, 2H) 4.49 (s, 2H) 7.32-7.40 (m, 9H) 7.55-7.58 (d, 1H) 8.19 (d, 1H) 11.26 (s, 1H) 12.69 (s, 1H).
HN’</ \ N\ s ‘N o | / NH O 635 10 /3 Compound 635 was prepared using procedures analogous to those above. 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.75 (brs, 4H) 2.91 (brs, 5H) rs, 2H) 3.82 (s, 4H) 4.49 (s, 2H) 7.32-7.40 (m, 9H) 7.55-7.58 (d, 1H) 8.19 (d, 1H) 11.26 (s, 1H) 12.69 (s, 1H). 127 WO 2013/078123 PCT/US2012/065816 NaSMe CIA/\S/ MCPBA CIA/\IS\/ K2003 DMF /\ DCM o O DMF CIA/\Br —> BrMS/ —> —> BFMR/ HO COOMe 1088 (mixture) 0 o 1092 1089 (mixture) | (I) K 0:”3 OK NM H2N SW,q \ 1024 / O NH COOMe ZO. 0 COOH ’ o —> HATU DIPEA 1090 1091 N‘N / HN \ N s ‘N o | / NH o 0M3/ 583 To a solution of 1,3-bromo chloropropane (1.57g, 10mmol) in DMF (lOmL) was added sodium thiomethoxide (0.63 g, 9mmol) and the resulting reaction mixture was stirred at room temperature overnight and at 70 0C for another day. The solution was partitioned between water and ethyl acetate. The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and ated to afford 1088 (1.3gm) which is used for the next step t purification.
To a solution of 1088 (l .3 g, 7.7mmol) in dichloromethane (100mL) was added MCPBA(5.15g, 23.34mmol) and the resulting mixture was stirred at room 10 temperature for overnight before it was d with aq. Sodium thiosulfate solution.
Organic layer was separated, washed with saturated aq. Sodium onate solution and water, dried over sodium sulfate, filtered and concentrated. The residue obtained was purified by silica gel chromatography eluting with EtOAc/Hexane to afford 1089 (0.3gm). 1H NMR (300MHz, Chloroform-d) 8 ppm 2.38-2.49(m, 2H) 2.99(s, 3H) 15 3.22-3.27(m, 2H) 3.57-3.77(m, 2H).
To a solution of 1092 (0.525g, 3.16mmol) in DMF (lSmL) was added potassium carbonate (0.873g, 6.32mmol), 1089 (0.74g, 4.74mmol) and sodium iodide .
The resulting mixture was stirred at 70 CC overnight before it was diluted with water (~100mL). The ing solution was partitioned between water and ethyl acetate. 128 WO 2013/078123 PCT/US2012/065816 The organic t was washed with more water, separated, dried over sodium e, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with EtOAc/Hexane to afford 1090 (0.53 g, 59% yield). 1H NMR (300MHz, Chloroform-d) 8 ppm 2.35-2.40(m, 2H) 2.99(s, 3H) 3.26-3.31(m, 2H) 3.63(s, 2H) 3.73(s, 3H)4.16(t, 2H) 6.81-6.93(m, 3H) 7.25(m, 1H).
To a solution of 1090 (0.53 g, 1.85mmol) in e (8mL) and water (4mL) was added lithium hydroxide monohydrate (0.156g, 3.7lmmol) and the resulting reaction mixture was stirred at room temperature for 5hr before it was acidified with acetic acid. The resulting solution was ioned between water and ethyl acetate. The 10 organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The e obtained was triturated with ether. The solid separated was filtered, washed with ether and dried at high vacuum overnight to afford 1091 (0.2g, 40%yield). 1H NMR (300MHz, Chloroform-d) 5 ppm 2.32- 2.42(m, 2H) 2.99(s, 3H) 3.26-3.3l(m, 2H) 3.66(s, 2H) .l6(t, 2H) 6.83-6.94(m, 15 3H) 7.26-7.3 l(m, 1H).
N~N OHN/<S\N°NI / NH o O’\/\S/ 583 0000 Compound 583 was ed by coupling of 1091 with 1024 using procedure described for Amide Coupling General Procedure. 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.74 (brs, 4H) 2.15-2.19(m, 2H) .03(m, 7H) 3.27- 20 3.39 (m, 2H) 3.78(s, 4H) 4.07-4.11 (t, 2H) 6.90-6.93 (m, 3H) 7.24-7.37 (m, 6H) 7.55- 7.58(d, 1H) 8.19 (d, 1H) 11.26 (s, 1H) 12.69 (s, 1H).
N~N HN’<’8\ N O N | / NH 0 129 WO 2013/078123 PCT/US2012/065816 nd 623 was prepared by coupling of 11 with 348 using ure described for Amide Coupling General Procedure. 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.74 (brs, 4H) 2.15-2.19(m, 2H) .03(m, 7H) 3.27-3.39 (m, 2H) 3.75- 3.78(m, 4H) 4.07-4.11 (t, 2H) 6.90-6.97 (m, 3H) 7.26-7.34 (m, 6H) 7.58(d, 1H) 8.19 (d, 1H) 11.26 (s, 1H) 12.69 (s, 1H).
Hog/lomfimé’l: ffléjpfavw 0 1093 1094 1095 To a solution of 3-hydroxyphenylacetic acid (1 g, 0.00657 mol) in MeOH (10 ml) at 0 0C was added (Trimethylsilyl) diazomethane solution (2 M in hexanes, 20 ml) dropwise. The resulting mixture was stirred at room temperature for 30 minutes 10 before it was evaporated to dryness. The crude al was purified by silica gel chromatography eluting with 0-25% EtOAc in Hexanes to afford 1093. 1094 was made using procedure described for compound 1119. 1095 was made using procedure described for compound 1102. o N‘N HN’q \ N s \‘N | / 646 WW 0 15 646 was made using ure described for compound 666. 1H NMR (300 MHz, CDC13)8 10.32 (s, 1H), 8.50-8.47 (d, J: 8.52 Hz, 1H), 7.90-7.70 (m, 1H), 7.40-7.36 (m, 6H), 7.03-6.86 (m, 3H), 4.72 (s, 2H), 4.02 (s, 2H), 3.90 (s, 2H), 3.44-3.39 (m, 4H), 3.09-2.96 (d, 4H), 1.87 (bs, 4H), 1.24-1.16 (m, 6H). 130 WO 2013/078123 2012/065816 647 647 was made using procedure described for compound 666. 1H NMR (300 MHz, DMSO-d6) 8 12.61 (s, 1H), 11.22 (s, 1H), 8.22-8.19 (d, J: 9.18 Hz, 1H), 8.02-8.10 (t, 1H), 7.58-7.55 (d, ,J= 9.12 Hz, 1H), .24 (m, 5H), 6.99-6.84 (m, 3H), 4.48 (s, 2H), 3.82 (s, 2H), 3.75 (s, 2H), 3.50 (s, 2H), 3.01-2.90 (m, 5H), 1.73 (bs, 4H), 0.82- 0.80 (d, ,J= 6.69 Hz, 6H). ,0H MeCN, H2NOH ' NI H o 90°C2 ’ NH2 1096 A solution of hydroxylamine (50% in water, 7.4 mL) was added to acetonitrile (60 mL) and the mixture heated to 90°C for 16 hours. The mixture was cooled to room 10 temperature then cooled in a wet-ice bath giving a precipitate. The solids were collected by filtration and rinsed with cold acetonitrile (10 mL) and dried under high vacuum giving 4.47 g ofN'-hydroxyacetimidamide 1096. See Zemolka, S. et al PCT Int Appl 20091 18174. 1H NMR 300 MHz CDClgI 8 4.57 (br s, 2H), 1.89 (s, 3H).
NH,0 Br ANHZ Br 1096 OEt NaH, 4A sieves THF, 60°C /NY / O O‘N 1097 1098 15 A flask was charged with N'-hydroxyacetimidamide 1096 (0.45 g, 6.17 mmol) followed by THF (25 mL), NaH (60% in oil, 0.246 g, 6.17 mmol), 4A molecular sieves (4.5 g) and the e heated to 60°C under an atmosphere of argon for 1 hour. A solution of ethyl 2-(3-bromophenyl)acetate 1097 (1.5 g, 6.17 mmol) in THF (12.5 mL) was added to the N'-hydroxyacetimidamide mixture and heated at 60°C for 13 1 WO 2013/078123 PCT/US2012/065816 16 hours. The mixture was diluted with water (100 mL) and extracted with EtOAc (2 x 25 mL). The c layers were combined, washed with water (25 mL), brine (2 x 25 mL) and dried over NaZSO4. The NaZSO4 was removed by filtration and the volatiles removed under reduced pressure. The crude material was purified by normal phase chromatography 0-30% EtOAc / hexanes giving 0.56 g of 5-(3-bromobenzyl)— 3-methyl-1,2,4-oxadiazole 1098. 1H NMR 300 MHz CDClg: 8 7.48-7.42 (m, 2H), 7.26-7.24 (m, 2H), 4.15 (s, 2H), 2.38 (s, 3H).
Br 0 (tBu3P)2Pd(O) o 7< e, RT N ClZn/\n’o N / r / r O K \N O\N 1098 1099 To a solution of 5-(3-bromobenzyl)methyl-1,2,4-oxadiazole 1098 (0.50 g, 1.97 10 mmol) in dioxane (1 mL), under an atmosphere of Argon, was added Bis(tri-t- butylphosphine)palladium(0) (0.15 g, 0.295 mmol) ed by the addition of 2-tert- butoxyoxoethylzinc chloride (0.5 M in l ether, 4.92 mmol, 9.84 mL). The mixture was allowed to stir under argon for 20 hours and the volatiles were removed under reduced pressure. The residue was taken up in EtOAc (10 mL) and washed with 15 water (2 x 5 mL), brine (2 x 5 mL) and dried over NaZSO4. The NaZSO4 was removed by filtration and the volatiles d under reduced pressure. The crude material was purified by normal phase chromatography 0-50% EtOAc / Hexanes to give 0.300 g tert-butyl 2-(3-((3-methyl-1,2,4-oxadiazolyl)methyl)phenyl)acetate 1099. 1H NMR 300 MHz CDClgC 8 7.40-7.18 (m, 4H), 4.17 (s, 2H), 3.51 (s, 2H), 2.36 (s, 3H), 20 1.43 (s, 9H).
HC|,dioxane —> N N O\N O\N 1099 1100 To a e of tert-butyl 2-(3-((3 -methyl-1,2,4-oxadiazolyl)methyl)phenyl)acetate 1099 (0.127 g, 0.44 mmol) in dioxane (3 mL) was added 4N HCl in dioxane (1 mL) and stirred under an atmosphere of argon for 2 hours. The volatiles were removed 132 WO 2013/078123 PCT/US2012/065816 under reduced pressure and the residue diluted with water (5 mL) and the pH adjusted to 12 with 2.5 N NaOH. The e was washed with dichloromethane (4 x 2 mL) and the pH adjusted to 6 with 1 N HCl. The mixture was extracted with EtOAc (3 x 2 mL) and the organic layers ed, washed with brine and dried over Na2S04. The Na2S04 was removed by filtration and the volatiles d under reduced pressure to give 0.041 g of 2-(3-((3-methyl-1,2,4-oxadiazolyl)methyl)phenyl)acetic acid 1100. 1H NMR 300 MHz CDClgC 8 7.40-7.18 (m, 4H), 4.18 (s, 2H), 3.63 (s, 2H), 2.36 (s, 3H). m | EDC, HOBt / DIEA, DMF NH2 N / 2/ 348 Owl 1100 N “ O N H Q \ N 648 N=< 10 To a solution of N—(5-(4-(6-aminopyridazinyl)butyl)-1,3,4-thiadiazolyl) phenylacetamide 348 (0.061 g, 0.0165 mmol), 2-(3-((3-methyl- 1 ,2,4-oxadiazol yl)methyl)phenyl)acetic acid 1100 (0.040 g, 0.18 mmol), 1-ethyl(3- dimethylaminopropyl) carbodiimide (0.078 g, 0.41 mmol), l-hydroxybenzotriazole (0.055 g, 0.41 mmol) in DMF (3 mL) was added DIEA (0.085 g, 0.115 mL, 0.66 15 mmol) and the mixture stirred for 16 hours. The mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 20 e organic layers were combined, washed with water (3 x 20 mL), brine (2 x 20 mL) and dried over Na2S04. The Na2S04 was removed by filtration and the volatiles removed under reduced pressure.
The crude al was purified by normal phase chromatography 0-5% MeOH / 20 dichloromethane giving 0.003 g of 2-(3-((3-methyl-l,2,4-oxadiazol yl)methyl)phenyl)-N-(6-(4-(5-(2-phenylacetamido)- 1 ,3 ,4-thiadiazol yl)butyl)pyridazinyl)acetamide 648. 1H NMR 300 MHZ CDC13: 8 12.59 (s, 1H), 133 WO 2013/078123 2012/065816 10.53 (s, 1H), 8.45 (d, 1H, J: 12.2 Hz),7.4-7.1 (m, 10H), 4.15 (s, 2H), 4.03 (s, 2H), 3.94 (s, 2H), 3.02 (m, 2H), 2.94 (m, 2H), 2.33 (s, 3H), 1.85 (m, 4H). 1101 was made using procedure described for compound 1119. 5 To a solution of 1101 (470 mg, 1.41 mmol) in MeOH (5 ml) and H20 (5 ml) at 0 0C was added lithium hydroxide monohydrate (296 mg, 7.05 mmol). The ing mixture was stirred at room temperature for 3 days before it was evaporated to dryness. The mixture was then ed with 1N HCl (pH 4), and it was partitioned between water and EtOAc. The organic extract was washed with water, dried over 10 sodium sulfate, filtered and evaporated to afford 1102. k1 HN4N“\ o N s |N\N / NH 608 o 608 was made using procedure described for compound 664. 1H NMR (300 MHz, DMSO-d6) 8 12.71 (s, 1H), 11.32 (s, 1H), 8.22-8.19 (d, J: 9.15 Hz, 1H), 7.58-7.54 (d, J: 9.27 Hz, 1H), 7.38-7.28 (m, 8H), 4.63 (bs, 4H), 3.82 (s, 2H), 3.78 (s, 2H), 15 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H), 1.48-1.44 (d, ,J= 5.93 Hz, 9H). 0 HN4N7”/SW\ F3CO / NH 612 134 WO 2013/078123 PCT/US2012/065816 612 was made using procedure described for compound 666. 1H NMR (300 MHz, DMSO-d6) 8 11.32 (s, 1H), 8.22-8.19 (d, J: 9.78 Hz, 1H), 7.58-7.54 (d, J: 9.72 Hz, 1H), .28 (m, 7H), 4.67-4.61 (m, 4H), 3.88 (s, 2H), 3.80 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H), 1.48-1.44 (d, ,J= 9.93 Hz, 9H). 0 HN 8%\ F300 / NH 649 0 OF NHHOJYF F 649 was made using procedure described for nd 695. 1H NMR (300 MHz, DMSO-d6) 8 11.36 (s, 1H), 8.20-8.17 (d, J: 9.78 Hz, 1H), 7.60-7.57 (d, J: 8.92 Hz, 1H), 7.52-7.32 (m, 7H), 4.61-4.56 (d, J: 16.99 Hz, 4H), 3.91 (s, 2H), 3.87 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 N§ o N HOJKi/F HNfizF HN’</ \ N S ¢N I F / NH 650 O 10 650 was made using procedure described for compound 695. 1H NMR (300 MHz, DMSO-d6) 8 12.71 (s, 1H), 11.32 (s, 1H), 9.40 (bs, 1H), 8.22-8.19 (d, J: 9.09 Hz, 1H), 7.58-7.54 (d, J: 9.36 Hz, 1H), 7.38-7.28 (m, 8H), 4.63 (bs, 4H), 3.82 (s, 2H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 )kN FFN\ HN’<S)\/\/\£Nj\/ NH 651 15 135 WO 2013/078123 PCT/US2012/065816 To a solution of 650 (30 mg, 0.0468 mmol) in DMF (1 ml) at 0 0C was added triethylamine (13 ul, 0.0936 mmol) dropwise followed by acetic anhydride (4.64 ul, 0.0491 mmol) dropwise. The resulting mixture was stirred at 0 0C for 20 s before it was quenched by addition of ice water (~5 mL). The white precipitate was collected by suction filtration, rinsed with more water. The crude material was purified by silica gel chromatography g with 0-6% MeOH in CHzClz to afford 651. 1H NMR (300 MHz, DMSO-d6) 8 12.71 (s, 1H), 11.32 (s, 1H), 8.22-8.19 (d, J: 9.27 Hz, 1H), 7.58-7.54 (d, J: 9.00 Hz, 1H), 7.38-7.28 (m, 8H), 4.88 (bs, 2H), 4.67 (bs, 2H), 3.82 (s, 2H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 2.11 (s, 3H), 1.73 10 (bs, 4H).
Br Br EtOH, H2804 reflux temp OH OEt O O 1103 1097 To a solution of 2-(3-bromophenyl)acetic acid 1103 (10.0 g, 46.5 mmol) in 100 mL EtOH was added conc. H2SO4 (10 drops) and the mixture heated to relux temperature for 3 hours. The mixture was allowed to cool to room temperature and the volatiles 15 were removed under d pressure. The residue was taken up in EtOAc (100 mL) and washed with water (2 x 50 mL), saturated NaHC03 (1 x 25 mL), brine (2 x 25 mL) and dried over . The Na2S04 was removed by filtration and the volatiles removed under reduced pressure to give ethyl 2-(3-bromophenyl)acetate 1097 (11.1 grams) as a liquid). 1H NMR 300 MHz CDClg: 8 7.41 (m, 2 H), 7.20 (m, 2H), 4.14 20 (q, 2H, J: 9.5 Hz), 3.57 (s, 2H), 1.25 (t, 3H, J: 9.5 Hz).
Br Br , MeOH reflux temp OEt NHNHZ O O 1097 1104 To a solution of ethyl 2-(3 -bromophenyl)acetate 1097 (1.5 g, 6.17 mmol) in MeOH (20 mL) was added hydrazine (0.79 g, 24.7 mmol) and the mixture heated to reflux temperature for 4 hours. The mixture was allowed to cool to room temperature giving 136 WO 78123 PCT/US2012/065816 rise to a white precipitate which was collected by filtration and rinsed with MeOH (10 mL). After drying under reduced pressure 1.4 grams of 2-(3- bromophenyl)acetohydrazide 1104 was isolated. 1H NMR 300 MHz CDC13: 8 7.42 (s, 2H), 7.20 (s, 2H), 6.73 (br s, 1H), 3.51 (s, 2H), 1.81 (br s, 2H).
Br Br CH3C(OMe)3 AcOH, 115°C NHNH2 O \ b/ O N\N 1104 1105 To a solution of 2-(3-bromophenyl)acetohydrazide 1104 (1.0 g, 4.37 mmol) in AcOH (10 mL) was added trimethylorthoacetate (2.62 g, 21.83 mmol) and the mixture heated to 115°C for 18 hours. The volatiles were removed under reduced re and the residue purified by reverse phase chromatography to give 0.59 g of 2-(3- 10 bromobenzyl)methyl-1,3,4-oxadiazole 1105. 1H NMR 300 MHz CDC13: 8 7.45 (m, 2H), 7.23 (m, 2H), 4.12 (s, 2H), 2.49 (s, 3H).
Br 0 (tBU3P)2Pd(O) K dioxane, RT 0 0 0 Cer1/\g/ 7< O \ 22/ ,1] V‘N 1105 1106 To a solution of 2-(3-bromobenzyl)methyl-1,3,4-oxadiazole 1105 (0.50 g, 1.97 mmol) in dioxane (1 mL), under an atmosphere of Argon, was added Bis(tri-t- 15 butylphosphine)palladium(0) (0.15 g, 0.295 mmol) followed by the addition of 2-tertbutoxyoxoethylzinc chloride (0.5 M in diethyl ether, 4.92 mmol, 9.84 mL). The mixture was allowed to stir under Argon for 20 hours and the les were removed under d pressure. The residue was taken up in EtOAc (10 mL) and washed with water (2 x 5 mL), brine (2 x 5 mL) and dried over Na2S04. The Na2S04 was removed 20 by ion and the volatiles removed under reduced pressure. The crude material was purified by normal phase chromatography 0-50% EtOAc / Hexanes to give 0.338 g of tert-butyl 2-(3-((5 -methyl-1,3,4-oxadiazolyl)methyl)phenyl)acetate 1106. 1H 137 WO 2013/078123 PCT/US2012/065816 NMR 300 MHz CDClg: 5 7.24 (m, 4H), 4.12 (s, 2H), 3.51 (s, 2H), 2.46 (s, 3H), 1.43 (s, 9H).
HC|,dioxane —> O O \ V \ D/ N\N N\N 1106 1107 To a mixture of tert-butyl 2-(3-((5 -methyl-l,3,4-oxadiazolyl)methyl)phenyl)acetate 1106 (0.127 g, 0.44 mmol) in dioxane (3 mL) was added 4N HCl in dioxane (1 mL) and stirred under an atmosphere of Argon for 2 hours. The volatiles were removed under reduced re and the residue diluted with water (5 mL) and the pH adjusted to 12 with 2.5 N NaOH. The mixture was washed with romethane (4 x 2 mL) and the pH adjusted to 6 with l N HCl. The mixture was extracted with EtOAc (3 x 2 10 mL) and the organic layers combined, washed with brine and dried over . The NaZSO4 was removed by filtration and the volatiles removed under reduced pressure to give 0.023 g of 2-(3-((5-methyl-l,3,4-oxadiazolyl)methyl)phenyl)acetic acid 1 1 07.
M | EDC, HOBt / DMF NHZ o 348 \ r 1107 652 N 15 A solution of N-(5-(4-(6-aminopyridazinyl)butyl)-l ,3,4-thiadiazolyl) phenylacetamide 348 (0.035 g, 0.094 mmol), 2-(3-((5-methyl-l,3,4-oxadiazol yl)methyl)phenyl)acetic acid 1107 (0.023 g, 0.094 mmol), l(3- dimethylaminopropyl) carbodiimide (0.045 g, 0.235 mmol), l-hydroxybenzotriazole (0.032 g, 0.235 mmol) in DMF (1.75 mL) was stirred for 16 hours and diluted with 20 water (20 mL). The mixture was extracted with EtOAc (3 x 20 mL) the organic layers 1 3 8 WO 2013/078123 PCT/US2012/065816 combined, washed with water (3 x 20 mL), brine (2 x 20 mL) and dried over Na2S04.
The Na2S04 was removed by filtration and the volatiles removed under reduced re. The crude material was purified by reverse phase chromatography giving 0.004g of 2-(3-((5-methyl-1,3,4-oxadiazolyl)methyl)phenyl)-N-(6-(4-(5-(2- phenylacetamido)-1,3,4-thiadiazolyl)butyl)pyridazinyl)acetamide 652. 1HNMR 300 MHz DMSO-d6: 8 12.62 (s, 1H), 11.24 (s, 1H), 8.16 (d, 1H, J=12.2 Hz), 7.54 (d, 1H, J: 12.2 Hz), 7.3-7.1 (m, 9H), 4.20 (s, 2H), 3.78 (s, 2H), 3.74 (s, 2H), 2.99 (m, 2H), 2.87 (m, 2H), 2.41 (s, 3H), 1.72 (m, 4H).
HCOOH Br\©)\ HCONH2 DCM 3N HCI BOC anhydride Br 1108 1109 o o +0 NLOJ< LiOH.H20 HO NAOJ< —> H —> H O O 1110 1111 N-N N‘N H2N—<’ \ N OSHN’</ \ s N l 1024 O HATU DIPEA H —> NW/O 0 K 541 N ~N / HN \ N s N DCM O | TFA / NH —> o NH2 559 10 A mixture of 3-bromoacetophenone (5g, 25.1mmol) in formic acid (6gm) and formamide (25mL) was heated to 170 0C for overnight before it was extracted with toluene. Organic layer was separated and concentrated. The e ed was diluted with 3N HCl and the resulting mixture was refluxed overnight before it was cooled to room temperature. The solution was extracted with ether. Aqueous layer 15 was separated, d with aq. Sodium hydroxide on and extracted with ether.
Organic layer was separated, dried over sodium sulfate, filtered and concentrated to 139 WO 2013/078123 PCT/US2012/065816 afford 1108 (3g, 60% yield). 1H NMR (300MHz, Chloroform-d) 5 ppm 1.22-1.25(d, 3H) 3.97-3.99(q, 1H) 7.23-7.4(m, 3H) 7.6(s, 1H).
To a solution of 1108 (2.945 g, 14.7mmol) in dichloromethane (100mL) was added boc anhydride (3.21 g, 14.7mmol) and the reaction mixture was stirred at room temperature overnight before it was concentrated and purified by silica gel chromatography g with Hexane to afford 1109 (3g, 68% yield). 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 129-1 .3 1(d, 3H) l.38(s, 9H) 4.61- 4.63(q, 1H) 7.3(brs, 2H) 7.41-7.5(m, 3H).
To a degassed solution of 1109 (0.5g, 1.66mmol) and bis(tri-tert- 10 butylphosphine)palladium(0) (0.085 g, 0.166mmol) in dioxane(3mL) was added 2- tert-Butoxyoxoethylzinc chloride , 4.15mmol) under Argon and the resulting reaction mixture was stirred at room temperature for 4hr before it was quenched with saturated aqueous ammonium chloride solution. The resulting solution was partitioned between water and ethyl acetate. The organic extract was 15 washed with more water, ted, dried over sodium sulfate, filtered and evaporated. The e obtained was purified by silica gel chromatography g with EtOAc/Hexane to afford 1110 (0.35 g, 62% yield). 1H NMR z, Dimethylsulfoxide-d6) 8 ppm 1.29-1.31(d, 3H) 1.388-1.42(brs, 18H) 3.53(s, 2H) 4.59-4.63(q, 1H) 7.09 (brs, 1H) 7.12-7.20(brs, 2H) 7.25-7.27(m, 1H) 7.27-7.30(m, 20 1H).
To a solution of 1110 (0.44g, 1.3mmol) in methanol (40mL) and water (10mL) was added lithium ide monohydrate ) and the resulting reaction mixture was stirred at room temperature for 2days before it was concentrated. The residue obtained was diluted with ice cold water and ed with acetic acid. The resulting solution 25 was partitioned between water and ethyl e. The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with EtOAc/Hexane to afford 1111 (0.316g, 86% . 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm l.22-l.39(m, 12H) 3.55(s, 2H) 4.58-4.63(q, 1H) 7.11-7.38(m, 5H) l2.29(s, 1H). 140 WO 2013/078123 PCT/US2012/065816 N‘N HN’</ \ N\ 0 3% NH o H N 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.43 (m, 12H) 1.89 (brs, 4H) 2.97- 3.08 (m, 4H) 3.95-4.03 (m, 4H) 4.71-4.77 (q, 1H) 7.24-7.43 (m, 11H) 8.45-8.48 (d, 1H) 10.99 (s, 1H) 12.4 (brs, 1H).
N HN’<’ 1” N.
/ NH O 543 Y 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.43 (m, 12H) 1.89 (brs, 4H) 2.97- 3.08 (m, 4H) 3.95-4.03 (m, 4H) 4.71-4.77 (q, 1H) 7.24-7.43 (m, 11H) 8.45-8.48 (d, 1H) 10.22 (brs, 1H) 12.4 (brs, 1H).
N~N HN’</ ‘ N.
S ~N O l / NH o 559 H2N 10 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.5—1.52 (d, 3H) 1.75 (brs, 4H) .93 (m, 2H) 3.03—3.05 (m, 2H) 3.79(s, 2H) , 2H) 4.38-4.44 (q, 1H) 7.27— 7.59 (m, 10H) 8.20-8.23 (m, 4H) 11.27 (s, 1H) 12.71 (s, 1H). 141 WO 2013/078123 PCT/US2012/065816 N~N HN’q \ N. s ‘N o l / NH o NH2 560 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.5—1.52 (d, 3H) 1.75 (brs, 4H) 2.88-2.93 (m, 2H) 3.03—3.05 (111,2H)3.86(S,4H)4.38-4.44(q, 1H) 7.27—7.59 (m, 10H) 8.20-8.23 (m, 4H) 11.27 (s, 1H) 12.71 (s, 1H).
N- (348%\N N | /N NH 0 F H 624 5 Fm 1H NMR (300MHz, ylsulfoxide-d6) 5 ppm 1.5—1.52 (d, 3H) 1.75 (brs, 4H) .93 (m, 2H) 3.03—3.05 (m, 2H) 3.78(s, 2H) 3.82(s, 2H) 4.91-4.96 (q, 1H) 7.20— 7.35 (m, 9H) 7.55-7.58(d, 1H) 8.20-8.23(d, 1H) 8.68-8.71 (m, 1H) 11.27 (s, 1H) 12.71 (s, 1H). 10 142 WO 2013/078123 PCT/US2012/065816 E%\E>\)(:K—>3Ammonium acetateNaCNBH B\[:E\NH2—>Boc anhydrideBDC'V' Ni0J< 1112 1113 1rawHowtiok F 1114 1115 NN N~N HZN—<’S \ INN OHN—4( \ N‘ s ~N 1024 | ’/ NH HATU o mPEA H N 0 HN4M”/ \ DCM s ”w o TFA | / —> NH 0 NH2 655 To an ice cold solution of l-(5-bromofiuorophenyl)ethanone (4.5g, 20.7mmol) in methanol(100mL) was added ammonium acetate(32g, 4l4.7mmol) and sodium cyanoborohydride(6.ng, 28.98mmol). The reaction mixture was stirred at room temperatue over the weekend before it was concentrated. The residue obtained was diluted with water, basified to pH~l3 wih lN NaOH and extracted with dichloromethane. The c extract was ted, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with EtOAc/Hexane to afford 1112 (1.8g, 40% yield). 1H 10 NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm l.24-l.26(d, 3H) 4.22-4.24(q, 1H) 7.1- , lH) 7.4l-7.46(m, lH) , lH).
To a solution of 1112 (l .97g, 9mmol) in dichloromethane (100mL) was added boc ide (1 .97g, 9mmol) and the reaction mixture was stirred at room temperature overnight before it was concentrated and purified by silica gel chromatography 15 eluting with EtOAc/Hexane to afford 1113 (2.4g, 83% yield). 1H NMR (300MHz, ylsulfoxide-d6) 8 ppm l.29-l.32(d, 3H) , 9H) 4.87(q, lH) 7.l4-7.21(t, lH) 7.46-7.58(m, 3H). l43 WO 2013/078123 PCT/US2012/065816 To a degassed solution of 1113 (2.4g, 7.54mmol) and i-tert- butylphosphine)palladium(0) (0.77g, l.508mmol) in e(l2mL) was added 2- tert-Butoxyoxoethylzinc chloride (3 8mL, l8.85mmol) under Argon and the resulting reaction mixture was stirred at room temperature for 4hr before it was quenched with saturated aqueous ammonium chloride solution. The ing solution was partitioned between water and ethyl acetate. The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with Hexane to afford 1114 (2g, 75% yield). 1H NMR (300MHz, 10 Dimethylsulfoxide-d6) 5 ppm l.29-l .32(d, 3H) l.38-l .4l(m, 18H) 3.53(s, 2H) 4.87(q, lH) 7.05-7.l6(m, 2H) 7.26-7.29(m, lH) , lH).
To a solution of 1114 (2g, ol) in methanol (100mL) and water (25mL) was added lithium hydroxide monohydrate (2gm) and the resulting reaction mixture was stirred at room temperature for 2days before it was concentrated. The residue obtained 15 was diluted with ice cold water and ed with acetic acid. The ing solution was partitioned between water and ethyl acetate. The organic extract was washed with more water, separated, dried over sodium sulfate, filtered and evaporated. The residue obtained was purified by silica gel chromatography eluting with EtOAc/Hexane to afford 1115 (l .5 g, 89% yield). 1H NMR (300MHz, ylsulfoxide-d6) 5 ppm 20 l.29-l.3l(d, 3H) 1.38 (s, 9H) 3.53(s, 2H) 4.87(q, lH) 7.05-7.l9(m, 2H) 7.26-7.29(m, 1H) 7.45- 7.48(m, lH) l2.32(s, lH).
N~N HN’</ \ N\ 0 SW NH o H N O F E K 653 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.30-1.33 (m, 12H) 1.74 (brs, 4H) 2.89(m, 2H) 3.02 (m, 2H) 3.78 (s, 4H) 4.85 (q, 1H) 7.10—7.57 (m, 11H) 8.19-8.22 (d, 25 1H) 11.26 (s, 1H) 12.64 (s, 1H). 144 WO 2013/078123 PCT/US2012/065816 N~N HN’</ \ N s ‘N o | / NH 0 H N 654 WOTO F 1H NMR (300MHz, Dimethylsulfoxide-d6) 5 ppm 1.28—1.32 (m, 12H) 1.73—1.75 (brs, 4H) 2.87(m, 2H) 2.89 (m, 2H) 3.75 (s, 2H) 3.81(s, 2H) 4.85 (q, 1H) 7.06-7.57 (m, 11H) 8.18-8.21(d, 1H) 11.26 (s, 1H) 12.64 (s, 1H).
N‘N HN’</ \ N\ / NH O NH2 655 1H NMR (300MHz, Dimethylsulfoxide-d6) 8 ppm 1.51—1.53 (m, 3H) 1.75 (brs, 4H) 2.90(m, 2H) 3.02 (m, 2H) 3.78 (s, 2H) 3.85(s, 2H) 4.65 (q, 1H) 7.25-7.61 (m, 10H) 8.21-8.25 (d, 1H) 8.33-8.35(brs, 3H) 11.29 (s, 1H) 12.68 (s, 1H).
N‘N HN’</ \ N\ S ‘N o | / NH 0 656 H2N F 10 1H NMR (300MHz, ylsulfoxide-d6) 5 ppm 1.54 (d, 3H) 1.75-1.76 (brs, 4H) 2.91(m, 2H) 3.02 (m, 2H) 3.81—3.83(m, 4H) 4.65 (q, 1H) .63 (m, 10H) 8.22- 8.25 (d, 1H) 8.36(brs, 3H) 11.35 (s, 1H) 12.66 (s, 1H). 145 WO 2013/078123 PCT/US2012/065816 —> N' ”N HN\<\ I N N’N 413 1116 OCF3 \ I —> HN\<\N’N N I OCF3 660 To a mixture of 413 (1.62 g) in MeOH (25 mL), THF (10 mL) and H20 (10 mL) at room temperature was added 1N aq. NaOH (8 mL). This mixture was stirred for 24 h before the organic le was removed under reduced pressure. The residue was neutralized to pH 7 with 1N aq. HCl solution and extracted with EtOAc (2><20 mL).
The combined extract was dried (MgSO4) and concentrated. The crude was purified by silica gel chromatography eluting with 1—15% MeOH in dichloromethane to afford amine 1116. The resulting amine 1116 was ted to 660 as described for 335. 1H NMR (300 MHz, DMSO-d6) 8 12.68 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.2 Hz, 1H), 10 7.57 (d, J: 8.8 Hz, 1H), 7.52—7.21 (m, 8H), 3.90 (s, 2H), 3.87 (s, 2H), 3.06—2.86 (m, 4H), .72 (m, 4H).
H OHHN N, NN\ /C| /C| OCF3 OCFs 1117 3-Aminochloropyridazine (55.5 g, 0.428 mol) and 3- (Trifluoromethoxy)phenylacetic acid (1.1 equiv., 0.471 mol, 104 g) were dissolved in 15 DMF (30.0 vol., 1.66 L) in a 3000 mL three neck round-bottom flask. Addition of DIEA (1.1 equiv., 0.471 mol, 82 mL) via addition funnel was done over 5 minutes.
Propylphosphonic anhydride on (300 mL of a 50% solution in DMF, 1.1 equiv., 0.471 mol, ) was charged into a 500 mL addition funnel and added dropwise to reaction solution (keeping reaction ature 5 +30 0C). The reaction usually goes 20 to completion after 3 hours (TLC: 6:4 hexanes-ethyl e). Reaction mixture was then poured into 7.5% sodium bicarbonate (80.0 vol., 4.4 L) which was chilled in an ice bath. Off-white crystalline powder was filtered through a Biichner funnel, rinsed 146 WO 2013/078123 PCT/US2012/065816 with water (20.0 vol., 1.1 L). Dried in a 50 0C vacuum to a constant weight to afford N—(6-chloropyridazinyl)(3-(trifluoromethoxy)phenyl)acetamide 1 1 17: yield of 119.6 g (77%). 1H NMR (300 MHz, DMSO-d6) 5 11.63 (s, 1H), 8.38(d, J=9.4 Hz, 1H), , J=9.4 Hz, 1H), 7.52 — 7.27(m, 4H), 3.90(s, 2H).
H N N:N H | + Ban(CH2)4CN _> O / 0 CI F3CO OCF3 1117 1118 4-Cyanobutylzinc bromide solution (3.0 , 0.50 mol, 1.0 L) was charged into an argon gas purged 5000 mL 3 neck round bottom flask. Argon(g) purge for 5 minutes followed by the on of 1117 (1.0 equiv., 0.167 mol, 55.3 g) and NiC12(dppp) (0.15 equiv., 0.0251 mol, 13.6 g) under a blanket of argon(g). The reaction usually 10 goes to completion after 4 hours (TLC: 1:1 s-ethyl acetate). EtOAc (15 vol., 832 mL) added to deep red solution. Water (15 vol., 832 mL) was added, thick slurry formed. 1N HCl added until slurry breaks to pale blue layer (~6 vol., 333 mL).
Transferred to separatory funnel and organic layer was washed with 1N HCl (2X500 mL), dried (MgSO4) and concentrated by rotary evaporation (bath 5 30 0C) to a solid 15 reddish oil. Oil dissolved in dichloromethane (15 vol., 832 mL), silica gel (100g) was slurried into red solution, this was concentrated by rotary evaporation (bath 5 30 0C) to a solid reddish powder. Loaded onto a bed of silica gel (5 cm X 11 cm), flushed with 25% s in ethyl e (3 L), combined organics concentrated by rotary evaporation (bath 5 30 0C). Dried under high vacuum to a constant weight to afford 20 N—(6-(4-cyanobutyl)pyridazin-3 -yl)(3-(trifluoromethoxy)phenyl)acetamide 1 1 1 8: yield of58.2 g (92%). 1H NMR (300 MHz, DMSO-d6) 8 11.41 (s, 1H), 8.28(d, J=9.2 Hz, 1H), 7.65(d, J=9.2 Hz, 1H), 7.52 — 7.27(m, 4H), 3.89(s, 2H), 2.92(t, J=7.5 Hz, 2H), 2.56(t,.]=7.0 Hz, 2H), 1.80 (m, 2H), 1.61 (m, 2H). 147 WO 2013/078123 PCT/US2012/065816 1118 (1.0 equiv., 0.154 mol, 58.2 g) was charged into a 500 mL round bottom flask along with micarbazide (1.2 equiv., 0.184 mol, 16.8 g). TFA (5 vol., 291 mL) slowly added to reaction vessel while stirring. The reaction slurry was heated in a 65°C bath with an open top reflux condenser. The reaction usually goes to completion after 5 hours (determined by LC/MS). Toluene (10 vol., 582 mL) added to deep red solution, azeotroped by rotary evaporation (bath 5 30 0C) to a red oil.
Slowly transferred oil to a well stirred 6000 mL Erlenmeyer flask containing 7.5% sodium bicarbonate solution (69 vol., 4.0 L) cooled in a 0°C bath. The crystals were filtered h a Biichner funnel and rinsed twice with diethyl ether (5 vol., 2x250 10 mL). Dried under high vacuum to a constant weight to afford N—(6-(4-(5-amino- 1 ,3 ,4-thiadiazolyl)butyl)pyridazin-3 -(3 uoromethoxy)phenyl)acetamide 657; yield of 55.7 g (80%). 1H NMR (300 MHz, DMSO-d6) 8 11.33 (s, 1H), 8.21(d, J=9.2 Hz, 1H), 7.58(d, J=9.2 Hz, 1H), 7.51 — 7.26(m, 4H), 6.99(s, 2H), 3.88(s, 2H), 2.87(m, 4H), 1.71 (m, 4H). 661 15 00F3 To a solution of 657 (50 mg, 0.11 mmol) in DMF (3 mL) at 0 0C was added 4- fluorophenyl acetic acid (22 mg, 0.14 mmol), HOBt (30 mg, 0.22 mmol) and EDCI (42 mg, 0.22 mmol). The resulting mixture was stirred at room temperature for 1.5 h before it was cooled to 0 0C and quenched with H20. The precipitate was collected 20 by suction filtration and fiarther purified by silica gel chromatography g with 1— 10% MeOH in dichloromethane to afford 661. 1H NMR (300 MHZ, 6) 8 12.65 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.1 Hz, 1H), 7.57 (d, J: 9.4 Hz, 1H), 7.49— 7.14 (m, 8H), 3.87 (s, 2H), 3.81 (s, 2H), 3.06—2.86 (m, 4H), 1.77—1.72 (m, 4H). 148 WO 2013/078123 PCT/US2012/065816 / HN’<8 \ NgN I / NH 0 662 OCF3 662 was prepared by the procedure as described for compound 661. 1H NMR (300 MHz, DMSO-d6) 8 12.67 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.1 Hz, 1H), 7.57 (d, J = 9.1 Hz, 1H), 7.51—7.07 (m, 7H), 3.89 (s, 2H), 3.87 (s, 2H), 3.06—2.86 (m, 4H), 5 1.77—1.72 (m, 4H).
/ HN’<s \ N:N I / NH 0 663 00F3 663 was prepared by the ure as described for compound 661. 1H NMR (300 MHz, DMSO-d6) 8 12.74 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.2 Hz, 1H), 7.57 (d, J = 9.2 Hz, 1H), 7.51—7.19 (m, 7H), 3.97 (s, 2H), 3.87 (s, 2H), 3.06—2.86 (m, 4H), 10 1.77—1.72 (m, 4H). 0 0 Br /ko/ QOXF 2 HO/UE F F —> —> F 0*F 0*F 1119 1120 To a mixture of o(difluoromethoxy) benzene (1 g, 4.5 mmol), bis(tri-tert- hosphine) pa11adium(0) (460 mg, 0.9 mmol) in 1,4-dioxane (30 m1) under argon atmosphere was added 0.5 M of 2-tert-butoxyoxoethy1 zinc chloride in ether (22.5 15 ml). The resulting mixture was stirred at room temperature overnight. The mixture was partitioned between saturated NH4C1 and EtOAc. The organic extract was 149 WO 78123 PCT/US2012/065816 washed with brine, dried over sodium sulfate, filtered and ated. The crude material was purified by silica gel chromatography eluting with 0-10% EtOAc in Hexane to afford 1119.
To a solution of 1119 (300 mg, 1.16 mmol) in dichloromethane (5 ml) at 0 0C was added TFA (3 ml) dropwise. The resulting mixture was stirred at room temperature ght before it was evaporated to dryness then triturated the residue with ether to afford 1 120.
HO O/\CF3 1121 1121 was made using procedure described for compound 1120 from 1-Bromo 10 (2,2,2-trifiuoroethoxy)benzene.
/ F 2 4”“ H N \ HN4““\ S N“N F’k S N“N | o | / / NH _, NH O 664 O 1024 A flask was charged with 1024 (50 mg, 0.135 mmol), 1120 (28 mg, 0.142 mmol) in DMF (1 ml) at 0 0C was added HOBT (39 mg, 0.285 mmol) followed by EDCI (68 mg, 0.356 mmol). The resulting mixture was slowly warmed up to room temperature 15 and stirred for 2 h before it was quenched by addition of ice water (~5 mL). The white precipitate was collected by suction filtration, rinsed with more water to afford 664. 1H NMR (300 MHz, DMSO-d6) 8 12.71 (s, 1H), 11.32 (s, 1H), 8.22-8.19 (d, J: 9.12 Hz, 1H), .54 (d, J: 9.03 Hz, 1H), 7.48-6.99 (m, 10H), 3.85 (s, 2H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 150 WO 2013/078123 PCT/US2012/065816 O N~N / HN \ N\ s F3C’\ N O | / 665 O 665 was made using procedure described for compound 664. 1H NMR (300 MHz, 6) 8 12.71 (s, 1H), 11.32 (s, 1H), 8.22-8.19 (d, J: 9.12 Hz, 1H), 7.58-7.54 (d, J: 9.03 Hz, 1H), 7.38-7.28 (m, 6H), .97 (m, 3H), 4.77-4.74 (q, 2H), 3.80- 3.78 (d, J: 5.82 Hz, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 666 A flask was charged with 348 (50 mg, 0.135 mmol), 1120 (28 mg, 0.142 mmol) in DMF (1 ml) at 0 0C was added HOBT (39 mg, 0.285 mmol) followed by EDCI (68 mg, 0.356 mmol). The resulting mixture was slowly warmed up to room temperature 10 and stirred overnight before it was quenched by addition of ice water (~5 mL). The white precipitate was collected by suction filtration, rinsed with more water. The crude al was purified by silica gel chromatography eluting with 0-6% MeOH in dichloromethane to afford 666. 1H NMR (300 MHz, DMSO-d6) 8 12.71 (s, 1H), 11.32 (s, 1H), 8.22-8.19 (d, J: 9.12 Hz, 1H), 7.58-7.54 (d, J: 9.03 Hz, 1H), 7.48- 15 6.98 (m, 10H), 3.81 (bs, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 HN4M”/ \ / NH 0 667 o/\CF3 151 WO 2013/078123 PCT/US2012/065816 667 was made using procedure described for compound 666. 1H NMR (300 MHz, DMSO-d6) 8 12.71 (s, 1H), 11.32 (s, 1H), 8.22-8.19 (d, J: 9.12 Hz, 1H), 7.58-7.54 (d, J: 8.97 Hz, 1H), .28 (m, 6H), .97 (m, 3H), 4.77-4.74 (q, 2H), 3.87 (s, 2H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 N~N F HN’</ \ F’k N\ S \ N O I / NH 0 668 5 OCF3 668 was made using procedure described for compound 675. 1H NMR (300 MHz, DMSO-d6) 8 12.71 (s, 1H), 11.32 (s, 1H), 8.22-8.19 (d, J: 9.15 Hz, 1H), 7.58-6.99 (m, 10H), 3.87-3.84 (d, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 N~N HN’</ \ N\ S F3C’\O ~N | / NH 669 OCF3 10 669 was made using procedure described for compound 675. 1H NMR (300 MHz, DMSO-d6) 8 12.71 (s, 1H), 11.32 (s, 1H), 8.22-8.19 (d, J: 9.09 Hz, 1H), 7.58-7.54 (d, J: 9.37 Hz, 1H), 7.48-7.28 (m, 6H), 7.03-6.97 (m, 2H), 4.77-4.74 (q, 2H), 3.87 (s, 2H), 3.78 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
\ / O N /N~N N~N H2N’<S \ N‘,N HN’</S ‘ NCN | | / / NH —» NH 670 657 0 0 OCF3 00F3 152 WO 2013/078123 PCT/US2012/065816 A flask was charged with 657 (50 mg, 0.111 mmol), 2-pyridine acetic acid hydrochloride (20 mg, 0.116 mmol) in DMF (1 ml) at 0 0C was d with propylphosphonic anhydride solution (91 ul) followed by triethylamine (40 ul, 0.29 mmol). The resulting mixture was slowly warmed up to room temperature and stirred 5 for 1 h before it was quenched by addition of ice water (~5 mL). The yellow precipitate was collected by suction filtration, rinsed with more water. The crude material was purified by silica gel chromatography eluting with 0-6% MeOH in romethane to afford 670. 1H NMR (300 MHZ, DMSO-d6) 8 12.67 (s, 1H), 11.32 (s, 1H), 8.53-8.49 (m, 1H), 8.22-8.19 (d, J: 9.12 Hz, 1H), .76 (t, 1H), 10 7.58-7.26 (m, 7H), 4.01 (s, 2H), 3.87 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
N\/ 0 HN4M”\ s |N~N / NH 671 O OCF3 671 was made using procedure described for nd 670. 1H NMR (300 MHz, DMSO-d6) 8 12.70 (s, 1H), 11.32 (s, 1H), 8.53-8.48 (m, 2H), 8.22-8.19 (d, J: 9.12 15 Hz, 1H), 7.76-7.26 (m, 7H), 3.87 (s, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
HN”<5 / \ N:N I / NH 672 o 00F3 672 was made using procedure described for compound 670. 1H NMR (300 MHz, DMSO-d6) 8 11.32 (s, 1H), 8.53-8.52 (bs, 2H), 8.22-8.19 (d, J: 9.12 Hz, 1H), 7.58- 7.26 (m, 7H), 3.87 (s, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 20 153 WO 2013/078123 PCT/US2012/065816 / HN’<8 \ NgN I / NH o 673 ocr=3 673 was prepared by the procedure as described for compound 661. 1H NMR (300 MHz, DMSO-d6) 8 12.69 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.1 Hz, 1H), 7.57 (d, J = 9.1 Hz, 1H), 7.51—7.21 (n1, 8H), 3.90 (s, 2H), 3.87 (s, 2H), .86 (n1, 4H), 5 1.77—1.72 (m, 4H). 00F3 674 was prepared by the procedure as described for compound 661. 1H NMR (300 MHz, DMSO-d6) 8 12.63 (bs, 1H), 11.32 (s, 1H), 8.20 (d, J: 9.2 Hz, 1H), 7.57 (d, J = 9.2 Hz, 1H), 7.51—7.38 (n1, 3H), 7.33—7.09 (n1, 5H), 3.87 (s, 2H), 3.79 (s, 2H), 10 .86 (n1, 4H), 2.48 (s, 3H), 1.77—1.72 (m, 4H). 0 N‘N / HN \ , I<s N:N N / l \\/N / NH 0 675 OCF3 A flask was charged with 657 (70 mg, 0.155 mmol), 5-pyrin1idineacetic acid (22 mg, 0.162 mmol) in DMF (1 ml) at 0 0C was added HOBT (44 mg, 0.326 mmol) followed by EDCI (78 mg, 0.408 mmol). The resulting mixture was slowly warmed up to room 15 temperature and stirred for overnight before it was quenched by addition of ice water 154 WO 2013/078123 PCT/US2012/065816 (~5 mL). The white precipitate was collected by suction filtration, rinsed with more water. The crude material was purified by silica gel chromatography eluting with 0- 6% MeOH in dichloromethane to afford 675. 1H NMR (300 MHZ, DMSO-d6) 8 12.75 (s, 1H), 11.32 (s, 1H), 9.11 (s, 1H), 8.76 (s, 1H), 8.22-8.19 (d, J: 9.12 Hz, 1H), 7.59-7.26 (m, 6H), 3.94 (s, 2H), 3.87 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 N NW I / NH O 676 OCF3 676 was made using ure described for compound 675. 1H NMR (300 MHz, DMSO-d6) 8 12.75 (s, 1H), 11.32 (s, 1H), 8.70 (s, 1H), 8.61-8.57 (m, 2H), 8.22-8.19 10 (d, J: 9.36 Hz, 1H), 7.59-7.26 (m, 5H), 4.11 (s, 2H), 3.87 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 677 00F3 677 was made using procedure described for compound 675. 1H NMR (300 MHz, DMSO-d6) 8 12.75 (s, 1H), 11.32 (s, 1H), 8.89 (s, 1H), 8.22-8.19 (d, J: 9.15 Hz, 1H), 15 7.59-7.26 (m, 5H), 6.62 (s, 1H), 3.99 (s, 2H), 3.87 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 155 WO 2013/078123 PCT/US2012/065816 HN4N7“\ NL \ SW S / NH 678 OCF3 678 was made using procedure described for compound 675. 1H NMR (300 MHz, DMSO-d6) 8 12.75 (s, 1H), 11.32 (s, 1H), 9.06 (s, 1H), 8.22-8.19 (d, J: 9.21 Hz, 1H), 7.59-7.26 (rn, 6H), 4.03 (s, 2H), 3.87 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 5 4H). 679 00F3 679 was prepared by the procedure as described for compound 661. 1H NMR (300 MHz, DMSO-d6) 8 12.67 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.2 Hz, 1H), 7.57 (d, J = 9.2 Hz, 1H), 7.51—7.36 (rn, 4H), 7.29—7.12 (rn, 4H), 3.87 (s, 2H), 3.85 (s, 2H), 10 .86 (rn, 4H), 1.77—1.72 (rn, 4H). 680 00F3 680 was prepared by the procedure as described for compound 661. 1H NMR (300 MHz, DMSO-d6) 8 12.67 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.3 Hz, 1H), 7.57 (d, J = 9.0 Hz, 1H), 7.51—7.28 (rn, 8H), 3.87 (s, 2H), 3.84 (s, 2H), 3.06—2.86 (rn, 4H), 15 1.77—1.72 (rn, 4H). 156 WO 2013/078123 PCT/US2012/065816 HN’</ \ N s ~ N | / NH 0 682 00F3 To a solution of 674 (100 mg, 0.16 mmol) in dichloromethane at —78 0C was added m- CPBA (60 mg, 0.24 mmol) in 4 portions. The resulting mixture was stirred at that temperature for 1 h before it was slowly warmed up to —10 0C and ed with 25% aq. Na2S203 solution. The reaction was diluted with EtOAc, washed with saturated aq. NaHC03 (3>< 10 mL). The combined organic layer was separated, washed with brine, dried (MgSO4) and concentrated. The crude was purified by HPLC to afford 682. 1H NMR (300 MHz, DMSO-d6) 8 12.72 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.0 Hz, 1H), 7.68 (m, 1H), .26 (m, 8H), 3.91 (s, 2H), 3.87 (s, 2H), 10 3.06—2.86 (m, 4H), 2.76 (s, 3H), 1.77—1.72 (m, 4H). (<8/ HN \ NgN I / NH 0 681 OCF3 681 was prepared from 657 and 3-methylsulphonylphenyl acetic acid by the procedure as described for nd 661. 1H NMR (300 MHz, DMSO-d6) 8 12.72 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.0 Hz, 1H), 7.92 — 7.83 (m, 2H), 7.70—7.26 (m, 15 7H), 3.93 (s, 2H), 3.87 (s, 2H), 3.23 (s, 3H), 3.06—2.86 (m, 4H), 1.77—1.72 (m, 4H). 0 N~N / HN \ \ N / NH Cl 0 683 00F3 157 WO 2013/078123 2012/065816 683 was made using procedure described for compound 675. 1H NMR (300 MHz, DMSO-d6) 8 12.75 (s, 1H), 11.32 (s, 1H), 8.36 (s, 1H), 8.21-8.18 (d, J: 9.18 Hz, 1H), 7.84-7.80 (d, J: 9.36 Hz, 1H), 7.59-7.26 (m, 6H), 3.90-3.87 (d, 4H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 O HN’</i\lN / N\ s \“1 |~N / NH 684 O OCF3 684 was made using procedure bed for nd 675. 1H NMR (300 MHz, DMSO-d6) 8 12.75 (s, 1H), 11.32 (s, 1H), 8.57 (s, 1H), 8.51-8.49 (d, J: 9.18 Hz, 1H), 8.21-8.18 (d, J: 9.06 Hz, 1H), 7.79-7.75 (d, J: 9.36 Hz, 1H), 7.59-7.26 (m, 6H), 4.07 (t, 2H), 3.87 (s, 2H), 3.30-3.28 (m, 1H), 3.19 (s, 3H), 3.01 (bs, 2H), 2.90 (bs, 10 2H), 2.3-2.5 (m, 1H), 1.99-1.96 (m, 1H), 1.73 (bs, 4H). 685 OCF3 685 was prepared by the procedure as described for compound 661. 1H NMR (300 MHz, DMSO-d6) 8 12.52 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.1 Hz, 1H), 7.61—7.25 (m, 7H), 3.87 (s, 2H), 3.80 (s, 3H), 3.62 (s, 2H), 3.06—2.86 (m, 4H), 1.77—1.72 (m, 15 4H). 158 WO 2013/078123 PCT/US2012/065816 686 00:3 686 was prepared by the ure as bed for compound 661. 1H NMR (300 MHz, DMSO-d6) 8 12.53 (bs, 1H), 11.32 (s, 1H), 8.20 (d, J: 9.1 Hz, 1H), 7.58 (d, J = 9.2 Hz, 1H), 7.52—7.26 (rn, 4H), 5.96 (s, 1H), 3.87 (s, 2H), 3.67 (s, 2H), 3.64 (s, 5 3H), 3.06—2.86 (rn, 4H), 2.21 (s, 3H), 1.77—1.72 (rn, 4H).
N \ / o HN4N7”/ \ s N~‘N | / NH 0 687 OCF3 687 was prepared by the procedure as described for compound 661. 1H NMR (300 MHz, DMSO-d6) 8 12.56 (bs, 1H), 11.32 (s, 1H), 8.20 (d, J: 9.3 Hz, 1H), 7.61—7.38 (rn, 6H), 6.17 (d, J: 2.2 Hz, 1H), 3.87 (s, 2H), 3.79 (s, 3H), 3.75 (s, 2H), 3.03—2.90 10 (rn, 4H), 1.7 —1.72 (rn, 4H).
HN’</ \ N S 5N I / NH o 688 OCF3 688 was prepared by the procedure as described for compound 661. 1H NMR (300 MHz, DMSO-d6) 8 12.61 (bs, 1H), 11.32 (s, 1H), 8.20 (d, J: 9.3 Hz, 1H), 7.58 (d, J 159 WO 2013/078123 PCT/US2012/065816 = 9.3 Hz, 1H), 7.51—7.26 (m, 4H), 3.87 (s, 2H), 3.84 (s, 2H), 3.07—2.86 (m, 4H), 1.77—1.72 (m, 4H). \/_ go H N | 0 HQ HN\<NISW E? OCF3 / | m HOW 689 N’ H2N\<\N,NI 00F3 + OSWNO{\ng NHHN’N 690 To a solution of 657 (200 mg, 0.44 mmol) in DMF (4 mL) at 0 0C was added 5 mandelic acid (124 mg, 0.66 mmol), HOBt (119 mg, 0.88 mmol) and EDCI (170 mg, 0.88 mmol). The resulting mixture was stirred at room temperature for 1.5 h before it was cooled to 0 0C and quenched with H20. The precipitate was ted by suction filtration and further purified by silica gel chromatography eluting with 1—10% MeOH in dichloromethane to afford 690 and a more polar 689. 689: 1H NMR (300 10 MHz, DMSO-d6) 8 12.42 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.2 Hz, 1H), 7.58—7.27 (m, 10H), 6.35 (d, J: 4.4 Hz, 1H), 5.34 (d, J: 4.3 Hz, 1H), 3.87 (s, 2H), 3.03—2.89 (m, 4H), 1.77—1.73 (m, 4H). 690: 1H NMR (300 MHz, DMSO-d6) 8 13.05 (bs, 1H), 11.31 (s, 1H), 8.20 (d, J: 9.0 Hz, 1H), 7.59—7.26 (m, 15H), 6.26 (d, J: 5.5 Hz, 1H), 6.11 (s, 1H), 5.38 (d, J: 5.3 Hz, 1H), 3.87 (s, 2H), 3.03—2.88 (m, 4H), 1.76—1.73 (m, 15 4H).
Cl NH 0 447 00F3 447 was ed from 657 and romandelic acid by the procedure as described for compound 689. 1H NMR (300 MHz, DMSO-d6) 8 12.48 (bs, 1H), 11.31 (s, 1H), 160 WO 2013/078123 PCT/US2012/065816 8.20 (d, .1: 9.2 Hz, 1H), 7.59—7.26 (m, 9H), 6.53 (m, 1H), 5.36 (t, .1: 0.7 Hz, 1H), 3.87 (s, 2H), 3.03—2.90 (m, 4H), 1.75—1.71 (m, 4H). 692 o 00F3 692 was made using procedure described for compound 675. 1H NMR (300 MHz, 5 DMSO-d6) 8 12.75 (s, 1H), 11.32 (s, 1H), .18 (d, J: 9.18 Hz, 1H), 7.80-7.26 (m, 9H), 3.92 (s, 2H), 3.87 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 #4 9"”\ N HN’< N\ LN\ S ‘N I / NH 693 O 00F3 693 was made using procedure described for compound 675. 1H NMR (300 MHz, DMSO-d6) 8 12.75 (s, 1H), 11.32 (s, 1H), .19 (d, J: 9.06 Hz, 1H), 7.79 (s, 1H), 10 7.59-7.26 (m, 6H), 6.31 (s, 1H), 5.20 (s, 2H), 3.87 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H). 0 N~N ’ HN \ N 1 \ S °N N l \N / NH Oko O K 694 OCF3 694 was made using procedure described for compound 675. 1H NMR (300 MHz, DMSO-d6) 8 12.71 (s, 1H), 11.32 (s, 1H), 8.22-8.18 (d, J: 9.15 Hz, 1H), 7.58-7.54 15 (d, J: 9.18 Hz, 1H), 7.48-7.26 (m, 4H), 3.87 (s, 2H), 3.63 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 2.39 (s, 3H), 2.13 (s, 3H), 1.73 (bs, 4H), 1.57 (s, 9H). 161 WO 78123 2012/065816 o N‘N HN’< \ N\ N, \ S ‘N I ‘fi / NH 0 F3CJJ\OH O OCF3 To a solution of 694 (50 mg, 0.081 mmol) in dichloromethane (2 ml) was added TFA (2 ml) at 0 0C. The resulting mixture was stirred at room temperature for 1 h before it was evaporated under vacuo to dryness. Ether was added and the white precipitate was collected by suction filtration, rinsed with more ether to afford 695. 1H NMR (300 MHz, DMSO-d6) 8 12.71 (s, 1H), 11.32 (s, 1H), 8.22-8.19 (d, J: 9.36 Hz, 1H), 7.60-7.57 (d, J: 9.27 Hz, 1H), 7.51-7.28 (m, 4H), 3.88 (s, 2H), 3.57 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 2.45 (s, 3H), 2.15 (s, 3H), 1.73 (bs, 4H). 0 N~N ’ HN \ N / S \N N O N\// I Y / NH +0 O 696 10 00F3 696 was made using procedure described for compound 695. 1H NMR (300 MHz, DMSO-d6) 8 12.71 (s, 1H), 11.32 (s, 1H), 8.22-8.19 (d, J: 9.30 Hz, 1H), 8.15 (s, 1H), 7.58-7.54 (d, J: 9.30 Hz, 1H), 7.48-7.28 (m, 5H), 3.87 (s, 2H), 3.76 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H), 1.59 (s, 9H). 0 N‘N HN’</ \ N /N s N HN\// | / NH 0 JK 0 F30 OH 697 15 OCF3 162 WO 2013/078123 PCT/US2012/065816 697 was made using procedure bed for compound 695. 1H NMR (300 MHz, DMSO-d6) 8 14.22 (s, 1H), 12.71 (s, 1H), 11.32 (s, 1H), 9.01 (s, 1H), 8.22-8.19 (d, J = 9.15 Hz, 1H), .26 (m, 6H), 4.04 (s, 2H), 3.87 (s, 2H), 3.01 (bs, 2H), 2.90 (bs, 2H), 1.73 (bs, 4H).
Preparative HPLC Purification All reverse phase preparative HPLC purif1cations were performed using a Shimadzu Prominence Preparative Liquid Chromatograph with the column at ambient temperature. Mobile phases A and B ted of 0.1% formic acid in water and 0.1% formic acid in acetonitrile, respectively. Crude product mixtures were dissolved 10 in DMF, DMSO or mixtures thereof at concentrations of approximately 100 mg/mL and chromatographed according to the methods described in Table 2. riate chromatographic fractions were then evaporated under high vacuum at 45° C using a Savant Speed Vac Plus Model SC210A to yield purified products.
TABLE 2: Preparative HPLC Method Descriptions Compound Column Time %MPB Flow Product ID Rate Retention (mL/min) Time (min) MMKANN >1 4; 2 2 5 5 5 p-A WO 78123 PCT/US2012/065816 who: 0Ln NHO HOOH U.)U] OH b.) WO 2013/078123 PCT/US2012/065816 The following representative synthetic protocols may also be used for producing compounds of the ion. 3,6-Dichloropyridazine is d with di-tertbutyl malonate and sodium hydride in THF or DMF to give 1026. ediate 1026 is then treated with sodium hydride in THF or DMF followed by bis-(chloromethyl)sulfide to give 1027. Intermediate 1027 is treated with TFA in dichloromethane to give 1028. Intermediate 1028 is treated with ammonia to give 1029. Intermediate 1028 is also converted to 1029 by sequential treatment with 2, 4-dimethoxybenzyl amine and TFA. The bis-amino 10 intermediate 1029 may be converted to acylated products analogous to those described in Table 3 using the methods described in Synthetic Protocols section above for acylation of 1001-1008. 165 WO 2013/078123 PCT/US2012/065816 MsCI, pyridine HOVOH DCM S NaCN' DMSO 1030 8 HNH2 NCVCN s s H2N\<\m />/NH2 N’N N~N 1031 1032 Both trans- and cis-cyclopropane-l,2-diyldimethanols are converted into the corresponding bis-nitrile 1031 via bis-mesylated intermediate 1030. The ylate intermediate 1030 is prepared by treating the diol with methanesulfonyl chloride in the presence of pyridine or triethylamine in dichloromethane. The bisnitrile 1031 is prepared by treating 1030 with sodium cyanide in DMSO or ethanol/water. Using a procedure similar to that described for the preparation 1001, bis-nitrile 1031 undergoes cyclization with thiosemicarbazide in TFA to provide bis-amino intermediate 1032. The bis-amino intermediate 1032 may be converted to acy1ated 10 products analogous to those described in Table 3 using the methods described in Synthetic Protocols section above for acylation of 1001-1008.
S HZN N—N N: s xWSXNHz\ —\_\¥ TFA + JL N—N HZN NHNHz __N 1033 H 0 o EtZZn,CH2|2 s s N_N NY M‘_ H .w_ W The alkene analog 1033 is prepared from trans-3 edinitrile using a procedure similar to that described for the preparation 1001. The ino intermediate 1033 15 may be converted to acy1ated products analogous to those described in Table 3 (for example, 1034) using the methods described in Synthetic Protocols section above for acylation of 008. The products may be fiarther converted to ropyl analogs (exemplified by 1035) under the s-Smith conditions (EtZZn, CH212,1 ,2-dimethoxyethane). 20 Example 2: Compound Assays 166 WO 78123 PCT/US2012/065816 Compounds were d in both an in vitro biochemical assay and a cell proliferation assay as follows. The IC50 results are provided in Table 3.
Recombinant Enzyme assay Compounds were assessed for their ability to inhibit the enzymatic activity of a recombinant form of Glutaminase l (GAC) using a biochemical assay that couples the production of glutamate (liberated by GAC) to glutamate dehydrogenase (GDH) and measuring the change in absorbance for the reduction ofNAD+ to NADH.
Substrate solution was prepared (50 mM Cl pH 8.0, 0.2 mM EDTA, 150 mM 10 KZHPO4, 0.1 mg/ml BSA, 1 mM DTT, 20mM L-glutamine, 2 mM NAD+, and 10 ppm antifoam) and 50 uL added to a 96-well half area clear plate (Coming #3695).
Compound (2 uL) was added to give a final DMSO concentration of2% at 2X the desired concentration of compound. Enzymatic reaction was started with the addition of 50 uL of enzyme solution (50 mM Tris-HCl pH 8.0, 0.2 mM EDTA, 150 mM 15 KZHPO4, 0.1 mg/ml BSA, 1 mM DTT, 10 ppm antifoam, 4 units/ml GDH, 4 mM adenosine diphosphate, and 4 nM GAC) and read in a Molecular s M5 plate reader at 20°C. The plate reader was configured to read absorbance (9t=340 nm) in c mode for 15 minutes. Data was recorded as milli-absorbance units per minute and slopes were compared to a control compound and a DMSO-only l on the 20 same plate. Compounds with slopes less than the DMSO control were considered inhibitors and plate variability was assessed using the control compound.
Results from this assay for several compounds of the invention are shown in Table 3, expressed as IC50, or half maximal inhibitory concentration, wherein IC50 is a quantitative measure ting how much compound is needed to inhibit a given 25 biological activity by half. inant Enzyme assay — Time Dependence Compounds were assessed for their ability to inhibit the enzymatic activity of a recombinant form of inase l (GAC) using a biochemical assay that couples the production of glutamate (liberated by GAC) to glutamate dehydrogenase (GDH) 30 and measuring the change in absorbance for the reduction ofNAD+ to NADH.
Enzyme on was prepared (50 mM Cl pH 8.0, 0.2 mM EDTA, 150 mM KZHPO4, 0.1 mg/ml BSA, 1 mM DTT, 10 ppm antifoam, 4 units/ml GDH, 4 mM adenosine diphosphate, and 4 nM GAC) and 50 uL added to a 96-well half area clear l67 W0 2013/078123 PCT/US2012/065816 plate (Coming #3695). Compound (2 uL) was added to give a final DMSO concentration of 2% at 2X the desired concentration of compound. The enzyme/compound mix was sealed with sealing foil (USA Scientific) and allowed to incubate, with mild agitation, for 60 minutes at 20°C. Enzymatic reaction was started with the addition of 50 uL of substrate solution (50 mM Tris-HCl pH 8.0, 0.2 mM EDTA, 150 mM KZHPO4, 0.1 mg/ml BSA, 1 mM DTT, 20mM L-glutamine, 2 mM NADT, and 10 ppm antifoam) and read in a Molecular Devices M5 plate reader at 20°C. The plate reader was configured to read absorbance (1:340 nm) in kinetic mode for 15 minutes. Data was recorded as milli-absorbance units per minute and 10 slopes were compared to a l compound and a DMSO-only control on the same plate. Compounds with slopes less than the DMSO control were considered inhibitors and plate variability was assessed using the control compound.
Results from this assay for several compounds of the invention are shown in Table 3, expressed as IC50, or half maximal inhibitory concentration, wherein IC50 is 15 a quantitative measure indicating how much compound is needed to inhibit a given biological activity by half.
Cell proliferation assay P493-6 (myc “on”) cells were maintained in growth media (RPMI-l640, , 2mM glutamine, 100 units/ml Penicillin and 100ug/ml streptomycin) at 20 37°C with 5% C02. For nd assay, P493-6 cells were plated in 96-well V- bottom plates on the day of compound addition in 50 ul of growth media at a cell y of 200,000 cells/ml (10,000 cells/well). Compounds were serially diluted in 100% DMSO at 200-times the final concentration. Compounds were diluted 100- fold into growth media and then 50 ul of this mixture was added to cell plates making 25 the final concentration ofDMSO 0.5%. Cells were incubated with nd for 72 hrs at 37°C with 5% C02 and ed for antiproliferative effects either by Cell Titer Glo (Promega) or FACS is using the Viacount (Millipore) kit on the Guava ment.
Results from this assay for several nds of the invention are shown in 30 Table 3, expressed as IC50, or half maximal inhibitory concentration, wherein IC50 is a quantitative measure ting how much compound is needed to inhibit a given biological activity by half. 168 WO 78123 PCT/US2012/065816 Table 3: GAC Cell Delta prolif N2 P493 IC50 72h no IC50 premc ( u.w (HM) W fly. 20 0 m 4 1 O .m >50 >w 13 >w >50 >w >50 2 7 >50 1 o. >50 1 s 169 WO 78123 PCT/US2012/065816 170 WO 78123 PCT/US2012/065816 H 0‘ >50 0.80 \l 15 4.2 H 00 4.5 8.2 L0 11 1.7 NO 6.6 2.6 0.16 0.02 >50 >50 N U.) >50 >50 Nh 0.51 2.3 N U'l 1.2 1.5 171 WO 78123 PCT/US2012/065816 5.6 0.70 >50 0.47 >50 1.0 0.56 4.1 1.2 2.5 >50 4.3 7.0 11 WO 78123 PCT/US2012/065816 13 5.3 >50 >50 N N O O mmws s 3 ya ~ .8 ’ ‘ O 0.22 0.16 >50 >50 >50 3.2 26 4.5 173 WO 78123 PCT/US2012/065816 3.7 0.56 h H 7.9 33 hN >50 >50 2.3 >50 4.9 2.6 h (.11 >50 >50 >50 16 h\l 8.3 35 >50 0.42 174 WO 78123 PCT/US2012/065816 1.3 175 WO 78123 PCT/US2012/065816 >50 3.9 >50 40 >50 3.7 >50 24 14 >50 176 WO 78123 PCT/US2012/065816 19 25 2.6 1.3 0.23 1.3 0.52 20 3.0 1.8 4.9 0.34 177 WO 78123 PCT/US2012/065816 0.69 0.33 3.4 3.4 >50 6.9 0.59 0.47 >50 >50 >50 178 WO 78123 PCT/US2012/065816 >50 6.1 34 0.84 10 2.0 20 1.8 1.3 10 7.6 179 WO 78123 PCT/US2012/065816 080 1.3 180 WO 78123 PCT/US2012/065816 >20 >20 >20 0.38 0.47 0.90 2.0 0.28 0.47 2.9 45 181 WO 78123 PCT/US2012/065816 >20 0.56 17 >20 3.9 2.7 1.0 8.1 9.0 24 17 0.24 1.4 19 >50 >20 182 WO 78123 PCT/US2012/065816 9 9. 119 183 WO 78123 PCT/US2012/065816 0.51 0.89 >20 0.60 0.56 0.62 1.1 0.24 0.72 184 WO 78123 PCT/US2012/065816 2.4 6.2 5.0 36 >20 13 1.8 38 1.7 3.5 WO 78123 PCT/US2012/065816 3.5 43 12 6.6 >20 >20 5.8 12 1.8 0.45 186 WO 78123 PCT/US2012/065816 32 >50 O.51 0. 15 187 WO 78123 PCT/US2012/065816 28 4.7 >2O 3.4 >50 188 WO 78123 PCT/US2012/065816 1.7 4.3 >20 0.57 2.2 >20 >20 0.43 0.46 0.62 0.37 0.59 0.39 189 WO 78123 PCT/US2012/065816 15 >20 14 >50 0.73 1.1 1.0 >50 19 >50 0.27 1.9 0.12 0.63 WO 78123 PCT/US2012/065816 8.1 191 WO 78123 PCT/US2012/065816 1.4 15 13 192 WO 78123 PCT/US2012/065816 7.4 6.8 11 34 1.3 >50 0.71 3.4 7.4 9.3 >20 1.7 3.7 24 0.76 0.29 0.44 6.3 23 193 WO 78123 PCT/US2012/065816 0.57 1.5 1.1 >50 1.5 >50 3.1 >50 8.8 >50 0.33 30 0.58 >50 194 WO 78123 PCT/US2012/065816 >2O 0.09 195 WO 78123 PCT/US2012/065816 0.03 196 WO 78123 PCT/US2012/065816 1.3 17 197 WO 78123 PCT/US2012/065816 03.8 4.1 198 WO 78123 PCT/US2012/065816 >20 13 0.17 9.0 >20 22 0.38 0.42 1.2 1.0 >20 199 WO 78123 PCT/US2012/065816 4.4 1.2 >50 >50 200 WO 78123 PCT/US2012/065816 0.17 0.57 1.6 0.31 >20 >20 >20 >20 >20 201 WO 78123 PCT/US2012/065816 2.3 >50 9.9 3.3 0.57 0.13 3.9 12 7.4 9.8 15 202 WO 78123 PCT/US2012/065816 2.5 0.11 0.21 0.20 1.4 0.20 0.25 0.30 0.30 203 WO 78123 PCT/US2012/065816 0.54 1.3 0.38 0.87 0.36 0.22 33 0.84 1.7 0.52 2.5 204 WO 78123 PCT/US2012/065816 1.6 0.83 0.16 0.14 2.8 205 WO 78123 PCT/US2012/065816 6.3 0.38 0.11 0.12 0.073 0.19 0.18 206 WO 78123 PCT/US2012/065816 0.57 0.084 2.6 3.1 3.9 0.01 207 WO 78123 PCT/US2012/065816 0.27 0.31 2.2 >50 0.61 0.64 0.60 5.4 0.26 0.52 7.4 0.85 208 WO 78123 PCT/US2012/065816 0.63 0.07 0.68 2.2 0.34 56 WO 78123 PCT/US2012/065816 0.16 7.0 0.23 0.66 0.37 0.74 210 WO 78123 PCT/US2012/065816 >20 0.19 0.14 0.54 6.4 0.57 1.3 0.02 0.67 8 32 0.80 0.79 211 WO 78123 PCT/US2012/065816 1.5 1.8 0.01 0.12 0.24 0.04 0.20 1.1 0.057 0.039 0.10 0.17 WO 78123 PCT/US2012/065816 5.1 0.16 0.23 0.87 213 WO 78123 PCT/US2012/065816 4.9 102 1.5 0.066 9.3 1.2 214 WO 78123 PCT/US2012/065816 0.18 0.12 22.
N/D 215 WO 78123 PCT/US2012/065816 0.27 94 0.14 0.048 0.12 0.035 0.19 0.075 0.18 0.010 216 WO 78123 PCT/US2012/065816 0.18 0.017 0.64 10 0.40 0.19 2.5 2.6 2.8 3.0 0.056 0.20 4.6 0.10 217 WO 78123 PCT/US2012/065816 0.66 0.030 >20 N/D >20 0.15 >20 N/D 0.17 0.45 218 WO 78123 PCT/US2012/065816 N/D N/D 0.087 1.6 0.030 219 WO 78123 PCT/US2012/065816 0.062 0.050 0.068 0.052 0.073 0.021 0.15 0.043 0.16 0.009 220 WO 78123 PCT/US2012/065816 0.038 0.039 2.7 0.25 0.088 0.24 0.087 221 WO 78123 PCT/US2012/065816 0.13 0.098 0.22 0.71 1.0 1.7 0.12 0.12 0.079 0.029 0.11 0.049 222 WO 78123 PCT/US2012/065816 0.13 0.021 0.047 0.039 N/D >20 N/D 223 WO 78123 PCT/US2012/065816 0.11 0.91 0.67 >20 N/D 0.054 >20 WO 78123 PCT/US2012/065816 0.15 0.26 0.092 0.089 0.074 0.024 0.12 0.006 0.11 0.017 225 WO 78123 PCT/US2012/065816 0.81 1.9 0.28 0.70 0.43 5.2 0.16 0.15 0.17 0.28 0.26 0.47 0.38 0.041 0.35 0.091 0.28 0.10 226 WO 78123 PCT/US2012/065816 0.090 0.038 0.019 0.018 0.007 227 WO 78123 PCT/US2012/065816 0.086 0.022 0.081 0.005 0.26 0.72 0.085 0.15 1.2 2.3 0.21 0.75 228 WO 78123 PCT/US2012/065816 0.032 0.16 0.027 0.072 0.90 229 WO 78123 PCT/US2012/065816 1.2 0.015 0.005 0.041 0.023 0.026 230 WO 78123 PCT/US2012/065816 0.053 0.011 0.054 0.12 0.022 231 WO 78123 PCT/US2012/065816 0.67 0.27 0.044 0.19 0.037 232 WO 78123 PCT/US2012/065816 0.057 0.22 0.74 0.11 0.045 0.058 0.018 0.35 0.32 0.32 233 WO 78123 PCT/US2012/065816 0.064 0.070 0.16 0.006 0.042 234 WO 78123 PCT/US2012/065816 0.008 0.015 0.033 0.027 0.019 0.007 235 WO 78123 PCT/US2012/065816 0.027 0.026 0.004 0.007 0.017 236 WO 78123 PCT/US2012/065816 0.006 0.010 0.072 0.88 0.056 0.031 0.18 237 WO 78123 PCT/US2012/065816 0.025 0.10 0.008 0.022 0.15 0.016 0.051 238 WO 78123 PCT/US2012/065816 0.12 0.042 0.056 0.049 0.015 0.13 239 WO 78123 PCT/US2012/065816 0.012 0.024 0.11 0.013 0.57 0.031 240 WO 78123 PCT/US2012/065816 0.062 0.053 0.96 0.059 0.92 1.3 241 WO 78123 PCT/US2012/065816 0.047 0.27 0.049 0.009 0.006 0.024 0.006 242 WO 78123 PCT/US2012/065816 0.004 0.003 0.012 0.015 0.046 0.030 243 WO 78123 PCT/US2012/065816 6.3 0.012 0.038 0.009 0.011 244 WO 78123 PCT/US2012/065816 0.012 0.024 0.042 1.9 0.023 0.25 245 WO 78123 PCT/US2012/065816 0.023 0.014 0.057 0.58 0.014 0.017 246 WO 78123 PCT/US2012/065816 0.032 0.017 0.19 0.029 0.069 247 WO 78123 PCT/US2012/065816 0.075 0.15 0.12 0.24 0.17 0.041 248 WO 78123 PCT/US2012/065816 0.020 0.009 0.094 1.1 0.046 0.022 249 WO 78123 PCT/US2012/065816 0.063 0.059 0.028 0.046 0.063 250 WO 78123 PCT/US2012/065816 0.059 0.056 0.052 0.060 0.055 251 WO 78123 PCT/US2012/065816 0.044 0.16 0.28 0.042 0.059 0.041 0.044 0.090 252 WO 78123 PCT/US2012/065816 0.071 0.076 0.030 0.045 0.050 0.006 253 WO 78123 PCT/US2012/065816 0.043 0.005 0.044 0.046 0.027 254 WO 78123 PCT/US2012/065816 0.031 0.085 0.045 0.036 0.127 0.005 255 WO 78123 PCT/US2012/065816 0.019 0.172 0.010 0.12 256 WO 78123 PCT/US2012/065816 0.12 0.028 0.066 0.037 0.004 257 WO 78123 PCT/US2012/065816 0.002 0.003 0.002 0.013 0.015 0.021 0.028 258 WO 78123 PCT/US2012/065816 0.011 0.009 0.010 0.004 0.015 0.028 259 WO 78123 PCT/US2012/065816 0.040 0.013 0.034 0.022 0.009 260 WO 78123 PCT/US2012/065816 0.013 0.24 0.046 0.042 1.4 261 WO 78123 PCT/US2012/065816 0.070 0.031 0.057 0.27 0.025 0.087 262 WO 78123 PCT/US2012/065816 0.033 0.011 0.033 0.050 263 WO 78123 PCT/US2012/065816 0.059 0.33 0.017 0.004 0.039 264 WO 78123 PCT/US2012/065816 0.008 0.036 0.036 0.023 0.042 265 WO 78123 PCT/US2012/065816 0.018 0.045 0.047 0.037 266 WO 78123 PCT/US2012/065816 0.014 0.011 0.040 0.10 0.45 WO 78123 PCT/US2012/065816 0.082 0.12 0.13 0.040 0.035 0.15 0.011 268 WO 78123 PCT/US2012/065816 0.020 0.010 0.026 0.009 0.006 0.017 269 WO 78123 PCT/US2012/065816 0.85 0.17 0.065 0.009 0.006 0.20 270 WO 78123 PCT/US2012/065816 0.13 0.048 0.030 0.059 >20 >50 0.48 5.7 0.17 23 WO 78123 PCT/US2012/065816 0.12 0.070 0.14 0.50 0.013 0.015 0.037 272 WO 78123 PCT/US2012/065816 0.018 0.011 0.034 0.14 0.037 273 WO 78123 PCT/US2012/065816 0.039 0.010 0.007 0.35 0.40 1.5 0.040 WO 78123 PCT/US2012/065816 0.058 0.037 0.12 0.055 0.089 0.060 0.10 275 WO 78123 PCT/US2012/065816 0.058 0.11 0.026 0.026 0.030 276 WO 78123 PCT/US2012/065816 0.035 0.045 0.033 0.024 0.040 0.030 277 WO 78123 PCT/US2012/065816 0.056 0.026 0.036 0.033 0.019 0.017 0.024 278 WO 78123 PCT/US2012/065816 0.042 0.022 0.010 0.011 0.012 0.013 0.017 279 WO 78123 PCT/US2012/065816 0.020 0.070 0.029 0.030 0.034 280 WO 78123 PCT/US2012/065816 0.050 0.098 0.12 0.17 0.11 281 WO 78123 PCT/US2012/065816 0.31 0.012 0.88 0.032 14 0.085 282 WO 2013/078123 2012/065816 2.8 0.14 Exam le 3: Xeno raft efficac studies Certain compounds were assayed for in vivo efficacy in xenograft models as follows.
Female scid/bg mice, approximately 6 weeks of age, were implanted subcutaneously on the right flank with 5 x 106 HCTl 16 cells per mouse in a volume of 100 uL of sterile PBS. When tumors reached a volume of 50 - 100mm3 mice were , randomized to groups of n=lO to receive either vehicle or test compound red twice daily by intraperitoneal injection. Tumors were measured three times per week using Vernier calipers and tumor volume calculated using the formula: Volume = 10 (Length x Widch/Z), where length and width are the longest perpendicular sides of the tumor. Dosing ued twice daily until l tumors reached a size of 2000mm3. Statistical comparisons were made using a 2-way ANOVA with Bonferroni post-test.
Figure 1 shows that intraperitoneal administration of compound 188 to mice 15 results in reduced tumor size in this HCTl l6 colon carcinoma xenograft model.
Example 4: Caco-2 Permeability Assay Caco-2 cells are commonly used in a confluent monolayer on a cell culture insert filter. When cultured in this format and under specific conditions, the cells become differentiated and polarized such that their phenotype, morphologically and functionally 20 resembles the enterocytes lining the small intestine. The cell monolayer es a al and biochemical r to the passage of small molecules, and is widely used across the pharmaceutical industry as an in vitro model of the human small intestinal mucosa to predict 283 WO 2013/078123 PCT/US2012/065816 the absorption of orally administered drugs (Hidalgo et al., Gastroenterology, 1989; Artursson, J. Pharm. Sci., 1990). The correlation between the in vitro nt permeability (Pfiapp) across Caco-2 yers and the in vivo absorption is well established (Artursson et al., Biochem. Biophys. Res. Comm., 1991).
The present assay was used to determine the bidirectional permeability of the nds of the invention through Caco-2 cell monolayers. Caco-2 cells were grown in confluent monolayers where the media of both the apical (A) and basolateral (B) sides were at pH 7.4. Compounds were dosed at 1 uM in the ce of 200uM Lucifer Yellow, on the apical side (A—>B) or the basolateral side (B—>A) for 10 ment, in duplicate. s from both A and B sides were taken after 120 minutes exposure, and compound concentration (reported as percent recovery) was determined using a generic LC-MS/MS method with a minimum four-point calibration curve.
The absorption potential of compounds were classified as either Low (P-app < 15 1X10"6 cm/s) or High (P-app > 1X10"6 cm/s). The efflux ratio was calculated as (Papp B—>A)/(Papp A—>B), with effiux ratios being significant when greater than or equal to 3 when the Papp (B—>A) was greater than or equal to 1X10"6 cm/s. Results for certain compounds of the ion are shown in Table 4.
Table 4: Caco-2 Permeability Results Direction Recovery Permeability Significant % Ratio Classification Efflux Yes 585 3.1 ' Yes wi> 53 Yes Yes Yes Yes Yes Yes WO 2013/078123 2012/065816 Example 5: Solubility Ca. 1 mg ns of test article were combined with 120 uL solvent in wells of a 96 x 2 mL polypropylene plate. The plate was vigorously vortex mixed at room ature (ca. 20 C) for 18 hr and each well checked visually for undissolved solid; wells containing no visible solid were charged with additional solid test article and vortex mixed another 6 hr at room temperature after which all wells showed visible solid. The contents of all wells were then filtered through a 0.45 um GHP filter plate to yield clear filtrates. 5 uL of each filtrate was d into 100 uL DMF and vortex 10 mixed to yield HPLC samples. Duplicate quantitation standards for each test article were prepared by diluting weighed portions of solid test article in measured volumes of DMF. 2 uL of each HPLC sample and quantitation standard were analyzed by HPLC using the method outlined in Table 5. Dissolved test article concentrations were calculated by peak area ratio against the appropriate tation standards. 15 Solubility results are presented in Table 6.
Table 5: Outline of HPLC Method Shimadzu Prominence UFLC with Diode Array Instrument UV/Vis Detector VWR Sonoma C8(2), 3.5 um, 2.1 x 50 mm Column Temp 400 C 285 WO 2013/078123 PCT/US2012/065816 Mobile Phase A 0.1% (V/V) formic acid in water Mobile Phase B 0. 1% (V/V) formic acid in acetonitrile o4m Time (min) % Mobile Phase B 0 20 Table 6: Measured Solubilities 29Solubilit—111/mL < 0.002 < 00502 0—0204< < 0.0502 0.9% NaCl < 0.002 < 0.002 < 0.004 < 0.002 0.1 M HC1 < 0.002 0003 < 0.004 < 0.002 _--H2.3 < 0.002 < 0.002 < 0.004 < 0.002 _--H3.3 < 0.002 < 0.002 < 0.004 < 0.002 _--H4.4 < 0.002 < 0.002 < 0.004 < 0.002 4 < 0.002 < 0.002 < 0.004 < 0.002 < 0.002 < 0.002 < 0.004 < 0.002 ---NaOH 14.420 0.268 < 0.004 0.192 50 rnM cit 0.050 0.027 0.153 0.261 /50 rnM cit 0.076 0. 055 0. 157 0.228 20% SBECD / 50 rnM cit 0.046 0. 090 0.019 0.125 20% 50 rnM cit 0.042 0. 167 0.056 26 WO 2013/078123 PCT/US2012/065816 Labrasol 0.258 0.918 31.032 5.004 Capryol PGMC 0.042 1.540 11.210 1.780 — __—— 2.3 0.066 < 0.004 < 0.004 _--—oH3.3 0.003 < 0.004 < 0.004 _--—H4.4 < 0.002 < 0.004 < 0.004 _--—oH5.4 < 0.002 < 0.004 < 0.004 < 0.002 < 0.004 < 0.004 --——NaOH 0 227 0 192 0.656 150 mM cit 1 .204 0. 851 0.378 / 50 mM cit 0.458 0.732 0.309 20% 50 mM cit 5.256 2.718 0.476 20% HPBCD / 50 mM cit 9.685 2.177 0.651 5.042 77.164 20.727 Capryol PGMC 1.519 7.916 3.683 287 WO 2013/078123 PCT/US2012/065816 Incorporation by Reference All publications and patents ned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the t application, including any definitions herein, will control.
Eguiyalents While specific embodiments of the subject invention have been discussed, the above cation is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and 10 the claims below. The full scope of the invention should be determined by nce to the claims, along with their filll scope of equivalents, and the specification, along with such variations.

Claims (70)

1. Use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating cancer or an immunological or neurological disease, wherein formula I is: 5 (I), wherein: L represents CH2SCH2, CH2CH2, CH2CH2CH2, CH2, CH2S, SCH2, H2, CH=CH, or , wherein any en atom of a CH or CH2 unit may be ed by alkyl or alkoxy, any hydrogen of an NH unit may be replaced by 10 alkyl, and any hydrogen atom of a CH2 unit of CH2CH2, CH2CH2CH2 or CH2 may be replaced by hydroxy; one X represents S and the other X represents CH=CH, wherein any en atom of a CH unit may be replaced by alkyl; Y, independently for each occurrence, represents H or CH2O(CO)R7; 15 R7, independently for each occurrence, represents H or tuted or unsubstituted alkyl, alkoxy, aminoalkyl, alkylaminoalkyl, heterocyclylalkyl, or heterocyclylalkoxy; Z represents H or R3(CO); R1 and R2 each independently represent H, alkyl, alkoxy or hydroxy; R3, independently for each occurrence, ents substituted or unsubstituted alkyl, 20 hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, y, aryloxyalkyl, lkyl, cycloalkylalkyl, cyclyl, heterocyclylalkyl, aryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl or C(R8)(R9)(R10), N(R4)(R5) or OR6, wherein any free hydroxyl group may be acylated to form C(O)R7; 25 R4 and R5 each independently represent H or substituted or unsubstituted alkyl, hydroxyalkyl, acyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7; R6, independently for each occurrence, represents tuted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, 5 aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or aryloxyalkyl, wherein any free yl group may be acylated to form C(O)R7; and R8, R9 and R10 each independently represent H or substituted or unsubstituted alkyl, 10 y, hydroxyalkyl, amino, acylamino, aminoalkyl, inoalkyl, alkoxycarbonyl, alkoxycarbonylamino, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or R8 and R9 together with the carbon to which they are 15 attached, form a carbocyclic or heterocyclic ring system, wherein any free hydroxyl group may be acylated to form C(O)R7, and n at least two of R8, R9 and R10 are not H; wherein, where indicated, alkyl, hydroxyalkyl, lkyl, alkylaminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, 20 aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, cyclylalkyl, heterocyclylalkoxy, aryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl is optionally substituted with one or more substituents selected from halogen, hydroxyl, carboxyl, alkoxycarbonyl, formyl, acyl, thioester, etate, thioformate, alkoxyl, phosphoryl, phosphate, phosphonate, 25 phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, an arylalkyl, aryl, and heteroaryl.
2. The use of claim 1, wherein L represents CH2SCH2, CH2CH2, CH2S or SCH2.
3. The use of claim 1, n L ents CH2CH2. 30
4. The use of any one of the preceding claims, wherein Y represents H.
5. The use of any one of the preceding claims, wherein Z represents R3(CO).
6. The use of claim 5, wherein each occurrence of R3 is not cal.
7. The use of any one of the preceding claims, wherein R1 and R2 each represent H.
8. The use of any one of the preceding , wherein R3, independently for each 5 occurrence, represents substituted or unsubstituted arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl.
9. The use of any one of the ing claims, wherein R3, independently for each occurrence, represents R9)(R10), wherein R8 represents substituted or unsubstituted aryl, arylalkyl, heteroaryl or heteroaralkyl, R9 represents H, and R10 represents hydroxy, 10 hydroxyalkyl, alkoxy or alkyl.
10. The use of claim 9, wherein R8 represents substituted or unsubstituted aryl, arylalkyl, or heteroaryl.
11. The use of claim 9 or claim 10, wherein R10 represents hydroxy, hydroxyalkyl, or alkoxy. 15
12. The use of claim 1, wherein L represents CH2SCH2, CH2CH2, CH2S or SCH2, Y ents H, Z represents R3(CO), R1 and R2 each represent H, and R3, independently for each occurrence, ents substituted or unsubstituted arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl.
13. The use of claim 12, wherein each occurrence of R3 is identical. 20
14. The use of claim 1, wherein L represents CH2SCH2, CH2CH2, CH2S or SCH2, Y represents H, Z represents , R1 and R2 each represent H, and R3, independently for each occurrence, represents C(R8)(R9)(R10), wherein R8 represents substituted or unsubstituted aryl, arylalkyl, heteroaryl or heteroaralkyl, R9 represents H, and R10 represents hydroxy, hydroxyalkyl, alkoxy or alkoxyalkyl.
15. The use of claim 14, n L represents CH2CH2.
16. The use of claim 14 or claim 15, wherein R8 ents substituted or tituted aryl, arylalkyl or heteroaryl.
17. The use of claim 16, wherein R8 represents substituted or unsubstituted aryl. 5
18. The use of any one of claims 14-17, wherein R10 represents hydroxy, hydroxyalkyl or alkoxy.
19. The use of claim 18, wherein R10 represents hydroxyalkyl.
20. The use of any one of claims 14-19, wherein each occurrence of R3 is identical.
21. The use of claim 1, wherein L represents CH2CH2, Y ents H, Z represents 10 R3(CO), R1 and R2 each represent H, and R3, independently for each ence, represents arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl.
22. The use of claim 21, wherein each occurrence of R3 is identical.
23. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a nd of formula I, 15 (I), or a pharmaceutically acceptable salt f, wherein: L represents CH2SCH2, CH2CH2, CH2CH2CH2, CH2, CH2S, SCH2, CH2NHCH2, CH=CH, or , wherein any hydrogen atom of a CH or CH2 unit may be replaced by alkyl or alkoxy, any hydrogen of an NH unit may be replaced by 20 alkyl, and any hydrogen atom of a CH2 unit of CH2CH2, CH2CH2CH2 or CH2 may be replaced by hydroxy; one X represents S and the other X represents CH=CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl; Y, independently for each occurrence, represents H or CH2O(CO)R7; R7, independently for each occurrence, represents H or substituted or unsubstituted alkyl, alkoxy, aminoalkyl, alkylaminoalkyl, heterocyclylalkyl, or heterocyclylalkoxy; Z represents H or R3(CO); 5 R1 and R2 each independently represent H, alkyl, alkoxy or hydroxy; R3, ndently for each ence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, inoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, kyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl 10 or C(R8)(R9)(R10), N(R4)(R5) or OR6, wherein any free hydroxyl group may be ed to form C(O)R7; R4 and R5 each independently represent H or substituted or unsubstituted alkyl, hydroxyalkyl, acyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, y, aryloxyalkyl, lkyl, cycloalkylalkyl, heterocyclyl, 15 heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free yl group may be acylated to form C(O)R7; R6, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, 20 aryloxy, aryloxyalkyl, cycloalkyl, lkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form ; and R8, R9 and R10 each independently represent H or substituted or unsubstituted alkyl, 25 hydroxy, hydroxyalkyl, amino, acylamino, lkyl, acylaminoalkyl, alkoxycarbonyl, alkoxycarbonylamino, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, aryloxy, or heteroaryloxyalkyl, or R8 and R9 together with the carbon to which they are 30 attached, form a carbocyclic or heterocyclic ring system, wherein any free hydroxyl group may be acylated to form C(O)R7, and wherein at least two of R8, R9 and R10 are not H; wherein, where indicated, alkyl, hydroxyalkyl, lkyl, alkylaminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, lkylalkyl, cyclyl, heterocyclylalkyl, heterocyclylalkoxy, heteroaryl, heteroarylalkyl, heteroaryloxy, or 5 aryloxyalkyl is optionally substituted with one or more substituents selected from halogen, hydroxyl, carboxyl, carbonyl, formyl, acyl, thioester, thioacetate, thioformate, alkoxyl, oryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, an 10 arylalkyl, aryl, and heteroaryl.
24. The pharmaceutical composition of claim 23, wherein L ents CH2SCH2, CH2CH2, CH2S or SCH2.
25. The pharmaceutical composition of claim 23, wherein L represents CH2CH2.
26. The pharmaceutical composition of any one of claims 23-25, wherein Y 15 represents H.
27. The pharmaceutical composition of any one of claims 23-26, wherein Z represents R3(CO).
28. The pharmaceutical composition of claim 27, wherein each ence of R3 is not identical. 20
29. The pharmaceutical composition of any one of claims 23-28, wherein R1 and R2 each represent H.
30. The pharmaceutical ition of any one of claims 23-29, wherein R3, independently for each occurrence, represents substituted or unsubstituted arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl. 25
31. The pharmaceutical composition of any one of claims 23-30, wherein R3, independently for each occurrence, represents C(R8)(R9)(R10), wherein R8 represents substituted or unsubstituted aryl, arylalkyl, heteroaryl or heteroaralkyl, R9 represents H, and R10 represents hydroxy, hydroxyalkyl, alkoxy or alkoxyalkyl.
32. The pharmaceutical composition of claim 31, wherein R8 represents substituted or unsubstituted aryl, arylalkyl, or heteroaryl. 5
33. The pharmaceutical composition of claim 31 or claim 32, wherein R10 represents hydroxy, hydroxyalkyl, or alkoxy.
34. The pharmaceutical composition of claim 23, wherein L ents CH2CH2, CH2S or SCH2, Y represents H, Z represents R3(CO), R1 and R2 each represent H, and R3, independently for each ence, represents substituted or unsubstituted arylalkyl, 10 heteroarylalkyl, cycloalkyl or heterocycloalkyl.
35. The pharmaceutical composition of claim 23, wherein L represents CH2SCH2, Y represents H, Z represents R3(CO), R1 and R2 each represent H, and R3, independently for each occurrence, represents substituted or unsubstituted heteroarylalkyl, cycloalkyl or heterocycloalkyl. 15
36. The pharmaceutical composition of claim 34 or claim 35, wherein each occurrence of R3 is identical.
37. The pharmaceutical composition of claim 23, wherein L ents CH2SCH2, CH2CH2, CH2S or SCH2, Y represents H, Z represents R3(CO), R1 and R2 each represent H, and R3, independently for each occurrence, ents C(R8)(R9)(R10), wherein R8 20 represents tuted or unsubstituted aryl, kyl, heteroaryl or heteroaralkyl, R9 ents H, and R10 represents y, hydroxyalkyl, alkoxy or alkoxyalkyl.
38. The ceutical composition of claim 37, wherein L represents CH2CH2.
39. The pharmaceutical composition of claim 37 or claim 38, wherein R8 represents substituted or unsubstituted aryl, arylalkyl or heteroaryl.
40. The pharmaceutical composition of claim 39, wherein R8 represents substituted or unsubstituted aryl.
41 The pharmaceutical composition of any one of claims 37-40, wherein R10 represents hydroxy, hydroxyalkyl or alkoxy. 5
42. The pharmaceutical composition of claim 41, wherein R10 represents hydroxyalkyl.
43. The pharmaceutical composition of any one of claims 37-42, wherein each ence of R3 is identical.
44. The pharmaceutical composition of claim 23, wherein L represents CH2CH2, Y 10 represents H, Z represents R3(CO), R1 and R2 each represent H, and R3, independently for each ence, represents substituted or unsubstituted arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl.
45. The pharmaceutical composition of claim 44, wherein each ence of R3 is cal. 15
46. A compound of formula I, (I), or a pharmaceutically acceptable salt thereof, wherein: L represents 2, CH2CH2, CH2CH2CH2, CH2, CH2S, SCH2, CH2NHCH2, CH=CH, or , wherein any hydrogen atom of a CH or CH2 unit may be 20 replaced by alkyl or alkoxy, any hydrogen of an NH unit may be ed by alkyl, and any hydrogen atom of a CH2 unit of CH2CH2, CH2CH2CH2 or CH2 may be replaced by y; one X represents S and the other X represents CH=CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl; 25 Y, independently for each occurrence, represents H or CH2O(CO)R7; R7, ndently for each occurrence, ents H or substituted or unsubstituted alkyl, alkoxy, aminoalkyl, alkylaminoalkyl, heterocyclylalkyl, or heterocyclylalkoxy; Z represents H or R3(CO); R1 and R2 each independently represent H, alkyl, alkoxy or hydroxy; 5 R3, independently for each occurrence, represents tuted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, cyclylalkyl, heteroaryl, heteroarylalkyl, aryloxy, heteroaryloxyalkyl or C(R8)(R9)(R10), N(R4)(R5) or OR6, wherein any free hydroxyl group may be 10 acylated to form C(O)R7; R4 and R5 each independently represent H or substituted or unsubstituted alkyl, hydroxyalkyl, acyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or 15 heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R7; R6, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, 20 heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free yl group may be acylated to form C(O)R7; and R8, R9 and R10 each independently represent H or substituted or unsubstituted alkyl, hydroxy, hydroxyalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, 25 alkoxycarbonyl, alkoxycarbonylamino, l, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, yalkyl, cycloalkyl, cycloalkylalkyl, cyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or R8 and R9 together with the carbon to which they are attached, form a carbocyclic or cyclic ring system, wherein any free 30 hydroxyl group may be acylated to form C(O)R7, and wherein at least two of R8, R9 and R10 are not H; provided that when L represents CH2SCH2, X represents S, and Z represents R3(CO), both R3 groups are not ally substituted phenyl, aralkyl, heteroaryl, substituted or unsubstituted alkyl, or alkoxy; wherein, where indicated, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, 5 acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkoxy, heteroaryl, arylalkyl, aryloxy, or heteroaryloxyalkyl is optionally substituted with one or more substituents selected from halogen, hydroxyl, carboxyl, alkoxycarbonyl, formyl, acyl, 10 thioester, thioacetate, thioformate, alkoxyl, phosphoryl, phosphate, phosphonate, inate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, cyclyl, an arylalkyl, aryl, and heteroaryl.
47. The compound of claim 46, wherein L represents CH2SCH2, , CH2S or 15 SCH2.
48. The compound of claim 46, wherein L represents CH2CH2.
49. The compound of any one of claims 46-48, wherein Y represents H.
50. The compound of any one of claims 46-49, wherein Z represents R3(CO).
51. The compound of claim 50, wherein each occurrence of R3 is not identical. 20
52. The compound of any one of claims 46-51, wherein R1 and R2 each represent H.
53. The compound of any one of claims 46-52, wherein R3, ndently for each occurrence, represents substituted or unsubstituted arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl.
54. The compound of any of claims 46-53, wherein R3, independently for each 25 occurrence, ents R9)(R10), wherein R8 represents substituted or unsubstituted aryl, kyl, heteroaryl or heteroaralkyl, R9 represents H, and R10 represents y, hydroxyalkyl, alkoxy or alkoxyalkyl.
55. The compound of claim 54, wherein R8 represents substituted or unsubstituted aryl, arylalkyl, or heteroaryl. 5
56. The compound of claim 54 or claim 55, wherein R10 ents hydroxy, hydroxyalkyl, or alkoxy.
57. The compound of claim 46, wherein L represents CH2CH2, CH2S or SCH2, Y ents H, Z represents R3(CO), R1 and R2 each ent H, and R3, independently for each occurrence, represents substituted or unsubstituted arylalkyl, heteroarylalkyl, 10 cycloalkyl or heterocycloalkyl.
58. The compound of claim 46, wherein L represents CH2SCH2, Y represents H, Z represents R3(CO), R1 and R2 each represent H, and R3, independently for each occurrence, represents substituted or unsubstituted heteroarylalkyl, cycloalkyl or heterocycloalkyl. 15
59. The compound of claim 57 or claim 58, wherein each occurrence of R3 is identical.
60. The compound of claim 46, wherein L represents CH2SCH2, CH2CH2, CH2S or SCH2, Y represents H, Z represents R3(CO), R1 and R2 each represent H, and R3, independently for each occurrence, represents C(R8)(R9)(R10), wherein R8 represents 20 substituted or unsubstituted aryl, arylalkyl, heteroaryl or heteroaralkyl, R9 represents H, and R10 represents hydroxy, hydroxyalkyl, alkoxy or alkoxyalkyl.
61. The compound of claim 60, wherein L represents .
62. The compound of claim 60 or claim 61, wherein R8 ents tuted or unsubstituted aryl, arylalkyl or heteroaryl.
63. The compound of claim 62, wherein R8 represents substituted or unsubstituted aryl.
64. The compound of any one of claims 60-63, wherein R10 represents hydroxy, hydroxyalkyl or alkoxy. 5
65. The compound of claim 64, wherein R10 represents yalkyl.
66. The compound of any one of claims 60-65, wherein each occurrence of R3 is identical.
67. The compound of claim 46, wherein L represents , Y represents H, Z represents , R1 and R2 each represent H, and R3, independently for each 10 occurrence, ents substituted or unsubstituted arylalkyl, heteroarylalkyl, cycloalkyl or heterocycloalkyl. 68. The compound of claim 67, wherein each ence of R3 is identical.
68. The use of claim 1, substantially as herein described with reference to any one or more of the examples but excluding comparative examples. 15
69. The pharmaceutical composition of claim 23, ntially as herein described with reference to any one or more of the examples but excluding comparative examples.
70. The compound of claim 46, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.
NZ625913A 2011-11-21 2012-11-19 Heterocyclic inhibitors of glutaminase NZ625913B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161562266P 2011-11-21 2011-11-21
US61/562,266 2011-11-21
US201261665370P 2012-06-28 2012-06-28
US61/665,370 2012-06-28
US201261727195P 2012-11-16 2012-11-16
US61/727,195 2012-11-16
PCT/US2012/065816 WO2013078123A1 (en) 2011-11-21 2012-11-19 Heterocyclic inhibitors of glutaminase

Publications (2)

Publication Number Publication Date
NZ625913A NZ625913A (en) 2015-12-24
NZ625913B2 true NZ625913B2 (en) 2016-03-30

Family

ID=

Similar Documents

Publication Publication Date Title
EP2782570B1 (en) Heterocyclic inhibitors of glutaminase
US9938267B2 (en) Heterocyclic inhibitors of glutaminase
US11807606B2 (en) Sulfonamide derivatives for protein degradation
ES2899461T3 (en) Heterocyclic glutaminase inhibitors
WO2014089048A1 (en) Treatment of cancer with heterocyclic inhibitors of glutaminase
US20180354912A1 (en) Aryldiazepine derivatives as rsv inhibitors
AU2013344560A1 (en) Heterocyclic glutaminase inhibitors
CN106456580A (en) Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
WO2016196890A1 (en) Inhibitors of hexokinase and methods of use thereof
WO2018009539A1 (en) Inhibitors of hexokinase and methods of use thereof
NZ625913B2 (en) Heterocyclic inhibitors of glutaminase
NZ738078B2 (en) Mct4 inhibitors for treating disease